{"text_format":"1","workbook":"xlsx","n_sheets":16,"sheets":["Cover","Original","Key","Mapper","CitationIndex","Citations","Dashboard","custom","Setup","studymethodCategories","subpopulationCategories","studytypeCategories","diseaseCategories","protoolCategories","locationCategories","interventionCategories"],"not_rendered":{"charts":0,"images":5,"macros":1,"external_links":1,"defined_names":144,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Cover","index":0,"n_rows":31,"n_cols":4,"rows_kept":31,"cut":false,"hidden":false,"merged":[[29,2,29,8],[23,2,23,16],[25,2,25,23],[4,2,5,36],[18,3,18,27],[14,3,14,26],[17,3,17,36],[19,3,19,26]]}
[]
[]
[]
[]
[null,null,"This Excel workbook contains the Evidence Map  on \nPRO tools in non-Hodgkin's lymphoma."]
[]
[]
[]
[]
[null,null,"How this Evidence Map was generated"]
[null,null,"We searched heoro.com on the 10th January 2018 with the following field settings:"]
[null,null,"Disease: Non-Hodgkin lymphoma AND Study type: PRO studies"]
[null,null,"The search identified a total of 52 relevant abstracts published since 1960, which were  segmented with the following standard heoro.com fields:"]
[null,null,null,"Locations - the geographical setting of the study, or, where this is unknown, the authors' location."]
[null,null,null,"Disease - the stage of the disease e.g. local, advanced, metastatic, at risk"]
[null,null,null,"Interventions - the interventions evaluated int eh study, if any."]
[null,null,null,"PRO tools - the PRO intruments that were cited in the title or abstract."]
[null,null,null,"Study methodology - the type of study that was conducted, e.g. clinical trial, observational, systematic review."]
[null,null,null,"Subpopulation - whether the study assessed patients, caregivers, the general public or healthcare professionals (HCPs)"]
[null,null,null,"Stage - the disease stage being assessed."]
[null,null,"In addition the following publication date segmentations are used:"]
[null,null,null,"1960 to 1990, 1991 to 1995, 1996 to 1999, 2000 to 2004, 2005 to 2009, 2010 to 2014, 2015 to 2017"]
[]
[null,null,"All data in this Evidence Map is taken from the heoro.com database"]
[]
[null,null,"Details of the PubMed search strategy used to populate the heoro.com database can be found here."]
[]
[null,null,"Contact us:"]
[null,null,"Address: Crystallise Ltd. Unit 21, Thames Enterpise Centre, Thames Industrial Park, East Tilbury, Essex, UK RM18 8RH"]
[null,null,"Tel: +44 (0)1375 488020"]
[null,null,"Email: alison.martin@crystallise.com"]

{"sheet":"Original","index":1,"n_rows":53,"n_cols":33,"rows_kept":53,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNT(A2:A986)","v":52},"Full citation","DOI","Authors","Title","Abstract","Citation","Locations","Year","Diseases","Interventions","PROtools","Subpopulations","Study types","Study methodologies","LocationsTags","SubpopulationsTags","DiseaseTags","InterventionsTags","StudytypesTags","StudyMethodologyTags","PROtoolTags","DateBand","C1","C2","C3","C4","C5","C6","C7","C8","C9","C10"]
[1,"Attarbaschi,A.,et al. (2016). \"Non-Hodgkin lymphoma and pre-existing conditions: spectrum,clinical characteristics and outcome in 213 children and adolescents.\" Haematologica 101(12): 1581-1591.","10.3324/haematol.2016.147116","Attarbaschi,A.,et al.","Non-Hodgkin lymphoma and pre-existing conditions: spectrum,clinical characteristics and outcome in 213 children and adolescents","Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin lymphoma. However,large-scale data on patients with non-Hodgkin lymphoma and their entire spectrum of pre-existing conditions are scarce. A retrospective multinational study was conducted by means of questionnaires sent out to the national study groups or centers,by the two largest consortia in childhood non-Hodgkin lymphoma,the European Intergroup for Childhood non-Hodgkin Lymphoma,and the international Berlin-Frankfurt-Munster Study Group. The study identified 213 patients with non-Hodgkin lymphoma and a pre-existing condition. Four subcategories were established: a) cancer predisposition syndromes (n=124,58%); b) primary immunodeficiencies not further specified (n=27,13%); c) genetic diseases with no increased cancer risk (n=40,19%); and d) non-classifiable conditions (n=22,10%). Seventy-nine of 124 (64%) cancer predispositions were reported in groups with more than 20 patients: ataxia telangiectasia (n=32),Nijmegen breakage syndrome (n=26),constitutional mismatch repair deficiency (n=21). For the 151 patients with a known cancer risk,5-year event-free survival and overall survival rates were 40%+/-4% and 51%+/-4%,respectively. Five-year cumulative incidences of progression/relapse and treatment-related death as a first event were 22%+/-4% and 24%+/-4%,respectively. Ten-year incidence of second malignancy was 24%+/-5% and 7-year overall survival of the 21 patients with a second malignancy was 41%+/-11%. Patients with non-Hodgkin lymphoma and pre-existing conditions have an inferior survival rate with a large proportion of therapy-related deaths compared to patients with non-Hodgkin lymphoma and no pre-existing conditions. They may require special vigilance when receiving standard or modified/reduced-intensity chemotherapy or when undergoing allogeneic stem cell transplantation.","Haematologica 101(Number): 1581-1591","UK,Austria,Belarus,Belgium,Canada,Czech Republic,France,Germany,China,Hungary,Israel,Italy,Japan,Netherlands,Poland,Serbia,Slovenia,Switzerland",2016,"NHL","None","Unspecified","Children","","Cohort study",null,null,null,null,null,null,null,null,"Unspecified"]
[2,"Beynon,T.,et al. (2014). \"What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence.\" Br J Dermatol 170(3): 599-608.","10.1111/bjd.12644","Beynon,T.,et al.","What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence","BACKGROUND: Primary cutaneous T-cell lymphoma (CTCL) is progressive,can cause significant symptoms,and impacts on quality of life. Therefore supportive and palliative care might have a role in the care of patients and families. OBJECTIVES: To identify and appraise the available peer-reviewed evidence on the supportive and palliative care needs of patients and their caregivers. METHODS: A systematic review of the literature was conducted. Extracted data from eligible papers were collated in themes relating to supportive and palliative care needs and outcomes for patients,informal caregivers,health professionals and reported service models. RESULTS: Eighteen retained papers reported a symptom or quality-of-life measure. Five reported only these measures,13 reported outcomes in relation to an intervention. Systemic therapy targeted at disease remission was the most commonly reported intervention (12/13). No quality-of-life tool was consistently used. Pruritus was frequently reported as an outcome (n = 9) often using the visual analogue scale,VAS itch. Psychosocial,spiritual and caregiver needs were reported infrequently or not at all. CONCLUSIONS: No measure is routinely used to measure supportive and palliative care outcomes in CTCL. Physical needs,particularly pruritus,were reported commonly; however,qualitative evidence of experience is limited. Caregivers' needs are rarely explored. To compare outcomes from clinical studies,a single multidimensional tool used in routine practice would be useful. Further work is needed to explore a model of service that meets the specific physical,psychosocial and spiritual needs of this group of patients and their carers.","Br J Dermatol 170(Number): 599-608","International",2014,"Cutaneous T-cell","Targeted","VAS","Caregiver,Patient","","SLR",null,null,null,null,null,null,null,null,"Unspecified"]
[3,"Boele,F. W.,et al. (2013). \"Health-related quality of life of significant others of patients with malignant CNS versus non-CNS tumors: a comparative study.\" J Neurooncol 115(1): 87-94.","10.1007/s11060-013-1198-z","Boele,F. W.,et al.","Health-related quality of life of significant others of patients with malignant CNS versus non-CNS tumors: a comparative study","It is often assumed that brain tumor patients' significant others (SOs: partners,other family members or close friends) may face greater stress than those of patients with malignancies not involving the central nervous system (CNS),due to progressive changes in neurological and cognitive functioning. We compared health-related quality of life (HRQOL) of SOs of patients with high-grade glioma (HGG) and low-grade glioma (LGG) with that of SOs of patients with non-CNS tumors with similar prognosis and at a similar phase in the disease trajectory (i.e. non-small cell lung cancer (NSCLC) and low-grade hematological malignancies (NHL/CLL),respectively). HRQOL of SOs and patients was assessed using the Short Form-36 (SF-36) Health Survey. Patients' neurological functioning was indexed and they underwent comprehensive neurocognitive testing. SOs of 213 LGG patients,99 NHL/CLL patients,55 HGG patients and 29 NSCLC patients participated. The SOs of LGG and NHL/CLL patients reported similar levels of HRQOL. SOs of HGG patients reported significantly lower mental health scores (MCS; p = 0.041) and social functioning (p = 0.028) than those of NSCLC patients. Mental health scores (MCS) of HGG and NSCLC patients were associated significantly with the mental health of their SOs (p = 0.013 and p < 0.001,respectively). Surprisingly,HGG patients' cognitive and neurological functioning were not predictive of SOs' mental health at the multivariate level. SOs of patients with highly malignant CNS tumors in the acute phase are at increased risk of compromised HRQOL compared to those of patients with systemic tumors without CNS involvement and a comparable life expectancy.","J Neurooncol 115(Number): 87-94","Netherlands",2013,"NHL","None","SF-36","Caregiver,Patient",null,"Cross-sectional",null,null,null,null,null,null,null,null,"High grade,Low grade"]
[4,"Burke,J. M.,et al. (2016). \"Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.\" Clin Lymphoma Myeloma Leuk 16(4): 182-190.e181.","10.1016/j.clml.2016.01.001","Burke,J. M.,et al.","Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","BACKGROUND: We previously reported results of the phase III,randomized,noninferiority trial comparing bendamustine-rituximab (BR) with standard R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)/R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in previously untreated advanced indolent non-Hodgkin and mantle cell lymphomas. Here we report health-related quality of life (HRQOL) results from the trial. METHODS: HRQOL,as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30),was a secondary end point. Differences between group means in global health status (GHS),5-item functioning,and 9 symptoms/single-item measures at week 1 of cycle 1 and end-of- cycles 3 and 6 were examined using the screening (baseline) score as a covariate in analysis of covariance. RESULTS: Overall EORTC QLQ-C30 compliance was 75.2%,89.5%,and 89.9% at week 1 of cycle 1 and end-of-cycles 3 and 6,respectively. Patients treated with BR reported improvements in Cognitive Functioning,Physical Functioning,Social Functioning,Emotional Functioning,and GHS as well as reduction in dyspnea,constipation,and fatigue at some,but not all,time points. Patients treated with standard therapy reported less nausea/vomiting at one time point. CONCLUSION: Compared with patients treated with standard therapy,patients treated with BR reported better quality of life in several areas.","Clin Lymphoma Myeloma Leuk 16(Number): 182-190.e181","UK,Australia,Canada,New Zealand",2016,"NHL,Mantle cell","Bendamustine-rituximab,Rituximab,Chemotherapy","EORTC QLQ-C30","Patient","","RCT",null,null,null,null,null,null,null,null,"Advanced"]
[5,"Cheson,B. D.,et al. (2017). \"Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.\" Ann Hematol 96(2): 253-259.","10.1007/s00277-016-2878-5","Cheson,B. D.,et al.","Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","We present health-related quality of life (HRQoL) data from GADOLIN,comparing bendamustine (B) alone or combined with obinutuzumab (G-B) in rituximab-refractory indolent non-Hodgkin lymphoma patients. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire was administered on day 1 of cycles 1,3,and 5 during treatment,at end of induction (EOI),bi-monthly for 2 years during maintenance/follow-up,and annually during extended follow-up until progression/death. Time to first >/=6-point worsening from baseline in the FACT-Lym trial outcome index (TOI) was estimated. Minimally important differences at individual subscale and total score level were used to define the proportion of patients reporting improvement on the FACT-Lym lymphoma-specific subscale (>/=3 points),FACT-Lym TOI (>/=6 points),and FACT-Lym total score (>/=7 points). Overall,396 patients were randomized. Analysis was conducted when 175 Independent Review Committee-assessed progression-free survival (PFS) events were observed. Questionnaire completion rates were generally balanced between arms at baseline,EOI,and final follow-up. Median time to >/=6-point worsening from baseline on the FACT-Lym TOI was 8.0 months in the G-B arm and 4.6 months in the B arm (HR 0.74; 95% CI 0.56-0.98). More G-B patients reported meaningful improvements on the FACT-Lym questionnaire subscales. Results were similar when follicular lymphoma patients were analyzed separately. The delayed time to worsening and greater proportion of patients reporting meaningful improvement in HRQoL in the G-B arm suggest that benefit in PFS is not at the expense of an increase in treatment-related toxicity that could lead to reduced HRQoL.","Ann Hematol 96(Number): 253-259","UK,USA,Canada,France,Netherlands,Sweden,Switzerland",2017,"NHL","Bendamustine,Obinutuzumab","FACT-Lym","Patient","","RCT",null,null,null,null,null,null,null,null,"Refractory"]
[6,"Chuang,T. Y.,et al. (2017). \"A nurse facilitated mind-body interactive exercise (Chan-Chuang qigong) improves the health status of non-Hodgkin lymphoma patients receiving chemotherapy: Randomised controlled trial.\" Int J Nurs Stud 69: 25-33.","10.1016/j.ijnurstu.2017.01.004","Chuang,T. Y.,et al.","A nurse facilitated mind-body interactive exercise (Chan-Chuang qigong) improves the health status of non-Hodgkin lymphoma patients receiving chemotherapy: Randomised controlled trial","BACKGROUND: Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies. Chemotherapy can improve patient survival rates,yet it is also associated with many adverse physical and psychosocial effects. It is suggested that qigong practices may be used to reduce patient distress and side effects. OBJECTIVES: To evaluate the effects of Chan-Chuang qigong on fatigue,complete blood cells,sleep quality,and quality of life for patients with non-Hodgkin lymphoma who had undergone the first course of chemotherapy. DESIGN: A randomized controlled study. SETTINGS: An oncology ward of medical centre in northern Taiwan. PARTICIPANTS: Fifty participants in each of the two groups. METHODS: Participants were randomly assigned to either the qigong group (n=50) that received a 21-day Chan-Chuang qigong programme,or the control group (n=50). The primary outcome was fatigue measured by Brief Fatigue Inventory. The secondary outcomes were complete blood cell counts,sleep quality measured by Verran and Snyder-Halpern Sleep Scale,and quality of life measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. RESULTS: After 21 days of intervention,the results obtained from ninety six participants were analysed. Participants in the qigong group exhibited decreased fatigue intensity and fatigue interference from 5.49 (SD=1.02) and 5.53 (SD=1.27) to 0.37 (SD=1.39) and 0.20 (SD=1.93),respectively. Generalized estimating equations analyses revealed that the qigong group,when compared to the control group,had significant improvement in fatigue intensity and fatigue interference over time (beta=-1.04,95% confidence interval [CI] from -1.59 to -0.48,p<0.001; and beta=-1.22,95% CI from -1.86 to -0.59,p<0.001,respectively). There was a significant between-group difference in the improvement in white blood cell counts (t=5.14,p<0.001),hemoglobin levels (t=3.17,p=0.002),and sleep quality (t=17.73,p<0.001),but not in platelet counts (p=0.05). With regard to quality of life,the scores of the qigong group improved in all subscales and all symptom items when compared to that of the control group. No adverse effects were observed in the qigong group. CONCLUSIONS: The findings of this study indicate that the 21-day Chan- Chuang qigong can reduce fatigue intensity and fatigue interference,and improved white blood cell counts,haemoglobin levels,sleep quality,and quality of life for patients with non-Hodgkin lymphoma who had undergone the first course of chemotherapy. Further studies involving a prolonged extended intervention period and follow-up are necessary for determining the long-term effect of qigong exercise.","Int J Nurs Stud 69(Number): 25-33","China",2017,"NHL","Chemotherapy,Various","BFI,VSHSS,EORTC QLQ-C30","Patient","","RCT",null,null,null,null,null,null,null,null,"Unspecified"]
[7,"Crespi,C. M.,et al. (2013). \"A procedure for obtaining impact of cancer version 2 scores using version 1 responses.\" Qual Life Res 22(1): 103-109.","10.1007/s11136-012-0127-5","Crespi,C. M.,et al.","A procedure for obtaining impact of cancer version 2 scores using version 1 responses","PURPOSE: Psychometric scales often change over time,complicating comparison of scores across different versions. The Impact of Cancer (IOC) scale was developed to measure quality of life of long-term cancer survivors. We sought to develop a method for scoring the earlier version,IOCv1,to obtain scores comparable to IOCv2,which is the recommended version. METHODS: Data from 1,828 cancer survivors who had completed a questionnaire including all IOCv1 and IOCv2 items were randomly split into training,validation and test sets. The training and validation sets were used to develop and validate linear regression models for predicting each IOCv2 item missing from IOCv1. The models were then applied to the test set to obtain pseudo-IOCv2 scores,which were compared to observed scores to assess predictive performance of the models in independent data. RESULTS: Observed and pseudo-IOCv2 scale scores were highly correlated in the test sample and had mean differences near zero. The models performed especially well in predicting summary scale scores,with correlations exceeding 0.98. CONCLUSIONS: The approach facilitates comparison across samples of survivors surveyed using different versions of the IOC and may be useful to other investigators trying to compare participants surveyed using different versions of the same instrument.","Qual Life Res 22(Number): 103-109","USA",2013,"Other","None","IOC","Survivor","","Validation",null,null,null,null,null,null,null,null,"Any"]
[8,"Crespi,C. M.,et al. (2010). \"Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors.\" J Cancer Surviv 4(1): 45-58.","10.1007/s11764-009-0106-1","Crespi,C. M.,et al.","Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors","INTRODUCTION: Self-report instruments such as the Impact of Cancer (IOC) are designed to measure quality of life (QOL) impacts that cancer survivors attribute to their cancer experience. Generalizability of QOL findings across distinct diagnostic categories of survivors is untested. We compare measurement of the impact of cancer using the IOC instrument in breast cancer (BC) survivors (n = 1,188) and non-Hodgkin lymphoma (NHL) survivors (n = 652). METHODS: A registry-based sample of NHL survivors completed the IOC questionnaire and the FACT-G,FACT-LYM,Medical Outcomes Study (MOS) SF-36,Post-Traumatic Stress Disorder Checklist-Civilian Version,Post-Traumatic Growth Inventory and MOS Social Support scales. IOC responses of the NHL survivors were subjected to de novo scaling to identify impact domains for comparison to IOC version 2 (IOCv2) domains,which were previously developed based on BC survivor responses. Concurrent validity was assessed by correlating the IOCv2 scales with the other measures. IOCv2 scores were compared between the BC and NHL survivor samples. RESULTS: The BC and NHL survivors exhibited similar impact domains and had factor structures that were largely congruent. The concurrent validity analysis revealed patterns of association that supported the interpretation and validity of the IOCv2 scales. Differences in IOCv2 scores between the BC and NHL groups suggested differential impacts in distinct survivor groups that could be detected using the IOCv2. CONCLUSION: The results suggest that the IOCv2 measures common and important survivor concerns and support its generalizability to the broader long-term cancer survivor population. IMPLICATIONS FOR CANCER SURVIVORS: Instruments such as the IOCv2 can provide valid assessment of QOL impacts in long-term cancer survivors,facilitating the characterization of these impacts and development of appropriate interventions.","J Cancer Surviv 4(Number): 45-58","USA",2010,"NHL","None","IOC,FACT-G,FACT-LYM,SF-36,PTSDCC,PTGI,MOS-SSS","Survivor","","Cross-sectional",null,null,null,null,null,null,null,null,"Any"]
[9,"Crott,R.,et al. (2013). \"An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.\" Qual Life Res 22(5): 1045-1054.","10.1007/s11136-012-0220-9","Crott,R.,et al.","An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences","BACKGROUND: Although cancer-specific Health-related Quality-of-Life measures are commonly included in randomized clinical trials or other prospective non-randomized clinical studies,it is rare that preference-based instruments are used,which allow the calculation of a Utility weight suitable for estimating Quality-adjusted Life-Years gained. OBJECTIVE: To test the external validity of a previously published mapping algorithm to transform the EORTC QLQ-C30 questionnaire responses into EQ-5D-derived utilities by predicting EQ-5D utilities from QLQ-C30 scores. STUDY DESIGN AND METHODS: Comparative retrospective data analysis of four multicentre,prospective clinical trials in Breast,Multiple Myeloma,Non-Hodgkin Lymphoma and Non-Small-Cell Lung cancer patients with,respectively,219,172,132 and 172 patients. Regression analysis of individual pairs of EQ-5D and QLQ-C30 scores. RESULTS: Although the internal predictive power of a previously published mapping equation was high,its external validity when tested on a set of unrelated external data sets in other cancers proved to underestimate both the mean and variance of the mapped EQ-5D utilities. Furthermore,it appears that the relationship between QLQ-C30 scores and EQ-5D values is not stable across the different data sets. CONCLUSIONS: Validation of the proposed algorithm in other external clinical data sets should be encouraged as well as the application of other more complex mapping methods to enhance accuracy of mapping. In the meanwhile,direct mapping from QLQ-C30 profiles to EQ-5D utilities using published algorithms should be performed with reservations.","Qual Life Res 22(Number): 1045-1054","Netherlands",2013,"NHL","None","EQ-5D,EORTC QLQ-C30","Patient","","Validation",null,null,null,null,null,null,null,null,"Unspecified"]
[10,"Deconinck,E.,et al. (2010). \"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.\" Pharmacoeconomics 28(1): 35-46.","10.2165/11314070-000000000-00000","Deconinck,E.,et al.","Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation","BACKGROUND: Rituximab maintenance therapy was shown to significantly extend overall survival (OS) and progression-free survival (PFS) in relapsed/refractory follicular lymphoma (FL) in the pivotal EORTC 20981 trial. OBJECTIVE: To assess the long-term costs and cost effectiveness of rituximab maintenance therapy after induction therapy versus current standard practice (observation) from the French National Health Service perspective. METHODS: A lifetime transition model was developed comparing rituximab maintenance with observation. PFS and OS were obtained from the EORTC 20981 trial with a median follow-up of 28 months and extrapolated from 2-year Kaplan-Meier curves using a Weibull distribution. PFS and OS benefits of rituximab were conservatively assumed to last only 5 years. Utility data were obtained from a multicentre observational study using the EQ-5D questionnaire. Direct medical costs were obtained from French official sources. All costs are reported in euro,year 2006 values. RESULTS: The EORTC 20981 study demonstrated that rituximab maintenance was effective in the management of relapsed/refractory FL. The model results showed that life expectancy and QALYs were increased by 22% and 28%,respectively,in patients treated with rituximab. The incremental cost-effectiveness ratios (ICERs) were euro 7612 per life-year gained and euro 8729 per QALY gained. In a one-way sensitivity analysis,most of the ICERs fell within the range of euro 7000-12,000. The results tend to show that rituximab maintenance therapy may be a cost-effective strategy in the management of relapsed/refractory FL in France,with ICERs below those observed for other therapies in the oncology field. The cost of rituximab was partly offset by the lower cost of relapse due to a longer time in the disease-free health state for patients in the rituximab arm.","Pharmacoeconomics 28(Number): 35-46","France",2010,"Follicular","Rituximab","EQ-5D","Patient","","Economic evaluation",null,null,null,null,null,null,null,null,"Refractory"]
[11,"Diamond,C.,et al. (2010). \"Quality of life,characteristics and survival of patients with HIV and lymphoma.\" Qual Life Res 19(2): 149-155.","10.1007/s11136-009-9565-0","Diamond,C.,et al.","Quality of life,characteristics and survival of patients with HIV and lymphoma","PURPOSE: We sought to compare the quality of life (QOL),characteristics,and survival of patients with non-Hodgkin lymphoma (NHL) with and without human immunodeficiency virus (HIV) infection. METHODS: Using the population-based cancer registry for Orange and San Diego Counties,We recruited 50 patients with HIV and systemic NHL (cases) and 50 age,sex and race-matched NHL patients without HIV (controls) diagnosed with NHL during 2002-2006. Patients completed a medical history survey and QOL instrument,the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) for cases and Functional Assessment of Cancer Therapy-General (FACT G) for controls. RESULTS: HIV-infected patients had worse overall QOL and survival than uninfected patients. QOL differences were more marked in the areas of functional,physical and social well-being than in the area of emotional well-being. HIV-infected patients had lower income and were less likely to have private insurance and more likely to have diffuse large B cell histology than uninfected patients. CONCLUSION: HIV-infected NHL patients had worse QOL and survival than uninfected patients,due to a combination of co-morbidity,aggressive histology and lack of social support. However,their emotional well-being was comparable to that of uninfected NHL patients and better than historical norms for the HIV-infected.","Qual Life Res 19(Number): 149-155","USA",2010,"NHL","None","FAHI,FACT-G","Patient","","Case-control",null,null,null,null,null,null,null,null,"Unspecified"]
[12,"Doorduijn,J.,et al. (2005). \"Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy.\" Eur J Haematol 75(2): 116-123.","10.1111/j.1600-0609.2005.00438.x","Doorduijn,J.,et al.","Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy","We studied the impact of CHOP chemotherapy on the quality of life (QoL) of elderly patients with aggressive non-Hodgkin's lymphoma (NHL). 132 patients aged 65 or older,who participated in a randomized,multicenter trial,completed QoL questionnaires (EuroQol-5D,EORTC QLQ-C30 and MFI-20) on 8 predefined time-points before,during and following treatment. At baseline,QoL was significantly better on almost all dimensions in patients with a lower compared to patients with a higher age-adjusted International Prognostic Index (aaPI). During treatment,physical and role functioning and global QoL deteriorated and fatigue increased in the lower aaPI group,whereas QoL of the higher aaPI group remained stable. During follow-up,the QoL was significantly better for patients in complete response (CR) or partial remission (PR) than for patients with progression/relapse. Soon after completion of therapy,the QoL of the lower aaPI group returned to pretreatment levels or better,while patients with higher aaPI showed a significant improvement in QoL compared to baseline levels. The effect of CHOP on the quality of life of elderly patients could be used in counseling this group of patients.","Eur J Haematol 75(Number): 116-123","Netherlands",2005,"NHL","Chemotherapy","EQ-5D,EORTC QLQ-C30,MFI-20","Patient","","RCT",null,null,null,null,null,null,null,null,"Aggressive"]
[13,"Duvic,M.,et al. (2002). \"Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).\" Clin Lymphoma 2(4): 222-228.",null,"Duvic,M.,et al.","Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)","Cutaneous T-cell lymphoma (CTCL) can be associated with painful,pruritic,disfiguring lesions. As part of a multicenter,randomized phase III trial in patients with heavily pretreated advanced and/or recurrent CTCL,the effects of an interleukin-2 receptor-targeted fusion protein,denileukin diftitox (DAB389IL-2,ONTAK),on patient-rated overall quality of life (QOL),skin appearance,and pruritus severity were evaluated. A total of 71 patients with stage IB-IVA CTCL received intravenous denileukin diftitox 9 microg/kg/day or 18 microg/kg/day over 15-60 minutes for 5 consecutive days on an outpatient basis; cycles were planned for every 21 days for a total of 8 cycles over 6 months. Prior to each treatment cycle,patients were evaluated for disease response and were asked to self-rate their overall QOL via the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire,skin appearance (7-point scale),and pruritus severity (10-cm visual analogue scale). Composite FACT-G and most individual subscale scores (physical,social/family,emotional,and functional well being) in documented responders (n = 21) gradually increased during the study period,generally reaching statistical significance (P < 0.05) by cycle 3,and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint. Additionally for responders,assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline. Adverse transfusion-related events (eg,hypersensitivity reactions,flu-like syndrome) were common during cycles 1 and 2,and vascular-leak syndrome occurred in 25% of patients. Denileukin diftitox was not associated with any clinically significant myelosuppression. Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL,skin appearance,and pruritus severity.","Clin Lymphoma 2(Number): 222-228","USA",2002,"Cutaneous T-cell","Denileukin diftitox","FACT-G,VAS","Patient","","RCT",null,null,null,null,null,null,null,null,"Advanced"]
[14,"Fargier,E.,et al. (2018). \"SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma.\" Ann Hematol 97(1): 123-131.","10.1007/s00277-017-3147-y","Fargier,E.,et al.","SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma","Rituximab is used as a standard of care for follicular lymphoma and is usually administered intravenously. A novel subcutaneous formulation recently showed non-inferior efficacy with similar pharmacokinetic and safety profiles compared to intravenous rituximab in patients with follicular lymphoma. This new approach is promising in terms of comfort for patients and time-saving for hospital staff. To evaluate the real-life economic impact of subcutaneous rituximab as maintenance therapy in patients with follicular lymphoma in real life,we conducted a cost-consequence analysis from the hospital's point of view in three French teaching hospitals. Health-related quality of life (EQ-5D-3L) was investigated as well as patients' and nurses' perception. Compared to intravenous rituximab,subcutaneous administration showed an estimated cost-saving of euro109.20 per patient per cycle (p < 0.001),78.6% of which could be attributed to the rituximab cost. Health-related quality of life showed no significant difference between the two groups despite tendencies for greater pain in the subcutaneous group and greater anxiety in the intravenous group. Thus,subcutaneous rituximab had a favorable pharmacoeconomic profile,with clinical efficacy similar to that of intravenous rituximab. The subcutaneous form was preferred by almost all patients,but further consideration should be given to improve the patients' experience: a dedicated day unit with trained medical,nursing,and pharmaceutical staff could be helpful.","Ann Hematol 97(Number): 123-131","France",2018,"Follicular","Rituximab","EQ-5D","Patient","","Economic evaluation",null,null,null,null,null,null,null,null,"Unspecified"]
[15,"Furlan,C.,et al. (2017). \"Low-dose radiotherapy in diffuse large B-cell lymphoma.\" Hematol Oncol 35(4): 472-479.","10.1002/hon.2368","Furlan,C.,et al.","Low-dose radiotherapy in diffuse large B-cell lymphoma","Low-dose radiotherapy (LDRT) given in 2 x 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise,very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation. Low-dose radiotherapy was administered on symptomatic areas only. Clinical response was assessed 21 days after LDRT and defined as reduction >50% of maximum diameter of the radiated lesions. Quality of life was scored by the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire. Tumor subtype (germinal center B-cell type versus activated B-cell type) and the presence of TP53 mutations in pathologic specimens of the target lesion were also evaluated. Twenty-three of twenty-five radiated patients were evaluable for response,and 2 died of disease before the visit at 21 days. The overall response rate was 70% (16 of 23 patients),with 7 complete responses and 9 partial responses (mean duration of response,6 months; range,1-39 months). Fifteen patients answered to the QLQ-C30 questionnaires,and an improved quality of life was documented in 9 cases. TP53 mutations were detected in 2 of 6 (33%) nonresponders and in none of the responders (P = .12). Germinal center B-cell type responded better than activated B-cell type (response rate was 83% and 29%,respectively,P = .01). These findings indicate that LDRT is effective for palliation in patients with DLBCL.","Hematol Oncol 35(Number): 472-479","Italy",2017,"DLBCL","Radiotherapy","EORTC QLQ-C30","Patient","","Clinical Trial",null,null,null,null,null,null,null,null,"Unspecified"]
[16,"Geffen,D. B.,et al. (2003). \"Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma in Israel.\" Leuk Lymphoma 44(11): 1925-1929.","10.1080/1042819031000123573","Geffen,D. B.,et al.","Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma in Israel","Post-traumatic stress disorder (PTSD) has not been examined systematically in long-term survivors of lymphoma. In this study,PTSD and health related quality of life (HRQoL) were assessed in 44 patients with Hodgkin's disease (n = 8) or non-Hodgkin's lymphoma (n = 36). Forty-four individuals who had experienced traumatic events as defined by the Diagnostic and Statistical Manual-IV (DSM-IV) as possible triggers for PTSD served as controls. The study participants were administered two questionnaires-the PTSD inventory scale and the Short Form-36 (SF-36) HRQoL instrument measuring physical and mental HRQoL. Full PTSD was defined as meeting the DSM-IV criteria for the diagnosis in all three symptom groups measured on the PTSD inventory scale-intrusion,avoidance and hyper-arousal and partial PTSD as meeting the diagnostic criteria in two of the symptom groups. There was a significant increase in the hyper-arousal scale in the lymphoma survivor group (F 5,P < 0.05). Overall,full or partial PTSD was found in 14 lymphoma survivors (32%) and in 11 individuals (25%) in the control group (difference not significant). Survivors whose disease had started at an earlier age suffered significantly more intensive intrusion and avoidance symptoms. The lymphoma survivor group had a significantly lower physical HRQoL than the control group independent of PTSD symptoms. In both groups,the presence of PTSD symptoms correlated with a lower HRQoL. These results suggest that lymphoma is a trauma similar to other more accepted definitions of trauma which can lead to PTSD,and is associated with more severe hyper-arousal symptoms. Psychological interventions in the early stages of treatment or follow-up may help reduce the morbidity from PTSD and improve quality of life.","Leuk Lymphoma 44(Number): 1925-1929","Israel",2003,"Hodgkins,NHL","None","SF-36,PTSDIS","Survivor","","Case-control",null,null,null,null,null,null,null,null,"Unspecified"]
[17,"Glossmann,J. P.,et al. (2003). \"Recombinant human erythropoietin,epoetin beta,in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial.\" Ann Hematol 82(8): 469-475.","10.1007/s00277-003-0695-0","Glossmann,J. P.,et al.","Recombinant human erythropoietin,epoetin beta,in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial","The aim of the study was to investigate the effects of erythropoietin (epoetin beta) on red blood cell (RBC) transfusions,hemoglobin (Hb) levels,and quality of life (QOL) in patients with relapsed lymphoma treated with an aggressive sequential salvage chemotherapy (SSCT) regimen. Sixty patients with early or late relapsed Hodgkin's disease ( n=39) or first relapse of aggressive non-Hodgkin's lymphoma ( n=21) were randomized to receive epoetin beta 10,000 IE subcutaneously three times a week or no epoetin during salvage chemotherapy. Patients in both study arms received two cycles of DHAP (dexamethasone,high-dose cytarabine,cisplatin); patients in partial remission (PR) or complete remission (CR) then received cyclophosphamide,followed by peripheral blood stem cell (PBSC) harvest,methotrexate plus vincristine,and etoposide. The final myeloablative course was BEAM (carmustine,etoposide,cytarabine,and melphalan) followed by autologous stem cell support. The primary endpoint of the study was the number of RBC units needed during SSCT. In addition,Hb levels and QOL were measured. The mean number of RBC units given in the epoetin beta arm was 4.5 compared to 8.3 in the control arm ( P=0.0134). The mean Hb levels during therapy were 10.4 g/dl in the epoetin beta arm and 9.7 g/dl in the control ( P=0.018). From baseline until BEAM therapy QOL (EORTC QLQ C30) and fatigue (MFI) assessment showed little QOL worsening or stable levels in both arms with a steeper increase of fatigue levels in the control group. Patients with relapsed lymphoma undergoing aggressive chemotherapy and stem cell support benefited from epoetin beta therapy,with a decrease of RBC transfusion requirements and lower rise of fatigue levels.","Ann Hematol 82(Number): 469-475","Germany",2003,"Hodgkins,NHL","Chemotherapy,SCT,Epoetin","EORTC QLQ-C30,MFI","Patient","","RCT",null,null,null,null,null,null,null,null,"Refractory,Aggressive,Early"]
[18,"Guha-Thakurta,N.,et al. (1999). \"Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.\" J Neurooncol 43(3): 259-268.",null,"Guha-Thakurta,N.,et al.","Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients","In anticipation of a consortium study of methotrexate (MTX) therapy provided to patients with primary central nervous system lymphoma (PCNSL) we have provided intravenous MTX without irradiation therapy to 31 nonimmunosuppressed individuals. Twenty (65%) achieved complete response and 11 (35%) partial response to therapy. For the 31 patients the median survival was 30.43 months with an actuarial median follow-up time of 30.69 months. The 2+ year survival was 63% for all patients and 90% for complete responders. Of 375 drug cycles,grade 3 leukopenia was identified in 3 cycles,mucositis in 6 cycles and delayed drug clearance in 47 cycles. Recurrences included brain (9/20) and/or spinal fluid (2/20). The median Karnofsky scale improved from 40 (10-80) prior to therapy to 90 after treatment. Eleven patients,in complete response for a median of 22+ months after diagnosis were evaluated using 4 instruments that assess Quality of Life Functional Assessment of Cancer Therapy - Brain (FACT-BR) modified,Symptom Questionnaire,Social Adjustment Scale-Self-Report and Problem Solving Inventory. Their psychosocial adjustment,well-being and stress coping abilities were comparable to the normative groups. Further there was no evidence of any MTX-induced,Magnetic Resonance Imaging (MRI)-detected encephalopathy in these individuals and there was preservation of clinical cognition and memory. We conclude that therapy with MTX,without radiation can be used in PCNSL patients without limitations of age or pretreatment Karnofsky scores. Further rates of response and median survival approach those of therapies using multiple drugs and radiation,but with a less likely risk of dementia.","J Neurooncol 43(Number): 259-268","USA",1999,"PCNSL","Chemotherapy","KS,FACT-BR,SymQ,SAS,PSI","Patient","","Clinical Trial",null,null,null,null,null,null,null,null,"Unspecified"]
[19,"Hanf,M.,et al. (2016). \"The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.\" BMC Cancer 16(1): 802.","10.1186/s12885-016-2844-6","Hanf,M.,et al.","The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma","BACKGROUND: Mantle Cell Lymphoma (MCL) is often associated with progression,temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MCL is classified as an incurable disease,therapeutic resistance is of great interest. However,knowledge about the biological mechanisms underlying resistance associated with MCL therapies and about associated predictors remains poor. The REFRACT-LYMA Cohort,a multicenter prospective cohort of patients with MCL,is set up to address this limitation. We here describe the study background,design and methods used for this cohort. METHODS/DESIGN: The REFRACT-LYMA Cohort Study aims at including all patients (>18 years old) who are diagnosed with MCL in any stage of the disease and treated in specialized oncology centers in three public hospitals in Northwestern France. Any such patient providing a signed informed consent is included. All subjects are followed up indefinitely,until refusal to participate in the study,emigration or death. The REFRACT-LYMA follow-up is continuous and collects data on socio-economic status,medical status,MCL therapies and associated events (resistance,side effects). Participants also complete standardized quality of life (QOL) questionnaires. In addition,participants are asked to donate blood samples that will support ex vivo analysis of expression and functional assays required to uncover predictive biomarkers and companion diagnostics. If diagnostic biopsies are performed during the course of the disease,extracted biological samples are kept in a dedicated biobank. DISCUSSION: To our knowledge,the REFRACT-LYMA Cohort Study is the first prospective cohort of patients with MCL for whom \"real-life\" medical,epidemiological and QOL data is repeatedly collected together with biological samples during the course of the disease. The integrative cohort at mid-term will be unique at producing a large variety of data that can be used to conceive the most effective personalized therapy for MCL patients. Additionally,the REFRACT-LYMA Cohort puts the medical care of MCL patients in a health and pharmacoeconomic perspective.","BMC Cancer 16(Number): 802","France",2016,"Mantle cell","None","Unspecified","Patient","","Cohort",null,null,null,null,null,null,null,null,"Any"]
[20,"Jensen,R. E.,et al. (2015). \"Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients.\" Qual Life Res 24(10): 2333-2344.","10.1007/s11136-015-0992-9","Jensen,R. E.,et al.","Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients","PURPOSE: To evaluate the validity of the Patient-Reported Outcomes Measurement Information System (PROMIS) physical function measures in a diverse,population-based cancer sample. METHODS: Cancer patients 6-13 months post-diagnosis (n = 4840) were recruited for the Measuring Your Health study. Participants were diagnosed between 2010 and 2013 with non-Hodgkin lymphoma or cancers of the colorectum,lung,breast,uterus,cervix,or prostate. Four PROMIS physical function short forms (4a,6b,10a,and 16) were evaluated for validity and reliability across age and race-ethnicity groups. Covariates included gender,marital status,education level,cancer site and stage,comorbidities,and functional status. RESULTS: PROMIS physical function short forms showed high internal consistency (Cronbach's alpha = 0.92-0.96),convergent validity (fatigue,pain interference,FACT physical well-being all r >/= 0.68),and discriminant validity (unrelated domains all r </= 0.3) across survey short forms,age,and race-ethnicity. Known-group differences by demographic,clinical,and functional characteristics performed as hypothesized. Ceiling effects for higher-functioning individuals were identified on most forms. CONCLUSIONS: This study provides strong evidence that PROMIS physical function measures are valid and reliable in multiple race-ethnicity and age groups. Researchers selecting specific PROMIS short forms should consider the degree of functional disability in their patient population to ensure that length and content are tailored to limit response burden.","Qual Life Res 24(Number): 2333-2344","USA",2015,"NHL","None","PROMIS","Patient","","Validation",null,null,null,null,null,null,null,null,"Any"]
[21,"Jerkeman,M.,et al. (1999). \"CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial.\" Ann Oncol 10(9): 1079-1086.",null,"Jerkeman,M.,et al.","CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial","BACKGROUND: The long-term survival of patients with advanced stage aggressive lymphoma has not improved significantly during the last twenty years. In a randomised trial,the efficacy of MACOP-B,a six-drug weekly chemotherapy regimen,was compared to CHOP,the current standard regimen,in terms of overall and failure-free survival,toxicity and health related quality of life. PATIENTS AND METHODS: Four hundred five patients with aggressive lymphoma,stage II-IV,age 18-67,were randomised to receive either 12 weeks of MACOP-B or 8 courses of CHOP over 24 weeks. Special emphasis was put in the definition of Ann Arbor stage in extranodal disease. A subset of 95 patients also entered a quality of life study,based on the EORTC QLQ-C30. RESULTS: Thirty-one patients were ineligible. Among the remaining 374 patients,the median age was 52 years. According to the age-adjusted International Prognostic Index,37% were 'high-intermediate' or 'high-risk' patients. No difference could be demonstrated,either in overall survival (60% at five years in the MACOP-B group and 59% in the CHOP group) or in failure-free survival (47% at five years with MACOP-B and 44% with CHOP). In terms of quality of life,physical function and global quality of life were more impaired in patients receiving MACOP-B,who also exhibited more non-haematological toxicity. CONCLUSION: No superiority of MACOP-B compared to CHOP could be demonstrated. CHOP remains the treatment of choice in low-risk patients. At present,intensified or experimental treatment should be reserved for high-risk disease.","Ann Oncol 10(Number): 1079-1086","Sweden",1999,"NHL","Chemotherapy","EORTC QLQ-C30","Patient","","RCT",null,null,null,null,null,null,null,null,"Advanced,Aggressive"]
[22,"Jerkeman,M.,et al. (2001). \"Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial.\" Med Oncol 18(1): 85-94.","10.1385/mo:18:1:85","Jerkeman,M.,et al.","Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial","This study was conducted to explore treatment and disease-related effects on health-related quality of life (HRQoL) in patients with aggressive lymphoma,to identify predictors for impaired long-term HRQoL,and to analyze the prognostic value of pretreatment HRQoL. Ninety-five patients with aggressive lymphoma,constituting a subset of a randomized multicenter trial comparing CHOP and MACOP-B,entered a HRQoL study,using the EORTC QLQ-C30 questionnaire. Patient scores were compared to scores from an age- and gender-adjusted reference population sample,and evaluation of the prognostic value of pretreatment QoL scores in relation to clinical prognostic factors was performed. Before treatment,patients exhibited lower scores of global QoL,physical,role,and social functions,and more appetite loss,compared to the reference population. Role functioning improved compared to baseline,but remained depressed compared to the reference group more than 8 mo after end of treatment. By then,the patient group displayed no difference in other HRQoL variables compared to that of the reference population. No reliable predictor for impaired long-term HRQoL could be identified. In multivariate analysis,including the factors of the International Prognostic Index,pretreatment global QoL was an independent prognostic marker for overall survival. In conclusion,in this population with aggressive lymphoma and favorable prognostic features,HRQoL was not substantially affected during the first year after diagnosis. Pretreatment global QoL may constitute a significant prognostic factor,meriting further investigation in prospective studies.","Med Oncol 18(Number): 85-94","Sweden",2001,"NHL","Chemotherapy","EORTC QLQ-C30","Patient","","RCT",null,null,null,null,null,null,null,null,"Aggressive"]
[23,"Kim,S. H.,et al. (2014). \"Health-related quality of life in Korean lymphoma survivors compared with the general population.\" Ann Hematol 93(9): 1531-1540.","10.1007/s00277-014-2091-3","Kim,S. H.,et al.","Health-related quality of life in Korean lymphoma survivors compared with the general population","The objective of this study was to evaluate the health-related quality of life (HRQOL) of lymphoma survivors,to compare it with that of the general population,and to identify its predictors in lymphoma survivors. We enrolled 837 participants (mean age,54.6 years; mean time since diagnosis,6.3 years) with a history of Hodgkin's lymphoma (HL) (n = 58) or non-Hodgkin's lymphoma (NHL) (n = 779) who had been treated at any of three Korean hospitals from 1989 through 2010. For controls,we selected 1,000 subjects randomly from a representative Korean population. We administered the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Hospital Anxiety and Depression Scale. Overall,the HRQOL in both groups of survivors and the general population were comparable,but we observed clinically meaningful worse social functioning in NHL survivors (p < 0.001) and more severe fatigue in HL survivors (p < 0.001) than in the general population. Analysis of covariance revealed no clinically meaningful difference in HRQOL associated with age or sex. Survivors who received peripheral blood stem cell transplants showed clinically meaningful worse role (p = 0.001) and social (p < 0.001) functioning than those who were treated with first-line chemotherapy alone. In multivariate analyses,fatigue,depression,and financial difficulties emerged as the strongest predictors for almost all subscales of functioning and global quality of life. Interventions for alleviating fatigue,depression,and financial difficulties are needed to enhance the HRQOL of Korean lymphoma survivors.","Ann Hematol 93(Number): 1531-1540","South Korea",2014,"Hodgkins,NHL","None","EORTC QLQ-C30,HADS","Survivor","","Case-control",null,null,null,null,null,null,null,null,"Any"]
[24,"Klasa,R. J.,et al. (2002). \"Randomized phase III study of fludarabine phosphate versus cyclophosphamide,vincristine,and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.\" J Clin Oncol 20(24): 4649-4654.",null,"Klasa,R. J.,et al.","Randomized phase III study of fludarabine phosphate versus cyclophosphamide,vincristine,and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen","PURPOSE: To compare in a phase III study the safety and efficacy of fludarabine to that of cyclophosphamide,vincristine,and prednisone (CVP) in recurrent,low-grade,non-Hodgkin's lymphoma after previous response to systemic treatment. PATIENTS AND METHODS: Patients were randomized to fludarabine (25 mg/m(2) intravenously on days 1 to 5,every 28 days) or CVP (cyclophosphamide 750 mg/m(2) and vincristine 1.2 mg/m(2) both intravenously on day 1 and prednisone 40 mg/m(2) orally on days 1 to 5,every 21 days). The primary outcome assessed was progression-free survival (PFS); secondary outcomes included treatment-free survival (TFS),overall survival (OS),treatment-related toxicity,and quality of life (QoL) according to the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire C-30 version 1.0 instrument. RESULTS: Ninety-one patients were randomized,47 to fludarabine and 44 to CVP. There was no difference in response rates,with 64% (complete response [CR],9%) for fludarabine versus 52% (CR,7%) for CVP (P =.72). With a median follow-up of 42 months,median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine. No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95). Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP. Peripheral neuropathy and alopecia were more common with CVP. Patients receiving fludarabine had higher scores for social function (P =.008); no other differences in QoL were detected. CONCLUSION: In recurrent low-grade lymphoma,fludarabine improves PFS,TFS,and social function scores in comparison with CVP but does not improve OS.","J Clin Oncol 20(Number): 4649-4654","Canada",2002,"NHL","Chemotherapy,Rituximab","EORTC QLQ-C30","Patient","","RCT",null,null,null,null,null,null,null,null,"Low grade"]
[25,"Kouroukis,T.,et al. (2004). \"An evaluation of age-related differences in quality of life preferences in patients with non-Hodgkin's lymphoma.\" Leuk Lymphoma 45(12): 2471-2476.","10.1080/10428190400002285","Kouroukis,T.,et al.","An evaluation of age-related differences in quality of life preferences in patients with non-Hodgkin's lymphoma","Health related quality of life is an important outcome measure. With aging,patients may experience changes in physical,socioeconomic and psychological functioning. This pilot study examined whether age influences the level of importance that patients with non-Hodgkin's lymphoma assign to questions addressing aspects of traditional quality of life domains. A questionnaire assessing six domains (physical,appearance,toxicity,social,financial,psychological) with 29 items was given to 76 outpatients with non-Hodgkin's lymphoma. Each question asked how important the content of the item was to the individual. Mean item scores were compared between patients aged < 65 and > 65 years. Reliability ranged from 0.57 (social domain) to 0.83 (physical domain). Test-retest reliability for the entire questionnaire was 0.63. Although there was a suggestion that older patients scored the items relating to faith,appearance to others,intimacy and toxicity trade-offs differently than younger patients,when accounting for multiple comparisons in this study,no apparent differences were seen in any of the items between age groups. It appears that in this group of patients with lymphoma,age does not obviously influence the preferences of patients for items contained in quality of life assessment.","Leuk Lymphoma 45(Number): 2471-2476","Canada",2004,"NHL","None","Unspecified","Patient","","Validation",null,null,null,null,null,null,null,null,"Unspecified"]
[26,"Lee,S.,et al. (2013). \"Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.\" Support Care Cancer 21(3): 841-846.","10.1007/s00520-012-1589-2","Lee,S.,et al.","Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis","PURPOSE: Treatment of non-Hodgkin lymphoma (NHL) with cyclophosphamide,vincristine,doxorubicin and prednisone (CHOP) is known to be associated with a significant risk of febrile neutropenia (FN) of up to 50% [Osby et al. 2003 Blood 101(10): 3840-3848; Lyman and Delgado 2003 Cancer 98(11): 2402-2409]. This study sought to examine the impact of primary granulocyte colony-stimulating factor (GCSF) prophylaxis on the incidence of FN,quality of life and overall cost. METHODS: In this retrospective cohort study,a group of 65 consecutive patients who received CHOP chemotherapy for NHL between December 2006 and October 2009 was studied. Patients either received filgrastim (300 mcg,average of seven doses),pegylated filgrastim (6 mg,single dose),or no GCSF prophylaxis. In addition,19 patients were asked to complete Functional Assessment of Cancer Therapy: General quality-of-life questionnaires. RESULTS: Overall,patients who received primary GCSF prophylaxis had significantly fewer FN compared to those who did not (5 vs. 60%,p < 0.0001; numbers needed to treat of 1.8; 95% confidence interval,1.6-2.9). Cost-benefit analysis showed that the GCSF prophylaxis was associated with only a small increase in direct financial cost ($238 NZD [US$189] more to give primary GCSF prophylaxis per patient vs. no prophylaxis). The quality of life assessment showed that the patients' quality of life scores were similar to the published data from the validation study population (466 patients with mixed cancers) for Functional Assessment of Cancer Therapy. CONCLUSIONS: Our study shows that primary GCSF prophylaxis is effective in preventing FN in patients receiving CHOP chemotherapy for NHL without adversely affecting their quality of life,and is cost effective.","Support Care Cancer 21(Number): 841-846","New Zealand",2013,"NHL","Filgrastim,Chemotherapy","FACT-G","Patient","","Cohort",null,null,null,null,null,null,null,null,"Unspecified"]
[27,"Martinez,J. M.,et al. (2014). \"Mucositis care in acute leukemia and non-Hodgkin lymphoma patients undergoing high-dose chemotherapy.\" Support Care Cancer 22(9): 2563-2569.","10.1007/s00520-014-2199-y","Martinez,J. M.,et al.","Mucositis care in acute leukemia and non-Hodgkin lymphoma patients undergoing high-dose chemotherapy","PURPOSE: This study intends to provide new insights into the incidence and care of mucositis by the epidemiological characterization of patients with hematological malignancy treated at our institution. It also aims to understand the effectiveness of several treatments used. METHODS: This is a longitudinal observational single-center study-convenience sample-which includes malignant hematologic inpatients submitted to high-dose CT from February to August 2012. We registered epidemiological data,diagnosis,oral mucositis daily questionnaire (OMDQ),World Health Organization (WHO) oral toxicity scale,and supportive medications used for mucositis. RESULTS: We evaluated 30 patients who had 73 episodes of hospitalization,having recorded the development of mucositis in 21.9 % (n = 16) episodes (22 patients with acute leukemia (AL) and 8 patients with non-Hodgkin lymphoma (NHL)). Grades 3-4 mucositis was reported in 4.1 % of the total episodes. The results of OMDQ showed some limitations in the quality of life,of patients with mucositis,related with the ability to eat and drink due to mouth pain (p < 0.001). In patients with NHL and AL,neutropenia entails an increased risk of mucositis (p < 0.001). Patients who did not initiate early prophylaxis with conservative measures developed mucositis earlier (p < 0.05). CONCLUSIONS: The incidence of mucositis is high,being reported mainly in AL patients,with limitations in quality of life. Grade 4 neutropenia increases mucositis risk. Early prophylaxis with basic oral care may delay mucositis. Further studies are crucial to characterize mucositis epidemiology,physiopathology,and its management.","Support Care Cancer 22(Number): 2563-2569","Portugal",2014,"NHL","Chemotherapy","OMDQ,WHO-OTS","Patient","","Cohort",null,null,null,null,null,null,null,null,"Unspecified"]
[28,"Merli,F.,et al. (2004). \"Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.\" Haematologica 89(8): 973-978.",null,"Merli,F.,et al.","Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi","BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate quality of life (QOL) in a group of elderly patients (> 65 years) with aggressive non-Hodgkin's lymphoma (NHL) treated with chemotherapy regimens containing anthracyclines. DESIGN AND METHODS: QOL was evaluated in a population of elderly patients with aggressive NHL enrolled in a phase III clinical trial run by the Intergruppo Italiano Linfomi (IIL) from 1996 to 1999 to compare two different anthracycline-containing regimens (mini-CEOP vs P-VEBEC). The EORTC-QLQ-C30 questionnaire,which has already been validated in oncology,was used. The questionnaire was administered at the time of diagnosis,half way through the chemotherapy and at the time of restaging. RESULTS: Ninety-one patients completed pre-therapy and post-therapy questionnaires and they are the subject of this report. Baseline QOL assessment showed a strong correlation of poor values of QOL with anemia and high risk according to the International Prognostic Index (IPI). At the end of treatment no functional scales showed worse values. A significant improvement was observed for pain (p=0.003),appetite (p=0.006),sleep (p=0.015) and global health (p=0.027). Considering only the 50 patients who achieved a complete remission (CR),an improvement was also recorded for emotional state (p=0.10),role (p=0.05),constipation (p=0.04) and global QOL (p=0.05). INTERPRETATION AND CONCLUSIONS: The EORTC-QLQ-C30 is feasible even in a population of elderly patients,in whom it had never been tested before. The improvement of QOL at the end of the treatment demonstrated that the symptoms of the disease have a greater negative influence on the patient's life than do the side effects of the therapy.","Haematologica 89(Number): 973-978","Italy",2004,"NHL","Chemotherapy","EORTC QLQ-C30","Patient","","RCT",null,null,null,null,null,null,null,null,"Aggressive"]
[29,"Mounier,N.,et al. (2000). \"Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).\" Blood 95(12): 3687-3692.",null,"Mounier,N.,et al.","Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA)","Evaluating high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in term of both duration and quality of life (QOL) presents major interests for patients with non-Hodgkin lymphoma. The quality-adjusted time without symptom and toxicity (Q-TWiST) methodology was applied to the LNH87-2 trial comparing HDT with ASCT versus sequential chemotherapy in 541 patients in first complete remission (CR). Overall survival (OS) and disease-free survival (DFS) curves were used to estimate duration of 4 health states: acute short-term toxicity (Tox1),secondary toxicity (Tox2),time without symptom and toxicity (TWiST),and relapse (Rel). Areas under survival curves (AUC) were retrospectively weighted according to QOL coefficients. HDT increased,but not significantly,TWiST (+2. 4 months in AUC,P =.17) and decreased Rel (-3 months,P <.01). Survival estimates did not differ between the 2 treatments (AUC 47.7 months for OS,39.7 months for DFS). High-risk patients treated by HDT versus chemotherapy had a significant benefit in DFS (AUC 28.8 versus 24.9 months,P <.01) but not in OS (AUC 37.3 versus 36 months,P =.27). Sensitivity analysis,performed by varying QOL coefficients,demonstrated significant quality-adjusted survival gain in high-risk patients treated by HDT. In low-risk patients,a diagram provided an aid to clinical decision-making. This analysis supports the use of HDT in these patients with adverse prognostic factors in the first CR,even after adjusting for QOL using the Q-TWiST method. (Blood. 2000;95:3687-3692)","Blood 95(Number): 3687-3692","France",2000,"NHL","Chemotherapy,SCT","Q-TWiST","Patient","","RCT",null,null,null,null,null,null,null,null,"Any"]
[30,"Murthy,V.,et al. (2008). \"Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study.\" Clin Lymphoma Myeloma 8(4): 241-245.","10.3816/CLM.2008.n.032","Murthy,V.,et al.","Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study","PURPOSE: To confirm the efficacy of low-dose involved-field radiation therapy (LD-IFRT) as palliative treatment in patients symptomatic from advanced lymphoma. PATIENTS AND METHODS: A total of 36 patients (47 sites),received 4 Gy in 2 fractions to the lymphoma with a 1.5-2-cm margin. Pathology subtypes included 29 (62%) sites with indolent lymphoma and 18 (36%) sites with aggressive lymphoma histology. Bulky disease was seen in 22 (48%) sites and,of these,6 sites had disease > 10 cm. A median of 3 previous chemotherapy regimens (range,0 to 9 regimens) preceded LD-IFRT. The primary endpoint of the study was in-field lymphoma control. Patients completed the European Organization for the Research and Treatment of Cancer QLQ-C30 quality of life (QOL) questionnaire before RT and at 3-4 weeks after treatment. RESULTS: The overall response rate (RR) at 1-3 months after the RT was 75%. A complete remission (CR) was observed in 13 patients (36%) lasting up to a maximum of 31.3 months and ongoing at analysis. A partial remission (PR) was achieved in 14 patients (39%) lasting up to 10 months. The response rate for non-diffuse large B-cell lymphoma (DLBCL) sites was 86%,while it was 50% for sites with DLBCL histology. Median time to local progression for the entire group was 15 months. There was no statistical difference between the QOL before and after LD-IFRT. CONCLUSION: LD-IFRT is an effective and easy treatment for patients with advanced lymphoma that can be repeated at previously irradiated sites,a particularly useful attribute because of the relapsing nature,especially of advanced follicular subtypes.","Clin Lymphoma Myeloma 8(Number): 241-245","UK",2008,"DLBCL,NHL","Radiotherapy","EORTC QLQ-C30","Patient","","Clinical Trial",null,null,null,null,null,null,null,null,"Advanced"]
[31,"Numbenjapon,T.,et al. (2002). \"Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.\" J Med Assoc Thai 85(11): 1156-1163.",null,"Numbenjapon,T.,et al.","Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma","Standard-dose (2 mg/day) oral granisetron seems to have more antiemetic efficacy than that of high-dose (0.5-1 mg/kg/dose) metoclopramide in moderately emetogenic chemotherapy. However,the cost of oral granisetron is much higher than that of metoclopramide so the authors tried to overcome this disadvantage by dose reduction and adding dexamethasone to enhance the antiemetic effect of oral granisetron. Twenty four young patients (aged < 50 years),with non-Hodgkin's lymphoma receiving CHOP-therapy were enrolled and evaluated in a randomized,double-blind,crossover study comparing the antiemetic efficacy,toxicity and patients' preference of a combination of low-dose oral granisetron plus intravenous dexamethasone (gran/dex) with a combination of high-dose metoclopramide plus intravenous dexamethasone (met/dex) on days 1-5 after chemotherapy. The acute,delayed (day 2-5) and 5-day total control of nausea and vomiting in the gran/dex group were significantly higher than those of the met/dex group (75.0% vs 25.0%; p-value = 0.004,79.2% vs 33.3%; p-value = 0.007 and 75.0% vs 25.0%; p-value = 0.004,respectively). Except for extrapyramidal reactions in the met/dex group,the side effects in both groups were comparable. The mean total score of antiemetic preference in the gran/dex group was also significantly higher than that of the met/dex group (9.0 vs 7.5; p-value = 0.004). In conclusion,low-dose oral granisetron combined with intravenous dexamethasone had significantly higher protective effects against both acute and delayed nausea and vomiting induced by CHOP-therapy. Thus,this regimen may be considered as an alternative outpatient antiemetic treatment for young patients with non-Hodgkin's lymphoma.","J Med Assoc Thai 85(Number): 1156-1163","Thailand",2002,"NHL","Chemotherapy,Granisetron","Unspecified","Patient","","RCT",null,null,null,null,null,null,null,null,"Unspecified"]
[32,"Olivieri,A.,et al. (2001). \"Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience.\" Bone Marrow Transplant 27(11): 1189-1195.","10.1038/sj.bmt.1703034","Olivieri,A.,et al.","Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience","Between May 1994 and May 2000,we autotransplanted 48 consecutive patients,21 females and 27 males aged over 60 years (range: 60-78,median: 63). Sixteen patients had multiple myeloma (MM),14 high-grade non-Hodgkin's lymphoma (HGNHL),six low-grade non-Hodgkin's lymphoma (LGNHL),nine acute myeloid leukemia (AML),one chronic lymphocytic leukemia (CLL),one Hodgkin's disease (HD) and one breast cancer; the performance status (WHO) was 0-1. Seventeen patients were in 1st CR (35.4%) and one in 2nd CR (2.1%),25 in PR (52.1%),while five patients had been transplanted with progressive disease (10.4%); seven patients with MM received a double transplant. Patients received high-dose therapy including melphalan alone (13) or associated with other drugs (26),busulfan-cyclophosphamide (three),BEAM (11) and TBI (two). All patients took a median of 11 (range: 8-25) days to reach neutrophils >500/microl,13 (range: 9-83) days to reach platelets > 20,000/microl and 17 (range: 11-83) days to reach platelets > 50,000/microl. Hematological toxicity,hospital stay and supportive care did not differ from those of a cohort of younger patients. At present,31 patients are alive (14 in CR,five in PR,five in PD and seven in relapse) and 16 died from PD at a median follow-up of 37 months (1-67). Only one patient died from transplant-related toxicity. Quality of life,evaluated using a QLQ-C30 questionnaire in 25 patients at day +90,was good. In our experience PBPC mobilization and transplantation is feasible in patients aged > or = 60 years and the toxicity of this procedure is acceptable,with an early transplant-related mortality of 1.8%; therefore patients with hematological malignancies potentially curable with high-dose therapy (HDT) should also be candidates for HDT.","Bone Marrow Transplant 27(Number): 1189-1195","Italy",2001,"NHL,Hodgkins","SCT","EORTC QLQ-C30","Patient","","Cohort",null,null,null,null,null,null,null,null,"High grade,Low grade"]
[33,"Olney,H. J.,et al. (2014). \"Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated,rituximab-exposed,indolent non-Hodgkin lymphoma.\" Leuk Lymphoma 55(12): 2754-2760.","10.3109/10428194.2014.894190","Olney,H. J.,et al.","Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated,rituximab-exposed,indolent non-Hodgkin lymphoma","Radioimmunotherapy offers a unique treatment modality for indolent non-Hodgkin lymphoma (iNHL). We report 5-year outcomes and quality of life (QoL) in tositumomab and iodine(131)-tositumomab (TST/I(131)-TST) treated patients with iNHL previously treated with rituximab. Ninety-three patients with >/= 2 lines of therapy,responding to last treatment,were enrolled at 12 Canadian centers. Median age,disease duration and number of prior therapies (#PTx) were 59 years,4.9 years and 5,respectively. Outcomes were response rate (43.0%),median progression-free survival (mPFS) (12.0 months),5-year PFS (27%) and median overall survival (OS) (59.8 months). In responders,median response duration and mPFS were not reached. Improvements in QoL were seen by week 7. In univariate and multivariate analyses,hemoglobin,disease bulk and body surface area (BSA) predicted OS,whereas lactate dehydrogenase (LDH),bulk,BSA and #PTx predicted PFS. Most common adverse events (AEs) were fatigue and nausea. Two cases of myelodysplastic syndrome (MDS) were reported. TST/I(131)-TST was associated with durable responses,and prolonged OS and PFS in heavily pretreated iNHL.","Leuk Lymphoma 55(Number): 2754-2760","Canada",2014,"NHL","Tositumomab","Unspecified","Patient","","Clinical Trial",null,null,null,null,null,null,null,null,"Unspecified"]
[34,"Park,Y. H.,et al. (2006). \"CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation.\" Leuk Lymphoma 47(7): 1253-1259.","10.1080/10428190600556239","Park,Y. H.,et al.","CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation","We aimed to define the role of cyclophosphamide,vincristine,doxorubicin,prednisone (CHOP) followed by involved field radiotherapy (IFRT) for treating localized primary gastric diffuse large B-cell lymphoma (DLBCL). Newly diagnosed patients with localized primary gastric DLBCL were to receive four cycles of CHOP followed by IFRT of 40.0 Gy. At 1 year after the completion of treatment,patients filled out the EORTC Quality of Life Questionnaire specified for stomach cancer (QLQ-C30-STO22). Fifty evaluable patients (25 men,25 women) were included. The median age was 54.5 years (range,21 - 73 years. The overall response rate to the CHOP was 94% (95% confidence interval [CI],87 - 100) in the intent-to-treat population. Forty-one of the 50 patients (82%; 95% CI,71 - 93) achieved complete remission (CR). After the completion of radiotherapy,five patients who were in PR following chemotherapy eventually attained CR. The overall complete response rate was thus 92% (95% confidence interval,84 - 99). With a median follow-up period of 30 months,the 2-year progression-free and overall survival rate was 92% and 92%,respectively. The gastric function was well preserved with negligible stomach-related symptoms at 1 year after the completion of treatment. This organ-preserving combined treatment is highly effective and well tolerated for the patients with localized gastric DLBCL.","Leuk Lymphoma 47(Number): 1253-1259","South Korea",2006,"DLBCL","Radiotherapy,Chemotherapy","EORTC QLQ-STO22","Patient","","Clinical Trial",null,null,null,null,null,null,null,null,"Unspecified"]
[35,"Razavi, D., et al. (1992). \"Screening for psychiatric disorders in a lymphoma out-patient population.\" Eur J Cancer 28a(11): 1869-1872.",null,"Razavi, D., et al.","Screening for psychiatric disorders in a lymphoma out-patient population","The Hospital Anxiety and Depression Scale (HADS), a four-point, 14-item self-assessment questionnaire, was tested as a screening method for psychiatric disorders in a sample of 117 Hodgkin's lymphoma and non-Hodgkin lymphoma consecutive out-patients. A receiver operating characteristic (ROC) analysis was performed, giving the relationship between the true positive rate (sensitivity) and the false positive rate (1--specificity). This makes it possible to choose an optimal cut-off score that takes into account the costs and benefits of treatment of psychiatric disorders (mainly adjustment, depressive and anxiety disorders) in a lymphoma out-patient population. A cut-off point of 10 gave 84% sensitivity and 66% specificity. HADS appears in this study to be a well accepted, simple, sensitive and specific tool.","Eur J Cancer 28a(Number): 1869-1872","Belgium",1992,"Hodgkins,NHL","None","HADS","Patient","","Validation",null,null,null,null,null,null,null,null,"Unspecified"]
[36,"Reeve, B. B., et al. (2009). \"Impact of cancer on health-related quality of life of older Americans.\" J Natl Cancer Inst 101(12): 860-868.","10.1093/jnci/djp123","Reeve, B. B., et al.","Impact of cancer on health-related quality of life of older Americans","BACKGROUND: The impact of cancer on health-related quality of life (HRQOL) is poorly understood because of the lack of baseline HRQOL status before cancer diagnosis. To our knowledge, this is the first population-based study to quantify the nature and extent of HRQOL changes from before to after cancer diagnosis for nine types of cancer patients and to compare their health with individuals without cancer. METHODS: The Surveillance, Epidemiology, and End Results cancer registry data were linked with the Medicare Health Outcomes Survey (MHOS) data; data were collected from Medicare beneficiaries who were aged 65 years and older from 1998 through 2003. Cancer patients (n = 1432; with prostate, breast, colorectal, lung, bladder, endometrial, or kidney cancers; melanoma; or non-Hodgkin lymphoma [NHL]) were selected whose first cancer diagnosis occurred between their baseline and follow-up MHOS assessments. Control subjects without cancer (n = 7160) were matched to cancer patients by use of propensity scores that were estimated from demographics and comorbid medical conditions. Analysis of covariance models were used to estimate changes in HRQOL as assessed with the Medical Outcomes Study Short Form-36 survey (mean score = 50, SD = 10). All statistical tests were two-sided. RESULTS: Patients with all cancer types (except melanoma and endometrial cancer) reported statistically significant declines in physical health (mean scores: prostate cancer = -3.4, 95% confidence interval [CI] = -2.5 to -4.2; breast cancer = -3.5, 95% CI = -2.5 to -4.5; bladder cancer = -4.3, 95% CI = -2.5 to -6.1; colorectal cancer = -4.4, 95% CI = -3.3 to -5.5; kidney cancer = -5.7, 95% CI = -3.2 to -8.2; NHL = -6.7, 95% CI = -4.4 to -9.1; and lung cancer = -7.5, 95% CI = -5.9 to -9.2) compared with the control subjects (mean score = -1.8, 95% CI = -1.6 to -2.0) (all P < .05). However, only lung (mean score = -5.4, 95% CI = -3.5 to -7.2), colorectal (mean score = -3.5, 95% CI = -2.2 to -4.7), and prostate (mean score = -2.8, 95% CI = -1.8 to -3.7) cancer patients showed statistically significant decreases in mental health relative to the mean change of the control subjects (mean score = -1.2, 95% CI = -0.9 to -1.4) (all P < .05). CONCLUSION: These findings provide validation of the specific deleterious effects of cancer on HRQOL and an evidence base for future research and clinical interventions aimed at understanding and remediating these effects.","J Natl Cancer Inst 101(Number): 860-868","USA",2009,"NHL","None","SF-36","Patient","","Cohort",null,null,null,null,null,null,null,null,"Unspecified"]
[37,"Ribi, K., et al. (2017). \"Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.\" Support Care Cancer 25(9): 2833-2842.","10.1007/s00520-017-3698-4","Ribi, K., et al.","Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma","PURPOSE: To evaluate the efficacy and tolerability of chemotherapy, a geriatric assessment is recommended in elderly patients with cancer. We aimed to characterize and compare patients with aggressive lymphoma by objective response and survival status based on pre-treatment cancer-specific geriatric (C-SGA) and quality of life (QoL) assessments. METHODS: Patients not eligible for anthracycline-based first-line therapy or intensive salvage regimens completed C-SGA and QoL assessment before and after a rituximab-bendamustine-lenalidomide (R-BL) treatment in a phase II clinical trial. Clinical outcomes were compared based on pre-treatment individual and summary C-SGA measures, their cutoff-based subcategories and QoL indicators, using Wilcoxon rank sum or chi-square tests. RESULTS: A total of 57 patients (41 included in the clinical trial) completed a C-SGA. Participants with pre-treatment impaired functional status (Vulnerable Elders Survey-13 score >/=3) were more likely to experience worse outcomes: a higher proportion were non-responders, died before the median follow-up of 31.6 months (interquartile range (IQR) 27.9-37.9) or died during treatment. Non-responders were patients categorized as having possible depression (Geriatric Depression Scale-5 score >/=2) and with worse QoL scores for functional performance. Patients with worse C-SGA summary scores and with greater tiredness were more likely to die during treatment. CONCLUSION: A pre-treatment impaired functional status is an important factor with respect to clinical outcomes in patients receiving an R-BL regimen. Individual geriatric and related QoL domains showed similar associations with clinical outcomes. Whether interventions targeting specific geriatric dimensions also translate in better symptom- or domain-specific QoL warrants further research.","Support Care Cancer 25(Number): 2833-2842","USA,Switzerland,Italy",2017,"B-cell","Rituximab,Chemotherapy,Lenalidomide","C-SGA,VES-13,GDS-13","Patient","","Clinical Trial",null,null,null,null,null,null,null,null,"Unspecified"]
[38,"Ruan, J., et al. (2015). \"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.\" N Engl J Med 373(19): 1835-1844.","10.1056/NEJMoa1505237","Ruan, J., et al.","Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","BACKGROUND: Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy. METHODS: We conducted a single-group, multicenter, phase 2 study with induction and maintenance phases. During the induction phase, lenalidomide was administered at a dose of 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles; the dose was escalated to 25 mg daily after the first cycle if no dose-limiting adverse events occurred during the first cycle and was reduced to 15 mg daily during the maintenance phase. Rituximab was administered once weekly for the first 4 weeks and then once every other cycle until disease progression. The primary end point was the overall response rate. Secondary end points included outcomes related to safety, survival, and quality of life. RESULTS: A total of 38 participants were enrolled at four centers from July 2011 through April 2014. The median age was 65 years. On the basis of the Mantle Cell Lymphoma International Prognostic Index scores, the proportions of participants with low-risk, intermediate-risk, and high-risk disease at baseline were similar (34%, 34%, and 32%, respectively). The most common grade 3 or 4 adverse events were neutropenia (in 50% of the patients), rash (in 29%), thrombocytopenia (in 13%), an inflammatory syndrome (\"tumor flare\") (in 11%), anemia (in 11%), serum sickness (in 8%), and fatigue (in 8%). At the median follow-up of 30 months (through February 2015), the overall response rate among the participants who could be evaluated was 92% (95% confidence interval [CI], 78 to 98), and the complete response rate was 64% (95% CI, 46 to 79); median progression-free survival had not been reached. The 2-year progression-free survival was estimated to be 85% (95% CI, 67 to 94), and the 2-year overall survival 97% (95% CI, 79 to 99). A response to treatment was associated with improvement in quality of life. CONCLUSIONS: Combination biologic therapy consisting of lenalidomide plus rituximab was active as initial therapy for mantle-cell lymphoma. (Funded by Celgene and Weill Cornell Medical College; ClinicalTrials.gov number, NCT01472562.).","N Engl J Med 373(Number): 1835-1844","USA",2015,"Mantle cell","Lenalidomide,Rituximab","Unspecified","Patient","","Clinical Trial",null,null,null,null,null,null,null,null,"Unspecified"]
[39,"Schimmer, A. D., et al. (2002). \"The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant.\" Support Care Cancer 10(3): 247-252.","10.1007/s00520-001-0316-1","Schimmer, A. D., et al.","The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant","The number of long-term survivors of autologous blood and marrow transplantation (ABMT) is increasing, but little is known about the models of care used to follow these patients. Such information would help in comparison of different methods of follow-up and allow other centers to create programs to follow their survivors. Here we describe a multidisciplinary long-term follow-up clinic for survivors of ABMT and report patient satisfaction with the clinic and economic analysis 1.5 years after its inception. In its first 1.5 years of operation, 83 new patients were seen in the clinic. Patients were evaluated a median of 4.0 years after ABMT (range 4.9 months to 12 years) and were a median of 48.5 years (range 22.5-69.0 years) old. Patients received their ABMT for non-Hodgkin's lymphoma ( n=26), Hodgkin's disease ( n=18), acute myeloid leukemia ( n=18), multiple myeloma ( n=15), breast cancer ( n=5), or desmoplastic round-cell tumor ( n=1). Patient satisfaction was assessed 1.5 years after the establishment of the long-term follow-up clinic by means of a self-report questionnaire. Seventy-five percent of patients returned the survey. Waiting times in the clinic were short, with 70% of patients seen within 30 minutes of arrival. Overall, patients were very satisfied with the new clinic model, with 85% patients reporting that the clinic met their expectations. An economic analysis indicated that the estimated annual cost of operating the clinic was approximately $53,000, which translates into $440 per patient visit, $962 per new patient or $172 per patient visit with the clinic operating at peak capacity. In conclusion, we present an inexpensive model of care for ABMT survivors that can be extended to adult survivors of malignancy not treated by ABMT.","Support Care Cancer 10(Number): 247-252","Canada",2002,"Hodgkins,NHL","SCT","Unspecified","Survivor","","Cross-sectional",null,null,null,null,null,null,null,null,"Any"]
[40,"Shin, D. Y., et al. (2016). \"Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.\" Cancer Chemother Pharmacol 77(4): 865-873.","10.1007/s00280-016-3005-y","Shin, D. Y., et al.","Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis","PURPOSE: Mantle cell lymphoma (MCL) is a disease that frequently relapses and primarily affects elderly people. We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL. METHODS: The treatment schedule was composed of four cycles of induction treatment with V-FND and subsequent consolidation therapy involving autologous hematopoietic stem cell transplantation or six cycles of vorinostat maintenance. QoL was assessed using EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) every 2 cycles. RESULTS: Data from a total of 20 patients were collected for an interim analysis. The median age was 67 years (range 49-75), and 14 or the patients (70 %) were male. The full course of V-FND induction treatment was completed in 11 patients, but only three completed all six cycles of maintenance therapy. Response to V-FND was not available in two patients. Among the other 18 patients, the objective response rate was 77.8 % (complete response in five patients + partial response in nine patients). Median progression-free survival was 9.3 months [95 % confidence interval (CI) 4.0-12.3]. Fifteen patients (75 %) experienced grade 3/4 toxicities. Analysis of QoL demonstrated significant deterioration of social functioning (p = 0.01), and significant aggravation of fatigue and nausea/vomiting (p = 0.04 and 0.01, respectively) after two cycles of V-FND induction. CONCLUSIONS: V-FND is effective in patients with relapsed or refractory MCL. However, significant toxicities were hurdles to sustained V-FND therapy.","Cancer Chemother Pharmacol 77(Number): 865-873","South Korea",2016,"Mantle cell","Vorinostat,Chemotherapy","EORTC QLQ-C30","Patient","","Clinical Trial",null,null,null,null,null,null,null,null,"Refractory"]
[41,"Silverman, D. H., et al. (2004). \"Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues.\" Cancer Treat Rev 30(2): 165-172.","10.1016/j.ctrv.2003.07.006","Silverman, D. H., et al.","Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues","Anti-CD20 antibodies radiolabeled with I-131 tositumomab (Bexxar) or Y-90-Ibritumomab tiuxetan (Zevalin), are similarly efficacious in treating chemotherapy-refractory non-Hodgkin's lymphoma. The relative merits of both radioimmunoconjugates with respect to practical issues, including radiation exposure risk, the advantages and disadvantages of the respective isotopes and other parameters that could affect a patient's quality of life are also important. I-131-labeled antibody treatment often requires inpatient hospitalization due to the inherent risk of exposure from gamma emissions, and patients and families should follow detailed instructions to prevent undue exposure. Other issues relevant to patients and medical staff include: (1) the need for dosimetry to calculate effective therapeutic doses of I-131-labeled anti-B1 (Bexxar) compared with the lack of correlation of dosimetry with marrow toxicity for IDEC-Y2B8 (Zevalin), (2) determining the acute and long-term toxic effects of each agent, (3) time commitments for nuclear medicine staff and patients along with the relative ease of administration, and (4) cost considerations. A more challenging future issue will be to determine the optimal use of Bexxar and Zevalin alone and in combination in ways that will significantly affect patient outcome without compromising quality of life. The recent demonstration of significant response rates in patients having chemotherapy-refractory Non-Hodgkin's Lymphoma (NHL) using both on I-131- and Y-90-labeled anti-CD20 antibodies with minimal toxicity has stimulated comparison of I-131 tositumomab (Bexxar) and Ibritumomab tiuxetan (Zevalin) in terms of radiation safety requirements, the advantages and disadvantages of both radionuclides, and quality-of-life (QOL) issues. Therefore, in this review, we attempt to compare the relative merits of (Bexxar and Zevalin) and address important practical considerations that may influence patient and physician choices regarding treatment using these agents.","Cancer Treat Rev 30(Number): 165-172","USA",2004,"NHL","Tositumomab,Ibritumomab","Unspecified","Patient","","Review",null,null,null,null,null,null,null,null,"Refractory"]
[42,"Smith, S. K., et al. (2008). \"Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors.\" J Clin Oncol 26(6): 934-941.","10.1200/jco.2007.12.3414","Smith, S. K., et al.","Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors","PURPOSE: A large body of evidence suggests that being diagnosed with and treated for cancer adversely affects functioning and quality of life, yet less is known about longer term outcomes. Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those that are amenable for screening and modifiable. PATIENTS AND METHODS: A total of 886 NHL survivors identified from the cancer registries of two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging from 2 to 44 years postdiagnosis. Survivors were mailed a survey that assessed PTSD symptoms and quality of life. RESULTS: Participants averaged 10.2 years postdiagnosis, and most (61%) reported no PTSD symptoms. The adjusted prevalence for full PTSD was 7.9%, with an additional 9.1% meeting criteria for partial PTSD. Modifiable risk factors that were independently associated with PTSD in multiple linear regression included less social support, negative appraisals of life threat and treatment intensity, and more employment and insurance issues. Additionally, several demographic characteristics (nonwhite race, less education, and younger age) and clinical or health-related factors (active disease, more recent diagnosis, and more comorbidity) were independently associated with PTSD. CONCLUSION: Although only 8% of survivors met PTSD diagnostic criteria, the impact of a cancer diagnosis and treatment persists for many survivors, as evidenced in 39% of this sample. Early identification of those at risk could enable treatment to minimize PTSD symptomatology.","J Clin Oncol 26(Number): 934-941","USA",2008,"NHL","None","Unspecified","Survivor","","Cross-sectional",null,null,null,null,null,null,null,null,"Any"]
[43,"Stalfelt, A. M. and B. Wadman (1993). \"Assessing quality of life in leukemia: presentation of an instrument for assessing quality of life in patients with blood malignancies.\" Qual Assur Health Care 5(3): 201-211.",null,"Stalfelt, A. M. and B. Wadman","Assessing quality of life in leukemia: presentation of an instrument for assessing quality of life in patients with blood malignancies","The Life Ingredient Profile (LIP)--a new instrument for iterated quality of life assessments in patients with haematological malignancies--is presented. It is intended to reflect the patient's estimation of the symptoms of disease as well as the side-effects of treatment and is designed for comparing different regimens of chemotherapy. In a pilot study of 35 patients with myeloma, lymphoma and acute leukaemia, the LIP showed good validity, reliability and sensitivity to change. It was easy to apply and the structured interviews took only 10-20 min. LIP appears to assess important dimensions of quality of life without being a burden to the patient or the nursing staff.","Qual Assur Health Care 5(Number): 201-211","Sweden",1993,"NHL","Chemotherapy","LIP","Patient","","Validation",null,null,null,null,null,null,null,null,"Unspecified"]
[44,"Stienen, J. J., et al. (2013). \"Improvement of hospital care for patients with non-Hodgkin's lymphoma: protocol for a cluster randomized controlled trial (PEARL study).\" Implement Sci 8: 77.","10.1186/1748-5908-8-77","Stienen, J. J., et al.","Improvement of hospital care for patients with non-Hodgkin's lymphoma: protocol for a cluster randomized controlled trial (PEARL study)","BACKGROUND: Malignant lymphomas constitute a diverse group of cancers of lymphocytes. One well-known disease is Hodgkin's lymphoma; the others are classified as non-Hodgkin's lymphoma (NHL). NHLs are the most common hematologic neoplasms in adults worldwide, and in 2012 over 170,000 new cases were estimated in the United States and Europe.In previous studies, several practice gaps in hospital care for patients with NHL have been identified. To decrease this variation in care, the present study aims to perform a problem analysis in which barriers to and facilitators for optimal NHL care will be identified and, based on these findings, to develop (tailored) improvement strategies. Subsequently, we will assess the effectiveness, feasibility and costs of the improvement strategies. METHODS/DESIGN: Barriers and facilitators will be explored using the literature, using interviews and questionnaires among physicians involved in NHL care, and patients diagnosed with NHL. The results will be used to develop a tailored improvement strategy. A cluster randomized controlled trial involving 19 Dutch hospitals will be conducted. Hospitals will be randomized to receive either an improvement strategy tailored to the barriers and facilitators found or, a standard strategy of audit and feedback.The effects of both strategies will be evaluated using previously developed quality indicators. Adherence to the indicators will be measured before and after the intervention period based on medical records from newly diagnosed NHL patients. To study the feasibility of both strategies, a process evaluation will be additionally performed. Data about exposure to the different elements of the strategies will be collected using questionnaires. Economic evaluation from a healthcare perspective will compare the two implementation strategies, where the costs of the implementation strategy and changes in healthcare consumption will be assessed. DISCUSSION: The presence of variation in the use of diagnostic tests, treatment, and follow-up between different physicians in different hospitals in the Netherlands is important for patients. To reduce the existing variation in care, implementation of tailored interventions to improve NHL care is necessary. TRIAL REGISTRATION: This trial is registered at ClinicalTrial.gov as the PEARL study, registration number NCT01562509.","Implement Sci 8(Number): 77","Netherlands",2013,"NHL","None","Unspecified","Patient","","Protocol",null,null,null,null,null,null,null,null,"Unspecified"]
[45,"Tchen, N., et al. (2002). \"Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients.\" Crit Rev Oncol Hematol 43(3): 219-226.",null,"Tchen, N., et al.","Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients","In the elderly population, cancer treatment aims to cure and/or maintain Quality of Life (QoL). However, there is little QoL data to provide evidence for QoL benefits for some of the cancer treatments. This pilot study developed valid QoL questionnaires in French, for patients over 65 years with a diagnosis of large cell lymphoma, part of the Lymage phase II study. They were asked to complete two questionnaires, the Medical Outcomes Study Short Form 20 (MOS SF20; generic) and the Rotterdam symptom checklist (RSCL; cancer-specific). Between June 1995 and April 1997, questionnaires were returned by 63 of 89 patients. This article reports the process undertaken to adapt the English version to a French setting, and provides the results of factor analysis, convergent and discriminant validity and reliability. Our data suggest that QoL questionnaires can be used in elderly patients. These two questionnaires are validated in French and would help us to analyse the QoL of elderly patients with the development of new treatments as done in the Lymage study.","Crit Rev Oncol Hematol 43(Number): 219-226","France",2002,"NHL","None","SF-20,RSCL","Patient","","Validation",null,null,null,null,null,null,null,null,"Unspecified"]
[46,"van Agthoven, M., et al. (2001). \"Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.\" Eur J Cancer 37(14): 1781-1789.",null,"van Agthoven, M., et al.","Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial","The cost-effectiveness of autologous peripheral blood stem cell transplantation (PBSCT) compared with autologous bone marrow transplantation (ABMT) for refractory or relapsed non-Hodgkin's lymphoma (NHL) or Morbus Hodgkin (MH) was assessed. Costs were determined from the induction chemotherapy regimen up to 3 months after discharge from hospital following the transplantation. Quality of life was measured by the EuroQol, the Rotterdam Symptom Checklist (RSCL) and the SF-36. Patients were randomised according to a 2:1 ratio to undergo either PBSCT or ABMT. 62 patients underwent PBSCT and 29 ABMT. Costs of the transplantation period were significantly lower in the PBSCT group (15008 Euros) than in the ABMT group (19000 Euros). Significant differences in quality of life were all in favour of PBSCT and emerged using the RSCL, both on 14 days after the transplantation and three months after discharge. We conclude that PBSCT is associated with lower costs and a better quality of life than ABMT for patients with refractory or relapsed NHL or MH.","Eur J Cancer 37(Number): 1781-1789","Netherlands",2001,"NHL","Chemotherapy,SCT","EQ-5D,RSCL,SF-36","Patient","","RCT",null,null,null,null,null,null,null,null,"Refractory"]
[47,"Versteegh, M. M., et al. (2012). \"Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.\" Med Decis Making 32(4): 554-568.","10.1177/0272989x11427761","Versteegh, M. M., et al.","Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D","BACKGROUND: Responses on condition-specific instruments can be mapped on the EQ-5D to estimate utility values for economic evaluation. Mapping functions differ in predictive quality, and not all condition-specific measures are suitable for estimating EQ-5D utilities. We mapped QLQ-C30, HAQ, and MSIS-29 on the EQ-5D and compared the quality of the mapping functions with statistical and clinical indicators. METHODS: We used 4 data sets that included both the EQ-5D and a condition-specific measure to develop ordinary least squares regression equations. For the QLQ-C30, we used a multiple myeloma data set and a non-Hodgkin lymphoma one. An early arthritis cohort was used for the HAQ, and a cohort of patients with relapsing remitting or secondary progressive multiple sclerosis was used for the MSIS-29. We assessed the predictive quality of the mapping functions with the root mean square error (RMSE) and mean absolute error (MAE) and the ability to discriminate among relevant clinical subgroups. Pearson correlations between the condition-specific measures and items of the EQ-5D were used to determine if there is a relationship between the quality of the mapping functions and the amount of correlated content between the used measures. RESULTS: The QLQ-C30 had the highest correlation with EQ-5D items. Average %RMSE was best for the QLQ-C30 with 10.9%, 12.2% for the HAQ, and 13.6% for the MSIS-29. The mappings predicted mean EQ-5D utilities without significant differences with observed utilities and discriminated between relevant clinical groups, except for the HAQ model. CONCLUSIONS: The preferred mapping functions in this study seem suitable for estimating EQ-5D utilities for economic evaluation. However, this research shows that lower correlations between instruments lead to less predictive quality. Using additional validation tests besides reporting statistical measures of error improves the assessment of predictive quality.","Med Decis Making 32(Number): 554-568","Netherlands",2012,"NHL","None","EORTC QLQ-C30,EQ-5D","Patient","","Validation",null,null,null,null,null,null,null,null,"Unspecified"]
[48,"Wettergren, L., et al. (2008). \"Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument.\" Psychooncology 17(4): 338-346.","10.1002/pon.1240","Wettergren, L., et al.","Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument","OBJECTIVE: The aim was to prospectively measure quality of life in patients with malignant blood disorders following stem cell transplantation (SCT) using an individualized and a standardized measure. METHODS: Twenty-two consecutive patients were assessed before and one year following SCT, using a generic and disease-related version of the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) and the EORTC QLQ-C30. Results of the QLQ-C30 were compared with Swedish norm values. RESULTS: A majority of the patients reported concerns related to health before as well as one year after SCT, recorded by both instruments. Mean scores produced by the SEIQoL-DW, and four scales of the EORTC QLQ-C30, showed a change over time, indicating improved quality of life one year after SCT. In comparison with Swedish norm values for the EORTC QLQ-C30, SCT recipients reported a worse functioning. CONCLUSIONS: In addition to well-known disease and treatment-related problems, areas not typically included in standardized instruments were nominated in the disease-related SEIQoL-DW. Such areas included positive aspects, e.g. a changed view of life and oneself. The results support the use of the generic and disease-related SEIQoL-DW to achieve a comprehensive picture of patient's clinical situation under treatment or when recovering from illness.","Psychooncology 17(Number): 338-346","Sweden",2008,"NHL","SCT","SEIQoL-DW,EORTC QLQ-C30","Patient","","Cohort",null,null,null,null,null,null,null,null,"Unspecified"]
[49,"Witzens-Harig, M., et al. (2009). \"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial.\" Ann Hematol 88(1): 51-57.","10.1007/s00277-008-0560-2","Witzens-Harig, M., et al.","Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial","The introduction of rituximab into the primary treatment of malignant lymphomas of the B cell lineage has had a major impact on the management of these diseases. In addition, prolonged exposure to rituximab as maintenance therapy has been beneficial in patients with follicular lymphoma and mantle cell lymphoma. For the individual patient, the effect of any prolonged antitumor therapy on the quality of life (QoL) is a very important question. However, so far, the question whether rituximab maintenance therapy may impair QoL in patients with non-Hodgkin's lymphoma remains unanswered. To investigate this subject, we have performed a prospective randomized trial of rituximab maintenance therapy (8 cycles rituximab 375 mg/m(2) every 3 months) versus observation in patients with CD20+B cell non-Hodgkin's lymphoma in our institution. Between July 2002 and December 2005, 122 patients were included into the trial. QoL was assessed with the standardized questionnaires EORTC-QLQ-C30, EuroQol-5D, and EuroQol-5D (VAS) in 91 patients. After statistical analysis with the exact Wilcoxon rank sum test, we found no significant differences of the QoL between the rituximab treatment group and the observation group. We conclude that rituximab maintenance therapy seems to be safe and does not impair quality of life in this patient population.","Ann Hematol 88(Number): 51-57","Germany",2009,"NHL","Rituximab","EORTC QLQ-C30,EQ-5D,EQ-VAS","Patient","","RCT",null,null,null,null,null,null,null,null,"Any"]
[50,"Wortman, M. S., et al. (2016). \"Brief multimodal psychosomatic therapy in patients with medically unexplained symptoms: feasibility and treatment effects.\" Fam Pract 33(4): 346-353.","10.1093/fampra/cmw023","Wortman, M. S., et al.","Brief multimodal psychosomatic therapy in patients with medically unexplained symptoms: feasibility and treatment effects","BACKGROUND: Patients repeatedly presenting with medically unexplained symptoms (MUS) to their GPs, suffer from their symptoms. Experts in the field suggest a multicomponent approach for these patients. Brief multimodal psychosomatic therapy (BMPT) is such an intervention. OBJECTIVES: To test the systematic identification of eligible patients, acceptability of BMPT and potential treatment effects of BMPT. METHODS: The participants in this randomized pilot trial, patients consulting their GPs more than once with MUS, were randomized to intervention [usual care (UC) and additional BMPT] or control condition (UC alone).We monitored the number of patients identified and recruited, trial recruitment and retention. Potential treatment effects were measured with perceived symptom severity [Visual Analogue Scale (VAS)]; patients' self-rated symptoms of distress, depression, anxiety and somatization [Four-Dimensional Symptom Questionnaire (4DSQ)]; symptoms of hyperventilation [Nijmegen Hyperventilation List (NHL)]; physical and mental health status and quality of life [Short-Form Health Survey-36 items (SF-36)]; and level of functioning (measure of general functioning). Follow-up was 1 year. RESULTS: A total of 42 patients could be included in the trial. Four patients withdrew after randomization and two patients were lost to follow-up, resulting in 36 patients (86%). During the 12-month follow-up after BMPT, there was an improvement in perceived symptom severity [adjusted mean difference -2.0, 95% confidence interval (CI) -3.6 to -0.3], in somatization (adjusted mean difference -4.4, 95% CI -7.5 to -1.4) and in symptoms of hyperventilation (adjusted mean difference -5.7, 95% CI -10.5 to -0.8). CONCLUSIONS: This randomized pilot study shows that a larger trial studying the effectiveness of BMPT in patients with MUS in primary care is feasible and useful.","Fam Pract 33(Number): 346-353","Netherlands",2016,"Other","Psychosomatic therapy","4DSQ,VAS,NHL,SF-36","Patient","","Cohort study",null,null,null,null,null,null,null,null,"Unspecified"]
[51,"Younossi, Z., et al. (2016). \"Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.\" Gastroenterology 150(7): 1599-1608.","10.1053/j.gastro.2016.02.039","Younossi, Z., et al.","Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden","BACKGROUND & AIMS: Hepatitis C virus (HCV) infection has hepatic and extrahepatic manifestations with various costs and impairments to health-related quality of life (HRQL). We performed a meta-analysis to determine the prevalence of extrahepatic manifestations in patients with HCV infection, how these impair HRQL, and their costs. METHODS: We performed systematic reviews of the literature using MEDLINE, CINAHL, and the Cochrane Systematic Review Database, from 1996 through December 2014, to identify studies of the following extrahepatic manifestations of HCV infection: mixed cryoglobulinemia, chronic kidney or end-stage renal disease, type 2 diabetes, B-cell lymphoma, lichen planus, Sjogren's syndrome, porphyria cutanea tarda, rheumatoid-like arthritis, or depression. We performed a separate meta-analysis for each condition to determine prevalence rates of extrahepatic manifestations of HCV infection and their effects on HRQL. We determined the annual costs (inpatient, outpatient, and pharmacy) associated with extrahepatic manifestations of HCV infection. RESULTS: In an analysis of data from 102 studies, we found the most common extrahepatic manifestations to be diabetes (in 15% of patients) and depression (in 25% of patients). HRQL data showed that HCV infection had negative effects on overall physical and mental health. Total direct medical costs of extrahepatic manifestations of HCV infection, in 2014 US dollars, were estimated to be $1506 million (range, $922 million-$2208 million in sensitivity analysis). CONCLUSIONS: In a systematic review and meta-analysis we determined the prevalence, risks, and costs associated with extrahepatic manifestations of HCV infection. These estimates should be added to the liver-related burden of disease to obtain a more accurate assessment of the total burden of chronic HCV infection. Prospective, real-world studies are needed to increase our understanding of the total clinical and economic effects of HCV infection and treatment on patients and society.","Gastroenterology 150(Number): 1599-1608","International",2016,"B-cell","None","Unspecified","Patient","","SLR",null,null,null,null,null,null,null,null,"Unspecified"]
[52,"Zhou, X., et al. (2015). \"Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma.\" Hematology 20(3): 129-136.","10.1179/1607845414y.0000000179","Zhou, X., et al.","Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma","OBJECTIVES: The randomized phase 3 PRIMA trial established that 2 years of rituximab maintenance therapy after attaining disease response to immunochemotherapy as first-line treatment of follicular lymphoma, reduced the risk of disease progression, compared with observation, without adversely affecting patient-reported quality of life (QoL). We now report additional analyses of symptom burden and toxicity. METHODS: Symptom burden was measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items. The proportion of patients with worsening, no change, or improvement in symptoms from maintenance baseline was compared between rituximab maintenance and observation groups with Pearson chi(2) tests. Improvement in symptoms after 1 and 2 years of maintenance was further analyzed using generalized mixed models. The adverse event (AE) rate was calculated from the toxicity checklist at each visit to explore the frequency and timing of the toxicity AE in each treatment arm. The study protocol was approved by local ethics committees and is registered at ClinicalTrials.gov under NCT00140582. RESULTS: Being tired, needing to rest, feeling weak, and trouble sleeping were the most frequently reported symptoms at the end of immunochemotherapy. By the end of maintenance, notable improvement was seen for fatigue symptoms, trouble sleeping, shortness of breath, lack of appetite, and nausea, with no significant difference in QoL symptoms between the rituximab maintenance and observation groups. The rate of AEs was low, and hematologic toxicity induced during chemotherapy treatment improved in both rituximab maintenance and observation groups. DISCUSSION: These results indicated that rituximab maintenance did not negatively impact disease- or treatment-related symptoms.","Hematology 20(Number): 129-136","Unclear",2015,"Follicular","Rituximab","EORTC QLQ-C30","Patient","","RCT",null,null,null,null,null,null,null,null,"Unspecified"]

{"sheet":"Key","index":2,"n_rows":42,"n_cols":2,"rows_kept":42,"cut":false,"hidden":false,"merged":[]}
[]
["Acronym","Full Name"]
["4DSQ","Four-Dimensional Symptom Questionnaire "]
["BFI","Brief Fatigue Inventory"]
["C-SGA","Cancer-specific geriatric assessment"]
["DLBCL","Non-diffuse large B-cell lymphoma "]
["EORTC QLQ-C30","European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 "]
["EORTC QLQ-STO22","EORTC Quality of Life Questionnaire specified for stomach cancer"]
["EQ-5D","Euroqol 5D index"]
["EQ-VAS","Euroqol visual analogue scale"]
["FACT-BR","Functional Assessment of Cancer Therapy - Brain "]
["FACT-G","Functional Assessment of Cancer Therapy - General"]
["FACT-Lym","Functional Assessment of Cancer Treatment-Lymphoma "]
["FAHI","Functional Assessment of Human Immunodeficiency Virus Infection"]
["GDS-13","Geriatric Depression Scale"]
["HADS","Hospital Anxiety and Depression Scale"]
["IOC","Impact of Cancer"]
["KS","Karnofsky scale"]
["LIP"," Life Ingredient Profile"]
["MFI","Multidimensional Fatigue Inventory"]
["MOS-SSS","Medical Outcomes Study Social Support scale"]
["NHL","Non-Hodgkin's lymphoma"]
["OMDQ","Oral mucositis daily questionnaire"]
["PROMIS","Patient-Reported Outcomes Measurement Information System"]
["PSI","Problem Solving Inventory"]
["PTGI","Post-Traumatic Growth Inventory"]
["PTSDCC","Post-Traumatic Stress Disorder Checklist"]
["PTSDIS","PTSD inventory scale"]
["Q-TWiST","Quality-adjusted time without symptom and toxicity"]
["RCT","Randomised controlled trial"]
["RSCL","Rotterdam symptom checklist"]
["SAS","Social Adjustment Scale"]
["SCT","Stem cell therapy"]
["SEIQoL-DW","Schedule for the Evaluation of Individual Quality of Life-Direct Weighting"]
["SF-20"," Medical Outcomes Study Short Form 20"]
["SF-36"," Medical Outcomes Study Short Form 36"]
["SLR","Systematic literature review"]
["SymQ","Symptom Questionnaire"]
["VAS","Visual analogue scale"]
["VES-13","Vulnerable Elders Survey"]
["VSHSS","Verran and Snyder-Halpern Sleep Scale"]
["WHO-OTS","World Health Organization oral toxicity scale"]

{"sheet":"Mapper","index":3,"n_rows":613,"n_cols":11,"rows_kept":613,"cut":false,"hidden":false,"merged":[[22,1,22,6]]}
[]
[]
[null,"1. Select the first category to be included in the",null,null,null,null,null,null,null,null,"Count"]
[null," Evidence Map. This will show as a series of rows",null,null,null,null,null,null,null,"Unallocated",0]
[null,"in the Map",null,null,null,null,null,null,null,"B-cell",2]
[null,"First dimension",null,null,null,null,null,null,null,"Cutaneous T-cell",2]
[null,3,{"$f":"OFFSET(C531,B7,0)","v":"Diseases"},null,{"$f":"COUNTA(J4:J503)","v":10},null,null,null,null,"DLBCL",3]
[null,null,null,null,null,null,null,null,null,"Follicular",3]
[null,null,null,null,null,null,null,null,null,"Hodgkins",6]
[null,"2. Then select the second category to be shown ",null,null,null,null,null,null,null,"Mantle cell",4]
[null,"as the columns of the Map, or leave blank",null,null,null,null,null,null,null,"NHL",37]
[null,"Second dimension",null,null,null,null,null,null,null,"Other",2]
[null,9,{"$f":"OFFSET(C531,B13,0)","v":"None"},null,{"$f":"COUNTA(K3:PZ3)","v":1},null,null,null,null,"PCNSL",1]
[]
[null,"3. Click on a cell in the Map, then click the Show"]
[null,"Citation button below to see the relevant"]
[null,"citations for that cell "]
[]
[]
[null,"Row",{"$f":"IF(AND(selectedRow>3,selectedRow<(4+E7)),OFFSET(tableLoc,(selectedRow-3),0),\"\")","v":""},null,null,null,null," "]
[null,"Column",{"$f":"IF(AND(selectedColumn>10,selectedColumn<(11+columnCount)),OFFSET(tableLoc,0,(selectedColumn-10)),\"\")","v":""},null,null,null,null," "]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[null,null,"Dates"]
[null,null,"None"]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[null,"Locations",{"$f":"COUNTA(C532:C550)","v":9}]
[1,"Locations","Locations"]
[2,"Interventions","Interventions"]
[3,"Diseases","Diseases"]
[4,{"$f":"INDEX(domainList,A535)","v":"PRO tools"},"PRO tools"]
[5,{"$f":"INDEX(domainList,A536)","v":"subPopulations"},"subPopulations"]
[6,{"$f":"INDEX(domainList,A537)","v":"Study types"},"Study methodologies"]
[7,{"$f":"INDEX(domainList,A538)","v":"Study methodologies"},"Stage"]
[1,{"$f":"INDEX(customList,A539)","v":"Stage"},"Dates"]
[2,"C2","None"]
[3,"C3"]
[4,"C4"]
[5,"C5"]
[6,"C6"]
[7,"C7"]
[8,"C8"]
[9,"C9"]
[10,"C10"]
[null,"Dates"]
[null,"None"]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[null,"Row",1]
[null,"Column",1]
[null,"columnCount",{"$f":"COUNTA(K3:ZZ3)","v":1}]

{"sheet":"CitationIndex","index":4,"n_rows":34,"n_cols":3,"rows_kept":34,"cut":false,"hidden":true,"merged":[]}
[null,"Column","Column number"]
[null,"Full citation",{"$f":"MATCH(B2,Citations!A$1:BB$1,0)","v":2}]
[null,"Authors",{"$f":"MATCH(B3,Citations!A$1:BB$1,0)","v":4}]
[null,"Title",{"$f":"MATCH(B4,Citations!A$1:BB$1,0)","v":5}]
[null,"Citation",{"$f":"MATCH(B5,Citations!A$1:BB$1,0)","v":7}]
[null,"DOI",{"$f":"MATCH(B6,Citations!A$1:BB$1,0)","v":3}]
[null,"Abstract",{"$f":"MATCH(B7,Citations!A$1:BB$1,0)","v":6}]
[null,"Locations",{"$f":"MATCH(B8,Citations!A$1:BB$1,0)","v":8}]
[null,"Year",{"$f":"MATCH(B9,Citations!A$1:BB$1,0)","v":9}]
[null,"Diseases",{"$f":"MATCH(B10,Citations!A$1:BB$1,0)","v":10}]
[null,"Interventions",{"$f":"MATCH(B11,Citations!A$1:BB$1,0)","v":11}]
[null,"Subpopulations",{"$f":"MATCH(B12,Citations!A$1:BB$1,0)","v":13}]
[null,"Study types",{"$f":"MATCH(B13,Citations!A$1:BB$1,0)","v":14}]
[null,"Study methodologies",{"$f":"MATCH(B14,Citations!A$1:BB$1,0)","v":15}]
[null,"PROtools",{"$f":"MATCH(B15,Citations!A$1:BB$1,0)","v":12}]
[null,"LocationsTags",{"$f":"MATCH(B16,Citations!A$1:BB$1,0)","v":16}]
[null,"SubpopulationsTags",{"$f":"MATCH(B17,Citations!A$1:BB$1,0)","v":17}]
[null,"DiseaseTags",{"$f":"MATCH(B18,Citations!A$1:BB$1,0)","v":18}]
[null,"InterventionsTags",{"$f":"MATCH(B19,Citations!A$1:BB$1,0)","v":19}]
[null,"StudytypesTags",{"$f":"MATCH(B20,Citations!A$1:BB$1,0)","v":20}]
[null,"StudyMethodologyTags",{"$f":"MATCH(B21,Citations!A$1:BB$1,0)","v":21}]
[null,"PROtoolTags",{"$f":"MATCH(B22,Citations!A$1:BB$1,0)","v":22}]
[null,"DateBand",{"$f":"MATCH(B23,Citations!A$1:BB$1,0)","v":23}]
[null,{"$f":"Custom1","v":"Stage"},{"$f":"MATCH(B24,Citations!A$1:BB$1,0)","v":24}]
[null,{"$f":"Custom2","v":"C2"},{"$f":"MATCH(B25,Citations!A$1:BB$1,0)","v":25}]
[null,{"$f":"Custom3","v":"C3"},{"$f":"MATCH(B26,Citations!A$1:BB$1,0)","v":26}]
[null,{"$f":"Custom4","v":"C4"},{"$f":"MATCH(B27,Citations!A$1:BB$1,0)","v":27}]
[null,{"$f":"Custom5","v":"C5"},{"$f":"MATCH(B28,Citations!A$1:BB$1,0)","v":28}]
[null,{"$f":"Custom4","v":"C4"},{"$f":"MATCH(B29,Citations!A$1:BB$1,0)","v":27}]
[null,{"$f":"Custom5","v":"C5"},{"$f":"MATCH(B30,Citations!A$1:BB$1,0)","v":28}]
[null,{"$f":"Custom4","v":"C4"},{"$f":"MATCH(B31,Citations!A$1:BB$1,0)","v":27}]
[null,{"$f":"Custom5","v":"C5"},{"$f":"MATCH(B32,Citations!A$1:BB$1,0)","v":28}]
[null,{"$f":"Custom4","v":"C4"},{"$f":"MATCH(B33,Citations!A$1:BB$1,0)","v":27}]
[null,{"$f":"Custom5","v":"C5"},{"$f":"MATCH(B34,Citations!A$1:BB$1,0)","v":28}]

{"sheet":"Citations","index":5,"n_rows":53,"n_cols":33,"rows_kept":53,"cut":false,"hidden":false,"merged":[]}
[52,"Full citation","DOI","Authors","Title","Abstract","Citation","Locations","Year","Diseases","Interventions","PROtools","Subpopulations","Study types","Study methodologies","LocationsTags","SubpopulationsTags","DiseaseTags","InterventionsTags","StudytypesTags","StudyMethodologyTags","PROtoolTags","DateBand","Stage","C2","C3","C4","C5","C6","C7","C8","C9","C10"]
[1,"Attarbaschi,A.,et al. (2016). \"Non-Hodgkin lymphoma and pre-existing conditions: spectrum,clinical characteristics and outcome in 213 children and adolescents.\" Haematologica 101(12): 1581-1591.","10.3324/haematol.2016.147116","Attarbaschi,A.,et al.","Non-Hodgkin lymphoma and pre-existing conditions: spectrum,clinical characteristics and outcome in 213 children and adolescents","Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin lymphoma. However,large-scale data on patients with non-Hodgkin lymphoma and their entire spectrum of pre-existing conditions are scarce. A retrospective multinational study was conducted by means of questionnaires sent out to the national study groups or centers,by the two largest consortia in childhood non-Hodgkin lymphoma,the European Intergroup for Childhood non-Hodgkin Lymphoma,and the international Berlin-Frankfurt-Munster Study Group. The study identified 213 patients with non-Hodgkin lymphoma and a pre-existing condition. Four subcategories were established: a) cancer predisposition syndromes (n=124,58%); b) primary immunodeficiencies not further specified (n=27,13%); c) genetic diseases with no increased cancer risk (n=40,19%); and d) non-classifiable conditions (n=22,10%). Seventy-nine of 124 (64%) cancer predispositions were reported in groups with more than 20 patients: ataxia telangiectasia (n=32),Nijmegen breakage syndrome (n=26),constitutional mismatch repair deficiency (n=21). For the 151 patients with a known cancer risk,5-year event-free survival and overall survival rates were 40%+/-4% and 51%+/-4%,respectively. Five-year cumulative incidences of progression/relapse and treatment-related death as a first event were 22%+/-4% and 24%+/-4%,respectively. Ten-year incidence of second malignancy was 24%+/-5% and 7-year overall survival of the 21 patients with a second malignancy was 41%+/-11%. Patients with non-Hodgkin lymphoma and pre-existing conditions have an inferior survival rate with a large proportion of therapy-related deaths compared to patients with non-Hodgkin lymphoma and no pre-existing conditions. They may require special vigilance when receiving standard or modified/reduced-intensity chemotherapy or when undergoing allogeneic stem cell transplantation.","Haematologica 101(Number): 1581-1591","UK,Austria,Belarus,Belgium,Canada,Czech Republic,France,Germany,China,Hungary,Israel,Italy,Japan,Netherlands,Poland,Serbia,Slovenia,Switzerland",2016,"NHL","None","Unspecified","Children",null,"Cohort study","UK,Austria,Belarus,Belgium,Canada,Czech Republic,France,Germany,China,Hungary,Israel,Italy,Japan,Netherlands,Poland,Serbia,Slovenia,Switzerland","Children","NHL","None",null,"Cohort study","Unspecified","2015:2018","Unspecified"]
[2,"Beynon,T.,et al. (2014). \"What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence.\" Br J Dermatol 170(3): 599-608.","10.1111/bjd.12644","Beynon,T.,et al.","What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence","BACKGROUND: Primary cutaneous T-cell lymphoma (CTCL) is progressive,can cause significant symptoms,and impacts on quality of life. Therefore supportive and palliative care might have a role in the care of patients and families. OBJECTIVES: To identify and appraise the available peer-reviewed evidence on the supportive and palliative care needs of patients and their caregivers. METHODS: A systematic review of the literature was conducted. Extracted data from eligible papers were collated in themes relating to supportive and palliative care needs and outcomes for patients,informal caregivers,health professionals and reported service models. RESULTS: Eighteen retained papers reported a symptom or quality-of-life measure. Five reported only these measures,13 reported outcomes in relation to an intervention. Systemic therapy targeted at disease remission was the most commonly reported intervention (12/13). No quality-of-life tool was consistently used. Pruritus was frequently reported as an outcome (n = 9) often using the visual analogue scale,VAS itch. Psychosocial,spiritual and caregiver needs were reported infrequently or not at all. CONCLUSIONS: No measure is routinely used to measure supportive and palliative care outcomes in CTCL. Physical needs,particularly pruritus,were reported commonly; however,qualitative evidence of experience is limited. Caregivers' needs are rarely explored. To compare outcomes from clinical studies,a single multidimensional tool used in routine practice would be useful. Further work is needed to explore a model of service that meets the specific physical,psychosocial and spiritual needs of this group of patients and their carers.","Br J Dermatol 170(Number): 599-608","International",2014,"Cutaneous T-cell","Targeted","VAS","Caregiver,Patient",null,"SLR","International","Caregiver,Patient","Cutaneous T-cell","Targeted",null,"SLR","VAS","2010:2014","Unspecified"]
[3,"Boele,F. W.,et al. (2013). \"Health-related quality of life of significant others of patients with malignant CNS versus non-CNS tumors: a comparative study.\" J Neurooncol 115(1): 87-94.","10.1007/s11060-013-1198-z","Boele,F. W.,et al.","Health-related quality of life of significant others of patients with malignant CNS versus non-CNS tumors: a comparative study","It is often assumed that brain tumor patients' significant others (SOs: partners,other family members or close friends) may face greater stress than those of patients with malignancies not involving the central nervous system (CNS),due to progressive changes in neurological and cognitive functioning. We compared health-related quality of life (HRQOL) of SOs of patients with high-grade glioma (HGG) and low-grade glioma (LGG) with that of SOs of patients with non-CNS tumors with similar prognosis and at a similar phase in the disease trajectory (i.e. non-small cell lung cancer (NSCLC) and low-grade hematological malignancies (NHL/CLL),respectively). HRQOL of SOs and patients was assessed using the Short Form-36 (SF-36) Health Survey. Patients' neurological functioning was indexed and they underwent comprehensive neurocognitive testing. SOs of 213 LGG patients,99 NHL/CLL patients,55 HGG patients and 29 NSCLC patients participated. The SOs of LGG and NHL/CLL patients reported similar levels of HRQOL. SOs of HGG patients reported significantly lower mental health scores (MCS; p = 0.041) and social functioning (p = 0.028) than those of NSCLC patients. Mental health scores (MCS) of HGG and NSCLC patients were associated significantly with the mental health of their SOs (p = 0.013 and p < 0.001,respectively). Surprisingly,HGG patients' cognitive and neurological functioning were not predictive of SOs' mental health at the multivariate level. SOs of patients with highly malignant CNS tumors in the acute phase are at increased risk of compromised HRQOL compared to those of patients with systemic tumors without CNS involvement and a comparable life expectancy.","J Neurooncol 115(Number): 87-94","Netherlands",2013,"NHL","None","SF-36","Caregiver,Patient",null,"Cross-sectional","Netherlands","Caregiver,Patient","NHL","None",null,"Cross-sectional","SF-36","2010:2014","High grade,Low grade"]
[4,"Burke,J. M.,et al. (2016). \"Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.\" Clin Lymphoma Myeloma Leuk 16(4): 182-190.e181.","10.1016/j.clml.2016.01.001","Burke,J. M.,et al.","Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","BACKGROUND: We previously reported results of the phase III,randomized,noninferiority trial comparing bendamustine-rituximab (BR) with standard R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)/R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in previously untreated advanced indolent non-Hodgkin and mantle cell lymphomas. Here we report health-related quality of life (HRQOL) results from the trial. METHODS: HRQOL,as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30),was a secondary end point. Differences between group means in global health status (GHS),5-item functioning,and 9 symptoms/single-item measures at week 1 of cycle 1 and end-of- cycles 3 and 6 were examined using the screening (baseline) score as a covariate in analysis of covariance. RESULTS: Overall EORTC QLQ-C30 compliance was 75.2%,89.5%,and 89.9% at week 1 of cycle 1 and end-of-cycles 3 and 6,respectively. Patients treated with BR reported improvements in Cognitive Functioning,Physical Functioning,Social Functioning,Emotional Functioning,and GHS as well as reduction in dyspnea,constipation,and fatigue at some,but not all,time points. Patients treated with standard therapy reported less nausea/vomiting at one time point. CONCLUSION: Compared with patients treated with standard therapy,patients treated with BR reported better quality of life in several areas.","Clin Lymphoma Myeloma Leuk 16(Number): 182-190.e181","UK,Australia,Canada,New Zealand",2016,"NHL,Mantle cell","Bendamustine-rituximab,Rituximab,Chemotherapy","EORTC QLQ-C30","Patient",null,"RCT","UK,Australia,Canada,New Zealand","Patient","NHL,Mantle cell","Bendamustine-rituximab,Rituximab,Chemotherapy",null,"RCT","EORTC QLQ-C30","2015:2018","Advanced"]
[5,"Cheson,B. D.,et al. (2017). \"Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.\" Ann Hematol 96(2): 253-259.","10.1007/s00277-016-2878-5","Cheson,B. D.,et al.","Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone","We present health-related quality of life (HRQoL) data from GADOLIN,comparing bendamustine (B) alone or combined with obinutuzumab (G-B) in rituximab-refractory indolent non-Hodgkin lymphoma patients. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire was administered on day 1 of cycles 1,3,and 5 during treatment,at end of induction (EOI),bi-monthly for 2 years during maintenance/follow-up,and annually during extended follow-up until progression/death. Time to first >/=6-point worsening from baseline in the FACT-Lym trial outcome index (TOI) was estimated. Minimally important differences at individual subscale and total score level were used to define the proportion of patients reporting improvement on the FACT-Lym lymphoma-specific subscale (>/=3 points),FACT-Lym TOI (>/=6 points),and FACT-Lym total score (>/=7 points). Overall,396 patients were randomized. Analysis was conducted when 175 Independent Review Committee-assessed progression-free survival (PFS) events were observed. Questionnaire completion rates were generally balanced between arms at baseline,EOI,and final follow-up. Median time to >/=6-point worsening from baseline on the FACT-Lym TOI was 8.0 months in the G-B arm and 4.6 months in the B arm (HR 0.74; 95% CI 0.56-0.98). More G-B patients reported meaningful improvements on the FACT-Lym questionnaire subscales. Results were similar when follicular lymphoma patients were analyzed separately. The delayed time to worsening and greater proportion of patients reporting meaningful improvement in HRQoL in the G-B arm suggest that benefit in PFS is not at the expense of an increase in treatment-related toxicity that could lead to reduced HRQoL.","Ann Hematol 96(Number): 253-259","UK,USA,Canada,France,Netherlands,Sweden,Switzerland",2017,"NHL","Bendamustine,Obinutuzumab","FACT-Lym","Patient",null,"RCT","UK,USA,Canada,France,Netherlands,Sweden,Switzerland","Patient","NHL","Bendamustine,Obinutuzumab",null,"RCT","FACT-Lym","2015:2018","Refractory"]
[6,"Chuang,T. Y.,et al. (2017). \"A nurse facilitated mind-body interactive exercise (Chan-Chuang qigong) improves the health status of non-Hodgkin lymphoma patients receiving chemotherapy: Randomised controlled trial.\" Int J Nurs Stud 69: 25-33.","10.1016/j.ijnurstu.2017.01.004","Chuang,T. Y.,et al.","A nurse facilitated mind-body interactive exercise (Chan-Chuang qigong) improves the health status of non-Hodgkin lymphoma patients receiving chemotherapy: Randomised controlled trial","BACKGROUND: Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies. Chemotherapy can improve patient survival rates,yet it is also associated with many adverse physical and psychosocial effects. It is suggested that qigong practices may be used to reduce patient distress and side effects. OBJECTIVES: To evaluate the effects of Chan-Chuang qigong on fatigue,complete blood cells,sleep quality,and quality of life for patients with non-Hodgkin lymphoma who had undergone the first course of chemotherapy. DESIGN: A randomized controlled study. SETTINGS: An oncology ward of medical centre in northern Taiwan. PARTICIPANTS: Fifty participants in each of the two groups. METHODS: Participants were randomly assigned to either the qigong group (n=50) that received a 21-day Chan-Chuang qigong programme,or the control group (n=50). The primary outcome was fatigue measured by Brief Fatigue Inventory. The secondary outcomes were complete blood cell counts,sleep quality measured by Verran and Snyder-Halpern Sleep Scale,and quality of life measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. RESULTS: After 21 days of intervention,the results obtained from ninety six participants were analysed. Participants in the qigong group exhibited decreased fatigue intensity and fatigue interference from 5.49 (SD=1.02) and 5.53 (SD=1.27) to 0.37 (SD=1.39) and 0.20 (SD=1.93),respectively. Generalized estimating equations analyses revealed that the qigong group,when compared to the control group,had significant improvement in fatigue intensity and fatigue interference over time (beta=-1.04,95% confidence interval [CI] from -1.59 to -0.48,p<0.001; and beta=-1.22,95% CI from -1.86 to -0.59,p<0.001,respectively). There was a significant between-group difference in the improvement in white blood cell counts (t=5.14,p<0.001),hemoglobin levels (t=3.17,p=0.002),and sleep quality (t=17.73,p<0.001),but not in platelet counts (p=0.05). With regard to quality of life,the scores of the qigong group improved in all subscales and all symptom items when compared to that of the control group. No adverse effects were observed in the qigong group. CONCLUSIONS: The findings of this study indicate that the 21-day Chan- Chuang qigong can reduce fatigue intensity and fatigue interference,and improved white blood cell counts,haemoglobin levels,sleep quality,and quality of life for patients with non-Hodgkin lymphoma who had undergone the first course of chemotherapy. Further studies involving a prolonged extended intervention period and follow-up are necessary for determining the long-term effect of qigong exercise.","Int J Nurs Stud 69(Number): 25-33","China",2017,"NHL","Chemotherapy,Various","BFI,VSHSS,EORTC QLQ-C30","Patient",null,"RCT","China","Patient","NHL","Chemotherapy,Various",null,"RCT","BFI,VSHSS,EORTC QLQ-C30","2015:2018","Unspecified"]
[7,"Crespi,C. M.,et al. (2013). \"A procedure for obtaining impact of cancer version 2 scores using version 1 responses.\" Qual Life Res 22(1): 103-109.","10.1007/s11136-012-0127-5","Crespi,C. M.,et al.","A procedure for obtaining impact of cancer version 2 scores using version 1 responses","PURPOSE: Psychometric scales often change over time,complicating comparison of scores across different versions. The Impact of Cancer (IOC) scale was developed to measure quality of life of long-term cancer survivors. We sought to develop a method for scoring the earlier version,IOCv1,to obtain scores comparable to IOCv2,which is the recommended version. METHODS: Data from 1,828 cancer survivors who had completed a questionnaire including all IOCv1 and IOCv2 items were randomly split into training,validation and test sets. The training and validation sets were used to develop and validate linear regression models for predicting each IOCv2 item missing from IOCv1. The models were then applied to the test set to obtain pseudo-IOCv2 scores,which were compared to observed scores to assess predictive performance of the models in independent data. RESULTS: Observed and pseudo-IOCv2 scale scores were highly correlated in the test sample and had mean differences near zero. The models performed especially well in predicting summary scale scores,with correlations exceeding 0.98. CONCLUSIONS: The approach facilitates comparison across samples of survivors surveyed using different versions of the IOC and may be useful to other investigators trying to compare participants surveyed using different versions of the same instrument.","Qual Life Res 22(Number): 103-109","USA",2013,"Other","None","IOC","Survivor",null,"Validation","USA","Survivor","Other","None",null,"Validation","IOC","2010:2014","Any"]
[8,"Crespi,C. M.,et al. (2010). \"Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors.\" J Cancer Surviv 4(1): 45-58.","10.1007/s11764-009-0106-1","Crespi,C. M.,et al.","Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors","INTRODUCTION: Self-report instruments such as the Impact of Cancer (IOC) are designed to measure quality of life (QOL) impacts that cancer survivors attribute to their cancer experience. Generalizability of QOL findings across distinct diagnostic categories of survivors is untested. We compare measurement of the impact of cancer using the IOC instrument in breast cancer (BC) survivors (n = 1,188) and non-Hodgkin lymphoma (NHL) survivors (n = 652). METHODS: A registry-based sample of NHL survivors completed the IOC questionnaire and the FACT-G,FACT-LYM,Medical Outcomes Study (MOS) SF-36,Post-Traumatic Stress Disorder Checklist-Civilian Version,Post-Traumatic Growth Inventory and MOS Social Support scales. IOC responses of the NHL survivors were subjected to de novo scaling to identify impact domains for comparison to IOC version 2 (IOCv2) domains,which were previously developed based on BC survivor responses. Concurrent validity was assessed by correlating the IOCv2 scales with the other measures. IOCv2 scores were compared between the BC and NHL survivor samples. RESULTS: The BC and NHL survivors exhibited similar impact domains and had factor structures that were largely congruent. The concurrent validity analysis revealed patterns of association that supported the interpretation and validity of the IOCv2 scales. Differences in IOCv2 scores between the BC and NHL groups suggested differential impacts in distinct survivor groups that could be detected using the IOCv2. CONCLUSION: The results suggest that the IOCv2 measures common and important survivor concerns and support its generalizability to the broader long-term cancer survivor population. IMPLICATIONS FOR CANCER SURVIVORS: Instruments such as the IOCv2 can provide valid assessment of QOL impacts in long-term cancer survivors,facilitating the characterization of these impacts and development of appropriate interventions.","J Cancer Surviv 4(Number): 45-58","USA",2010,"NHL","None","IOC,FACT-G,FACT-LYM,SF-36,PTSDCC,PTGI,MOS-SSS","Survivor",null,"Cross-sectional","USA","Survivor","NHL","None",null,"Cross-sectional","IOC,FACT-G,FACT-Lym,SF-36,PTSDCC,PTGI,MOS-SSS","2010:2014","Any"]
[9,"Crott,R.,et al. (2013). \"An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.\" Qual Life Res 22(5): 1045-1054.","10.1007/s11136-012-0220-9","Crott,R.,et al.","An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences","BACKGROUND: Although cancer-specific Health-related Quality-of-Life measures are commonly included in randomized clinical trials or other prospective non-randomized clinical studies,it is rare that preference-based instruments are used,which allow the calculation of a Utility weight suitable for estimating Quality-adjusted Life-Years gained. OBJECTIVE: To test the external validity of a previously published mapping algorithm to transform the EORTC QLQ-C30 questionnaire responses into EQ-5D-derived utilities by predicting EQ-5D utilities from QLQ-C30 scores. STUDY DESIGN AND METHODS: Comparative retrospective data analysis of four multicentre,prospective clinical trials in Breast,Multiple Myeloma,Non-Hodgkin Lymphoma and Non-Small-Cell Lung cancer patients with,respectively,219,172,132 and 172 patients. Regression analysis of individual pairs of EQ-5D and QLQ-C30 scores. RESULTS: Although the internal predictive power of a previously published mapping equation was high,its external validity when tested on a set of unrelated external data sets in other cancers proved to underestimate both the mean and variance of the mapped EQ-5D utilities. Furthermore,it appears that the relationship between QLQ-C30 scores and EQ-5D values is not stable across the different data sets. CONCLUSIONS: Validation of the proposed algorithm in other external clinical data sets should be encouraged as well as the application of other more complex mapping methods to enhance accuracy of mapping. In the meanwhile,direct mapping from QLQ-C30 profiles to EQ-5D utilities using published algorithms should be performed with reservations.","Qual Life Res 22(Number): 1045-1054","Netherlands",2013,"NHL","None","EQ-5D,EORTC QLQ-C30","Patient",null,"Validation","Netherlands","Patient","NHL","None",null,"Validation","EQ-5D,EORTC QLQ-C30","2010:2014","Unspecified"]
[10,"Deconinck,E.,et al. (2010). \"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.\" Pharmacoeconomics 28(1): 35-46.","10.2165/11314070-000000000-00000","Deconinck,E.,et al.","Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation","BACKGROUND: Rituximab maintenance therapy was shown to significantly extend overall survival (OS) and progression-free survival (PFS) in relapsed/refractory follicular lymphoma (FL) in the pivotal EORTC 20981 trial. OBJECTIVE: To assess the long-term costs and cost effectiveness of rituximab maintenance therapy after induction therapy versus current standard practice (observation) from the French National Health Service perspective. METHODS: A lifetime transition model was developed comparing rituximab maintenance with observation. PFS and OS were obtained from the EORTC 20981 trial with a median follow-up of 28 months and extrapolated from 2-year Kaplan-Meier curves using a Weibull distribution. PFS and OS benefits of rituximab were conservatively assumed to last only 5 years. Utility data were obtained from a multicentre observational study using the EQ-5D questionnaire. Direct medical costs were obtained from French official sources. All costs are reported in euro,year 2006 values. RESULTS: The EORTC 20981 study demonstrated that rituximab maintenance was effective in the management of relapsed/refractory FL. The model results showed that life expectancy and QALYs were increased by 22% and 28%,respectively,in patients treated with rituximab. The incremental cost-effectiveness ratios (ICERs) were euro 7612 per life-year gained and euro 8729 per QALY gained. In a one-way sensitivity analysis,most of the ICERs fell within the range of euro 7000-12,000. The results tend to show that rituximab maintenance therapy may be a cost-effective strategy in the management of relapsed/refractory FL in France,with ICERs below those observed for other therapies in the oncology field. The cost of rituximab was partly offset by the lower cost of relapse due to a longer time in the disease-free health state for patients in the rituximab arm.","Pharmacoeconomics 28(Number): 35-46","France",2010,"Follicular","Rituximab","EQ-5D","Patient",null,"Economic evaluation","France","Patient","Follicular","Rituximab",null,"Economic evaluation","EQ-5D","2010:2014","Refractory"]
[11,"Diamond,C.,et al. (2010). \"Quality of life,characteristics and survival of patients with HIV and lymphoma.\" Qual Life Res 19(2): 149-155.","10.1007/s11136-009-9565-0","Diamond,C.,et al.","Quality of life,characteristics and survival of patients with HIV and lymphoma","PURPOSE: We sought to compare the quality of life (QOL),characteristics,and survival of patients with non-Hodgkin lymphoma (NHL) with and without human immunodeficiency virus (HIV) infection. METHODS: Using the population-based cancer registry for Orange and San Diego Counties,We recruited 50 patients with HIV and systemic NHL (cases) and 50 age,sex and race-matched NHL patients without HIV (controls) diagnosed with NHL during 2002-2006. Patients completed a medical history survey and QOL instrument,the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) for cases and Functional Assessment of Cancer Therapy-General (FACT G) for controls. RESULTS: HIV-infected patients had worse overall QOL and survival than uninfected patients. QOL differences were more marked in the areas of functional,physical and social well-being than in the area of emotional well-being. HIV-infected patients had lower income and were less likely to have private insurance and more likely to have diffuse large B cell histology than uninfected patients. CONCLUSION: HIV-infected NHL patients had worse QOL and survival than uninfected patients,due to a combination of co-morbidity,aggressive histology and lack of social support. However,their emotional well-being was comparable to that of uninfected NHL patients and better than historical norms for the HIV-infected.","Qual Life Res 19(Number): 149-155","USA",2010,"NHL","None","FAHI,FACT-G","Patient",null,"Case-control","USA","Patient","NHL","None",null,"Case-control","FAHI,FACT-G","2010:2014","Unspecified"]
[12,"Doorduijn,J.,et al. (2005). \"Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy.\" Eur J Haematol 75(2): 116-123.","10.1111/j.1600-0609.2005.00438.x","Doorduijn,J.,et al.","Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy","We studied the impact of CHOP chemotherapy on the quality of life (QoL) of elderly patients with aggressive non-Hodgkin's lymphoma (NHL). 132 patients aged 65 or older,who participated in a randomized,multicenter trial,completed QoL questionnaires (EuroQol-5D,EORTC QLQ-C30 and MFI-20) on 8 predefined time-points before,during and following treatment. At baseline,QoL was significantly better on almost all dimensions in patients with a lower compared to patients with a higher age-adjusted International Prognostic Index (aaPI). During treatment,physical and role functioning and global QoL deteriorated and fatigue increased in the lower aaPI group,whereas QoL of the higher aaPI group remained stable. During follow-up,the QoL was significantly better for patients in complete response (CR) or partial remission (PR) than for patients with progression/relapse. Soon after completion of therapy,the QoL of the lower aaPI group returned to pretreatment levels or better,while patients with higher aaPI showed a significant improvement in QoL compared to baseline levels. The effect of CHOP on the quality of life of elderly patients could be used in counseling this group of patients.","Eur J Haematol 75(Number): 116-123","Netherlands",2005,"NHL","Chemotherapy","EQ-5D,EORTC QLQ-C30,MFI-20","Patient",null,"RCT","Netherlands","Patient","NHL","Chemotherapy",null,"RCT","EQ-5D,EORTC QLQ-C30,MFI-20","2005:2009","Aggressive"]
[13,"Duvic,M.,et al. (2002). \"Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).\" Clin Lymphoma 2(4): 222-228.",null,"Duvic,M.,et al.","Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)","Cutaneous T-cell lymphoma (CTCL) can be associated with painful,pruritic,disfiguring lesions. As part of a multicenter,randomized phase III trial in patients with heavily pretreated advanced and/or recurrent CTCL,the effects of an interleukin-2 receptor-targeted fusion protein,denileukin diftitox (DAB389IL-2,ONTAK),on patient-rated overall quality of life (QOL),skin appearance,and pruritus severity were evaluated. A total of 71 patients with stage IB-IVA CTCL received intravenous denileukin diftitox 9 microg/kg/day or 18 microg/kg/day over 15-60 minutes for 5 consecutive days on an outpatient basis; cycles were planned for every 21 days for a total of 8 cycles over 6 months. Prior to each treatment cycle,patients were evaluated for disease response and were asked to self-rate their overall QOL via the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire,skin appearance (7-point scale),and pruritus severity (10-cm visual analogue scale). Composite FACT-G and most individual subscale scores (physical,social/family,emotional,and functional well being) in documented responders (n = 21) gradually increased during the study period,generally reaching statistical significance (P < 0.05) by cycle 3,and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint. Additionally for responders,assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline. Adverse transfusion-related events (eg,hypersensitivity reactions,flu-like syndrome) were common during cycles 1 and 2,and vascular-leak syndrome occurred in 25% of patients. Denileukin diftitox was not associated with any clinically significant myelosuppression. Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL,skin appearance,and pruritus severity.","Clin Lymphoma 2(Number): 222-228","USA",2002,"Cutaneous T-cell","Denileukin diftitox","FACT-G,VAS","Patient",null,"RCT","USA","Patient","Cutaneous T-cell","Denileukin diftitox",null,"RCT","FACT-G,VAS","2000:2004","Advanced"]
[14,"Fargier,E.,et al. (2018). \"SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma.\" Ann Hematol 97(1): 123-131.","10.1007/s00277-017-3147-y","Fargier,E.,et al.","SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma","Rituximab is used as a standard of care for follicular lymphoma and is usually administered intravenously. A novel subcutaneous formulation recently showed non-inferior efficacy with similar pharmacokinetic and safety profiles compared to intravenous rituximab in patients with follicular lymphoma. This new approach is promising in terms of comfort for patients and time-saving for hospital staff. To evaluate the real-life economic impact of subcutaneous rituximab as maintenance therapy in patients with follicular lymphoma in real life,we conducted a cost-consequence analysis from the hospital's point of view in three French teaching hospitals. Health-related quality of life (EQ-5D-3L) was investigated as well as patients' and nurses' perception. Compared to intravenous rituximab,subcutaneous administration showed an estimated cost-saving of euro109.20 per patient per cycle (p < 0.001),78.6% of which could be attributed to the rituximab cost. Health-related quality of life showed no significant difference between the two groups despite tendencies for greater pain in the subcutaneous group and greater anxiety in the intravenous group. Thus,subcutaneous rituximab had a favorable pharmacoeconomic profile,with clinical efficacy similar to that of intravenous rituximab. The subcutaneous form was preferred by almost all patients,but further consideration should be given to improve the patients' experience: a dedicated day unit with trained medical,nursing,and pharmaceutical staff could be helpful.","Ann Hematol 97(Number): 123-131","France",2018,"Follicular","Rituximab","EQ-5D","Patient",null,"Economic evaluation","France","Patient","Follicular","Rituximab",null,"Economic evaluation","EQ-5D","2015:2018","Unspecified"]
[15,"Furlan,C.,et al. (2017). \"Low-dose radiotherapy in diffuse large B-cell lymphoma.\" Hematol Oncol 35(4): 472-479.","10.1002/hon.2368","Furlan,C.,et al.","Low-dose radiotherapy in diffuse large B-cell lymphoma","Low-dose radiotherapy (LDRT) given in 2 x 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise,very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation. Low-dose radiotherapy was administered on symptomatic areas only. Clinical response was assessed 21 days after LDRT and defined as reduction >50% of maximum diameter of the radiated lesions. Quality of life was scored by the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire. Tumor subtype (germinal center B-cell type versus activated B-cell type) and the presence of TP53 mutations in pathologic specimens of the target lesion were also evaluated. Twenty-three of twenty-five radiated patients were evaluable for response,and 2 died of disease before the visit at 21 days. The overall response rate was 70% (16 of 23 patients),with 7 complete responses and 9 partial responses (mean duration of response,6 months; range,1-39 months). Fifteen patients answered to the QLQ-C30 questionnaires,and an improved quality of life was documented in 9 cases. TP53 mutations were detected in 2 of 6 (33%) nonresponders and in none of the responders (P = .12). Germinal center B-cell type responded better than activated B-cell type (response rate was 83% and 29%,respectively,P = .01). These findings indicate that LDRT is effective for palliation in patients with DLBCL.","Hematol Oncol 35(Number): 472-479","Italy",2017,"DLBCL","Radiotherapy","EORTC QLQ-C30","Patient",null,"Clinical Trial","Italy","Patient","DLBCL","Radiotherapy",null,"Clinical Trial","EORTC QLQ-C30","2015:2018","Unspecified"]
[16,"Geffen,D. B.,et al. (2003). \"Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma in Israel.\" Leuk Lymphoma 44(11): 1925-1929.","10.1080/1042819031000123573","Geffen,D. B.,et al.","Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma in Israel","Post-traumatic stress disorder (PTSD) has not been examined systematically in long-term survivors of lymphoma. In this study,PTSD and health related quality of life (HRQoL) were assessed in 44 patients with Hodgkin's disease (n = 8) or non-Hodgkin's lymphoma (n = 36). Forty-four individuals who had experienced traumatic events as defined by the Diagnostic and Statistical Manual-IV (DSM-IV) as possible triggers for PTSD served as controls. The study participants were administered two questionnaires-the PTSD inventory scale and the Short Form-36 (SF-36) HRQoL instrument measuring physical and mental HRQoL. Full PTSD was defined as meeting the DSM-IV criteria for the diagnosis in all three symptom groups measured on the PTSD inventory scale-intrusion,avoidance and hyper-arousal and partial PTSD as meeting the diagnostic criteria in two of the symptom groups. There was a significant increase in the hyper-arousal scale in the lymphoma survivor group (F 5,P < 0.05). Overall,full or partial PTSD was found in 14 lymphoma survivors (32%) and in 11 individuals (25%) in the control group (difference not significant). Survivors whose disease had started at an earlier age suffered significantly more intensive intrusion and avoidance symptoms. The lymphoma survivor group had a significantly lower physical HRQoL than the control group independent of PTSD symptoms. In both groups,the presence of PTSD symptoms correlated with a lower HRQoL. These results suggest that lymphoma is a trauma similar to other more accepted definitions of trauma which can lead to PTSD,and is associated with more severe hyper-arousal symptoms. Psychological interventions in the early stages of treatment or follow-up may help reduce the morbidity from PTSD and improve quality of life.","Leuk Lymphoma 44(Number): 1925-1929","Israel",2003,"Hodgkins,NHL","None","SF-36,PTSDIS","Survivor",null,"Case-control","Israel","Survivor","Hodgkins,NHL","None",null,"Case-control","SF-36,PTSDIS","2000:2004","Unspecified"]
[17,"Glossmann,J. P.,et al. (2003). \"Recombinant human erythropoietin,epoetin beta,in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial.\" Ann Hematol 82(8): 469-475.","10.1007/s00277-003-0695-0","Glossmann,J. P.,et al.","Recombinant human erythropoietin,epoetin beta,in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial","The aim of the study was to investigate the effects of erythropoietin (epoetin beta) on red blood cell (RBC) transfusions,hemoglobin (Hb) levels,and quality of life (QOL) in patients with relapsed lymphoma treated with an aggressive sequential salvage chemotherapy (SSCT) regimen. Sixty patients with early or late relapsed Hodgkin's disease ( n=39) or first relapse of aggressive non-Hodgkin's lymphoma ( n=21) were randomized to receive epoetin beta 10,000 IE subcutaneously three times a week or no epoetin during salvage chemotherapy. Patients in both study arms received two cycles of DHAP (dexamethasone,high-dose cytarabine,cisplatin); patients in partial remission (PR) or complete remission (CR) then received cyclophosphamide,followed by peripheral blood stem cell (PBSC) harvest,methotrexate plus vincristine,and etoposide. The final myeloablative course was BEAM (carmustine,etoposide,cytarabine,and melphalan) followed by autologous stem cell support. The primary endpoint of the study was the number of RBC units needed during SSCT. In addition,Hb levels and QOL were measured. The mean number of RBC units given in the epoetin beta arm was 4.5 compared to 8.3 in the control arm ( P=0.0134). The mean Hb levels during therapy were 10.4 g/dl in the epoetin beta arm and 9.7 g/dl in the control ( P=0.018). From baseline until BEAM therapy QOL (EORTC QLQ C30) and fatigue (MFI) assessment showed little QOL worsening or stable levels in both arms with a steeper increase of fatigue levels in the control group. Patients with relapsed lymphoma undergoing aggressive chemotherapy and stem cell support benefited from epoetin beta therapy,with a decrease of RBC transfusion requirements and lower rise of fatigue levels.","Ann Hematol 82(Number): 469-475","Germany",2003,"Hodgkins,NHL","Chemotherapy,SCT,Epoetin","EORTC QLQ-C30,MFI","Patient",null,"RCT","Germany","Patient","Hodgkins,NHL","Chemotherapy,SCT,Epoetin",null,"RCT","EORTC QLQ-C30,MFI","2000:2004","Refractory,Aggressive,Early"]
[18,"Guha-Thakurta,N.,et al. (1999). \"Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.\" J Neurooncol 43(3): 259-268.",null,"Guha-Thakurta,N.,et al.","Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients","In anticipation of a consortium study of methotrexate (MTX) therapy provided to patients with primary central nervous system lymphoma (PCNSL) we have provided intravenous MTX without irradiation therapy to 31 nonimmunosuppressed individuals. Twenty (65%) achieved complete response and 11 (35%) partial response to therapy. For the 31 patients the median survival was 30.43 months with an actuarial median follow-up time of 30.69 months. The 2+ year survival was 63% for all patients and 90% for complete responders. Of 375 drug cycles,grade 3 leukopenia was identified in 3 cycles,mucositis in 6 cycles and delayed drug clearance in 47 cycles. Recurrences included brain (9/20) and/or spinal fluid (2/20). The median Karnofsky scale improved from 40 (10-80) prior to therapy to 90 after treatment. Eleven patients,in complete response for a median of 22+ months after diagnosis were evaluated using 4 instruments that assess Quality of Life Functional Assessment of Cancer Therapy - Brain (FACT-BR) modified,Symptom Questionnaire,Social Adjustment Scale-Self-Report and Problem Solving Inventory. Their psychosocial adjustment,well-being and stress coping abilities were comparable to the normative groups. Further there was no evidence of any MTX-induced,Magnetic Resonance Imaging (MRI)-detected encephalopathy in these individuals and there was preservation of clinical cognition and memory. We conclude that therapy with MTX,without radiation can be used in PCNSL patients without limitations of age or pretreatment Karnofsky scores. Further rates of response and median survival approach those of therapies using multiple drugs and radiation,but with a less likely risk of dementia.","J Neurooncol 43(Number): 259-268","USA",1999,"PCNSL","Chemotherapy","KS,FACT-BR,SymQ,SAS,PSI","Patient",null,"Clinical Trial","USA","Patient","PCNSL","Chemotherapy",null,"Clinical Trial","KS,FACT-BR,SymQ,SAS,PSI","1960:1999","Unspecified"]
[19,"Hanf,M.,et al. (2016). \"The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.\" BMC Cancer 16(1): 802.","10.1186/s12885-016-2844-6","Hanf,M.,et al.","The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma","BACKGROUND: Mantle Cell Lymphoma (MCL) is often associated with progression,temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MCL is classified as an incurable disease,therapeutic resistance is of great interest. However,knowledge about the biological mechanisms underlying resistance associated with MCL therapies and about associated predictors remains poor. The REFRACT-LYMA Cohort,a multicenter prospective cohort of patients with MCL,is set up to address this limitation. We here describe the study background,design and methods used for this cohort. METHODS/DESIGN: The REFRACT-LYMA Cohort Study aims at including all patients (>18 years old) who are diagnosed with MCL in any stage of the disease and treated in specialized oncology centers in three public hospitals in Northwestern France. Any such patient providing a signed informed consent is included. All subjects are followed up indefinitely,until refusal to participate in the study,emigration or death. The REFRACT-LYMA follow-up is continuous and collects data on socio-economic status,medical status,MCL therapies and associated events (resistance,side effects). Participants also complete standardized quality of life (QOL) questionnaires. In addition,participants are asked to donate blood samples that will support ex vivo analysis of expression and functional assays required to uncover predictive biomarkers and companion diagnostics. If diagnostic biopsies are performed during the course of the disease,extracted biological samples are kept in a dedicated biobank. DISCUSSION: To our knowledge,the REFRACT-LYMA Cohort Study is the first prospective cohort of patients with MCL for whom \"real-life\" medical,epidemiological and QOL data is repeatedly collected together with biological samples during the course of the disease. The integrative cohort at mid-term will be unique at producing a large variety of data that can be used to conceive the most effective personalized therapy for MCL patients. Additionally,the REFRACT-LYMA Cohort puts the medical care of MCL patients in a health and pharmacoeconomic perspective.","BMC Cancer 16(Number): 802","France",2016,"Mantle cell","None","Unspecified","Patient",null,"Cohort","France","Patient","Mantle cell","None",null,"Cohort","Unspecified","2015:2018","Any"]
[20,"Jensen,R. E.,et al. (2015). \"Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients.\" Qual Life Res 24(10): 2333-2344.","10.1007/s11136-015-0992-9","Jensen,R. E.,et al.","Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients","PURPOSE: To evaluate the validity of the Patient-Reported Outcomes Measurement Information System (PROMIS) physical function measures in a diverse,population-based cancer sample. METHODS: Cancer patients 6-13 months post-diagnosis (n = 4840) were recruited for the Measuring Your Health study. Participants were diagnosed between 2010 and 2013 with non-Hodgkin lymphoma or cancers of the colorectum,lung,breast,uterus,cervix,or prostate. Four PROMIS physical function short forms (4a,6b,10a,and 16) were evaluated for validity and reliability across age and race-ethnicity groups. Covariates included gender,marital status,education level,cancer site and stage,comorbidities,and functional status. RESULTS: PROMIS physical function short forms showed high internal consistency (Cronbach's alpha = 0.92-0.96),convergent validity (fatigue,pain interference,FACT physical well-being all r >/= 0.68),and discriminant validity (unrelated domains all r </= 0.3) across survey short forms,age,and race-ethnicity. Known-group differences by demographic,clinical,and functional characteristics performed as hypothesized. Ceiling effects for higher-functioning individuals were identified on most forms. CONCLUSIONS: This study provides strong evidence that PROMIS physical function measures are valid and reliable in multiple race-ethnicity and age groups. Researchers selecting specific PROMIS short forms should consider the degree of functional disability in their patient population to ensure that length and content are tailored to limit response burden.","Qual Life Res 24(Number): 2333-2344","USA",2015,"NHL","None","PROMIS","Patient",null,"Validation","USA","Patient","NHL","None",null,"Validation","PROMIS","2015:2018","Any"]
[21,"Jerkeman,M.,et al. (1999). \"CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial.\" Ann Oncol 10(9): 1079-1086.",null,"Jerkeman,M.,et al.","CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial","BACKGROUND: The long-term survival of patients with advanced stage aggressive lymphoma has not improved significantly during the last twenty years. In a randomised trial,the efficacy of MACOP-B,a six-drug weekly chemotherapy regimen,was compared to CHOP,the current standard regimen,in terms of overall and failure-free survival,toxicity and health related quality of life. PATIENTS AND METHODS: Four hundred five patients with aggressive lymphoma,stage II-IV,age 18-67,were randomised to receive either 12 weeks of MACOP-B or 8 courses of CHOP over 24 weeks. Special emphasis was put in the definition of Ann Arbor stage in extranodal disease. A subset of 95 patients also entered a quality of life study,based on the EORTC QLQ-C30. RESULTS: Thirty-one patients were ineligible. Among the remaining 374 patients,the median age was 52 years. According to the age-adjusted International Prognostic Index,37% were 'high-intermediate' or 'high-risk' patients. No difference could be demonstrated,either in overall survival (60% at five years in the MACOP-B group and 59% in the CHOP group) or in failure-free survival (47% at five years with MACOP-B and 44% with CHOP). In terms of quality of life,physical function and global quality of life were more impaired in patients receiving MACOP-B,who also exhibited more non-haematological toxicity. CONCLUSION: No superiority of MACOP-B compared to CHOP could be demonstrated. CHOP remains the treatment of choice in low-risk patients. At present,intensified or experimental treatment should be reserved for high-risk disease.","Ann Oncol 10(Number): 1079-1086","Sweden",1999,"NHL","Chemotherapy","EORTC QLQ-C30","Patient",null,"RCT","Sweden","Patient","NHL","Chemotherapy",null,"RCT","EORTC QLQ-C30","1960:1999","Advanced,Aggressive"]
[22,"Jerkeman,M.,et al. (2001). \"Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial.\" Med Oncol 18(1): 85-94.","10.1385/mo:18:1:85","Jerkeman,M.,et al.","Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial","This study was conducted to explore treatment and disease-related effects on health-related quality of life (HRQoL) in patients with aggressive lymphoma,to identify predictors for impaired long-term HRQoL,and to analyze the prognostic value of pretreatment HRQoL. Ninety-five patients with aggressive lymphoma,constituting a subset of a randomized multicenter trial comparing CHOP and MACOP-B,entered a HRQoL study,using the EORTC QLQ-C30 questionnaire. Patient scores were compared to scores from an age- and gender-adjusted reference population sample,and evaluation of the prognostic value of pretreatment QoL scores in relation to clinical prognostic factors was performed. Before treatment,patients exhibited lower scores of global QoL,physical,role,and social functions,and more appetite loss,compared to the reference population. Role functioning improved compared to baseline,but remained depressed compared to the reference group more than 8 mo after end of treatment. By then,the patient group displayed no difference in other HRQoL variables compared to that of the reference population. No reliable predictor for impaired long-term HRQoL could be identified. In multivariate analysis,including the factors of the International Prognostic Index,pretreatment global QoL was an independent prognostic marker for overall survival. In conclusion,in this population with aggressive lymphoma and favorable prognostic features,HRQoL was not substantially affected during the first year after diagnosis. Pretreatment global QoL may constitute a significant prognostic factor,meriting further investigation in prospective studies.","Med Oncol 18(Number): 85-94","Sweden",2001,"NHL","Chemotherapy","EORTC QLQ-C30","Patient",null,"RCT","Sweden","Patient","NHL","Chemotherapy",null,"RCT","EORTC QLQ-C30","2000:2004","Aggressive"]
[23,"Kim,S. H.,et al. (2014). \"Health-related quality of life in Korean lymphoma survivors compared with the general population.\" Ann Hematol 93(9): 1531-1540.","10.1007/s00277-014-2091-3","Kim,S. H.,et al.","Health-related quality of life in Korean lymphoma survivors compared with the general population","The objective of this study was to evaluate the health-related quality of life (HRQOL) of lymphoma survivors,to compare it with that of the general population,and to identify its predictors in lymphoma survivors. We enrolled 837 participants (mean age,54.6 years; mean time since diagnosis,6.3 years) with a history of Hodgkin's lymphoma (HL) (n = 58) or non-Hodgkin's lymphoma (NHL) (n = 779) who had been treated at any of three Korean hospitals from 1989 through 2010. For controls,we selected 1,000 subjects randomly from a representative Korean population. We administered the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Hospital Anxiety and Depression Scale. Overall,the HRQOL in both groups of survivors and the general population were comparable,but we observed clinically meaningful worse social functioning in NHL survivors (p < 0.001) and more severe fatigue in HL survivors (p < 0.001) than in the general population. Analysis of covariance revealed no clinically meaningful difference in HRQOL associated with age or sex. Survivors who received peripheral blood stem cell transplants showed clinically meaningful worse role (p = 0.001) and social (p < 0.001) functioning than those who were treated with first-line chemotherapy alone. In multivariate analyses,fatigue,depression,and financial difficulties emerged as the strongest predictors for almost all subscales of functioning and global quality of life. Interventions for alleviating fatigue,depression,and financial difficulties are needed to enhance the HRQOL of Korean lymphoma survivors.","Ann Hematol 93(Number): 1531-1540","South Korea",2014,"Hodgkins,NHL","None","EORTC QLQ-C30,HADS","Survivor",null,"Case-control","South Korea","Survivor","Hodgkins,NHL","None",null,"Case-control","EORTC QLQ-C30,HADS","2010:2014","Any"]
[24,"Klasa,R. J.,et al. (2002). \"Randomized phase III study of fludarabine phosphate versus cyclophosphamide,vincristine,and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.\" J Clin Oncol 20(24): 4649-4654.",null,"Klasa,R. J.,et al.","Randomized phase III study of fludarabine phosphate versus cyclophosphamide,vincristine,and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen","PURPOSE: To compare in a phase III study the safety and efficacy of fludarabine to that of cyclophosphamide,vincristine,and prednisone (CVP) in recurrent,low-grade,non-Hodgkin's lymphoma after previous response to systemic treatment. PATIENTS AND METHODS: Patients were randomized to fludarabine (25 mg/m(2) intravenously on days 1 to 5,every 28 days) or CVP (cyclophosphamide 750 mg/m(2) and vincristine 1.2 mg/m(2) both intravenously on day 1 and prednisone 40 mg/m(2) orally on days 1 to 5,every 21 days). The primary outcome assessed was progression-free survival (PFS); secondary outcomes included treatment-free survival (TFS),overall survival (OS),treatment-related toxicity,and quality of life (QoL) according to the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire C-30 version 1.0 instrument. RESULTS: Ninety-one patients were randomized,47 to fludarabine and 44 to CVP. There was no difference in response rates,with 64% (complete response [CR],9%) for fludarabine versus 52% (CR,7%) for CVP (P =.72). With a median follow-up of 42 months,median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine. No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95). Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP. Peripheral neuropathy and alopecia were more common with CVP. Patients receiving fludarabine had higher scores for social function (P =.008); no other differences in QoL were detected. CONCLUSION: In recurrent low-grade lymphoma,fludarabine improves PFS,TFS,and social function scores in comparison with CVP but does not improve OS.","J Clin Oncol 20(Number): 4649-4654","Canada",2002,"NHL","Chemotherapy,Rituximab","EORTC QLQ-C30","Patient",null,"RCT","Canada","Patient","NHL","Chemotherapy,Rituximab",null,"RCT","EORTC QLQ-C30","2000:2004","Low grade"]
[25,"Kouroukis,T.,et al. (2004). \"An evaluation of age-related differences in quality of life preferences in patients with non-Hodgkin's lymphoma.\" Leuk Lymphoma 45(12): 2471-2476.","10.1080/10428190400002285","Kouroukis,T.,et al.","An evaluation of age-related differences in quality of life preferences in patients with non-Hodgkin's lymphoma","Health related quality of life is an important outcome measure. With aging,patients may experience changes in physical,socioeconomic and psychological functioning. This pilot study examined whether age influences the level of importance that patients with non-Hodgkin's lymphoma assign to questions addressing aspects of traditional quality of life domains. A questionnaire assessing six domains (physical,appearance,toxicity,social,financial,psychological) with 29 items was given to 76 outpatients with non-Hodgkin's lymphoma. Each question asked how important the content of the item was to the individual. Mean item scores were compared between patients aged < 65 and > 65 years. Reliability ranged from 0.57 (social domain) to 0.83 (physical domain). Test-retest reliability for the entire questionnaire was 0.63. Although there was a suggestion that older patients scored the items relating to faith,appearance to others,intimacy and toxicity trade-offs differently than younger patients,when accounting for multiple comparisons in this study,no apparent differences were seen in any of the items between age groups. It appears that in this group of patients with lymphoma,age does not obviously influence the preferences of patients for items contained in quality of life assessment.","Leuk Lymphoma 45(Number): 2471-2476","Canada",2004,"NHL","None","Unspecified","Patient",null,"Validation","Canada","Patient","NHL","None",null,"Validation","Unspecified","2000:2004","Unspecified"]
[26,"Lee,S.,et al. (2013). \"Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.\" Support Care Cancer 21(3): 841-846.","10.1007/s00520-012-1589-2","Lee,S.,et al.","Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis","PURPOSE: Treatment of non-Hodgkin lymphoma (NHL) with cyclophosphamide,vincristine,doxorubicin and prednisone (CHOP) is known to be associated with a significant risk of febrile neutropenia (FN) of up to 50% [Osby et al. 2003 Blood 101(10): 3840-3848; Lyman and Delgado 2003 Cancer 98(11): 2402-2409]. This study sought to examine the impact of primary granulocyte colony-stimulating factor (GCSF) prophylaxis on the incidence of FN,quality of life and overall cost. METHODS: In this retrospective cohort study,a group of 65 consecutive patients who received CHOP chemotherapy for NHL between December 2006 and October 2009 was studied. Patients either received filgrastim (300 mcg,average of seven doses),pegylated filgrastim (6 mg,single dose),or no GCSF prophylaxis. In addition,19 patients were asked to complete Functional Assessment of Cancer Therapy: General quality-of-life questionnaires. RESULTS: Overall,patients who received primary GCSF prophylaxis had significantly fewer FN compared to those who did not (5 vs. 60%,p < 0.0001; numbers needed to treat of 1.8; 95% confidence interval,1.6-2.9). Cost-benefit analysis showed that the GCSF prophylaxis was associated with only a small increase in direct financial cost ($238 NZD [US$189] more to give primary GCSF prophylaxis per patient vs. no prophylaxis). The quality of life assessment showed that the patients' quality of life scores were similar to the published data from the validation study population (466 patients with mixed cancers) for Functional Assessment of Cancer Therapy. CONCLUSIONS: Our study shows that primary GCSF prophylaxis is effective in preventing FN in patients receiving CHOP chemotherapy for NHL without adversely affecting their quality of life,and is cost effective.","Support Care Cancer 21(Number): 841-846","New Zealand",2013,"NHL","Filgrastim,Chemotherapy","FACT-G","Patient",null,"Cohort","New Zealand","Patient","NHL","Filgrastim,Chemotherapy",null,"Cohort","FACT-G","2010:2014","Unspecified"]
[27,"Martinez,J. M.,et al. (2014). \"Mucositis care in acute leukemia and non-Hodgkin lymphoma patients undergoing high-dose chemotherapy.\" Support Care Cancer 22(9): 2563-2569.","10.1007/s00520-014-2199-y","Martinez,J. M.,et al.","Mucositis care in acute leukemia and non-Hodgkin lymphoma patients undergoing high-dose chemotherapy","PURPOSE: This study intends to provide new insights into the incidence and care of mucositis by the epidemiological characterization of patients with hematological malignancy treated at our institution. It also aims to understand the effectiveness of several treatments used. METHODS: This is a longitudinal observational single-center study-convenience sample-which includes malignant hematologic inpatients submitted to high-dose CT from February to August 2012. We registered epidemiological data,diagnosis,oral mucositis daily questionnaire (OMDQ),World Health Organization (WHO) oral toxicity scale,and supportive medications used for mucositis. RESULTS: We evaluated 30 patients who had 73 episodes of hospitalization,having recorded the development of mucositis in 21.9 % (n = 16) episodes (22 patients with acute leukemia (AL) and 8 patients with non-Hodgkin lymphoma (NHL)). Grades 3-4 mucositis was reported in 4.1 % of the total episodes. The results of OMDQ showed some limitations in the quality of life,of patients with mucositis,related with the ability to eat and drink due to mouth pain (p < 0.001). In patients with NHL and AL,neutropenia entails an increased risk of mucositis (p < 0.001). Patients who did not initiate early prophylaxis with conservative measures developed mucositis earlier (p < 0.05). CONCLUSIONS: The incidence of mucositis is high,being reported mainly in AL patients,with limitations in quality of life. Grade 4 neutropenia increases mucositis risk. Early prophylaxis with basic oral care may delay mucositis. Further studies are crucial to characterize mucositis epidemiology,physiopathology,and its management.","Support Care Cancer 22(Number): 2563-2569","Portugal",2014,"NHL","Chemotherapy","OMDQ,WHO-OTS","Patient",null,"Cohort","Portugal","Patient","NHL","Chemotherapy",null,"Cohort","OMDQ,WHO-OTS","2010:2014","Unspecified"]
[28,"Merli,F.,et al. (2004). \"Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.\" Haematologica 89(8): 973-978.",null,"Merli,F.,et al.","Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi","BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate quality of life (QOL) in a group of elderly patients (> 65 years) with aggressive non-Hodgkin's lymphoma (NHL) treated with chemotherapy regimens containing anthracyclines. DESIGN AND METHODS: QOL was evaluated in a population of elderly patients with aggressive NHL enrolled in a phase III clinical trial run by the Intergruppo Italiano Linfomi (IIL) from 1996 to 1999 to compare two different anthracycline-containing regimens (mini-CEOP vs P-VEBEC). The EORTC-QLQ-C30 questionnaire,which has already been validated in oncology,was used. The questionnaire was administered at the time of diagnosis,half way through the chemotherapy and at the time of restaging. RESULTS: Ninety-one patients completed pre-therapy and post-therapy questionnaires and they are the subject of this report. Baseline QOL assessment showed a strong correlation of poor values of QOL with anemia and high risk according to the International Prognostic Index (IPI). At the end of treatment no functional scales showed worse values. A significant improvement was observed for pain (p=0.003),appetite (p=0.006),sleep (p=0.015) and global health (p=0.027). Considering only the 50 patients who achieved a complete remission (CR),an improvement was also recorded for emotional state (p=0.10),role (p=0.05),constipation (p=0.04) and global QOL (p=0.05). INTERPRETATION AND CONCLUSIONS: The EORTC-QLQ-C30 is feasible even in a population of elderly patients,in whom it had never been tested before. The improvement of QOL at the end of the treatment demonstrated that the symptoms of the disease have a greater negative influence on the patient's life than do the side effects of the therapy.","Haematologica 89(Number): 973-978","Italy",2004,"NHL","Chemotherapy","EORTC QLQ-C30","Patient",null,"RCT","Italy","Patient","NHL","Chemotherapy",null,"RCT","EORTC QLQ-C30","2000:2004","Aggressive"]
[29,"Mounier,N.,et al. (2000). \"Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).\" Blood 95(12): 3687-3692.",null,"Mounier,N.,et al.","Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA)","Evaluating high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in term of both duration and quality of life (QOL) presents major interests for patients with non-Hodgkin lymphoma. The quality-adjusted time without symptom and toxicity (Q-TWiST) methodology was applied to the LNH87-2 trial comparing HDT with ASCT versus sequential chemotherapy in 541 patients in first complete remission (CR). Overall survival (OS) and disease-free survival (DFS) curves were used to estimate duration of 4 health states: acute short-term toxicity (Tox1),secondary toxicity (Tox2),time without symptom and toxicity (TWiST),and relapse (Rel). Areas under survival curves (AUC) were retrospectively weighted according to QOL coefficients. HDT increased,but not significantly,TWiST (+2. 4 months in AUC,P =.17) and decreased Rel (-3 months,P <.01). Survival estimates did not differ between the 2 treatments (AUC 47.7 months for OS,39.7 months for DFS). High-risk patients treated by HDT versus chemotherapy had a significant benefit in DFS (AUC 28.8 versus 24.9 months,P <.01) but not in OS (AUC 37.3 versus 36 months,P =.27). Sensitivity analysis,performed by varying QOL coefficients,demonstrated significant quality-adjusted survival gain in high-risk patients treated by HDT. In low-risk patients,a diagram provided an aid to clinical decision-making. This analysis supports the use of HDT in these patients with adverse prognostic factors in the first CR,even after adjusting for QOL using the Q-TWiST method. (Blood. 2000;95:3687-3692)","Blood 95(Number): 3687-3692","France",2000,"NHL","Chemotherapy,SCT","Q-TWiST","Patient",null,"RCT","France","Patient","NHL","Chemotherapy,SCT",null,"RCT","Q-TWiST","2000:2004","Any"]
[30,"Murthy,V.,et al. (2008). \"Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study.\" Clin Lymphoma Myeloma 8(4): 241-245.","10.3816/CLM.2008.n.032","Murthy,V.,et al.","Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study","PURPOSE: To confirm the efficacy of low-dose involved-field radiation therapy (LD-IFRT) as palliative treatment in patients symptomatic from advanced lymphoma. PATIENTS AND METHODS: A total of 36 patients (47 sites),received 4 Gy in 2 fractions to the lymphoma with a 1.5-2-cm margin. Pathology subtypes included 29 (62%) sites with indolent lymphoma and 18 (36%) sites with aggressive lymphoma histology. Bulky disease was seen in 22 (48%) sites and,of these,6 sites had disease > 10 cm. A median of 3 previous chemotherapy regimens (range,0 to 9 regimens) preceded LD-IFRT. The primary endpoint of the study was in-field lymphoma control. Patients completed the European Organization for the Research and Treatment of Cancer QLQ-C30 quality of life (QOL) questionnaire before RT and at 3-4 weeks after treatment. RESULTS: The overall response rate (RR) at 1-3 months after the RT was 75%. A complete remission (CR) was observed in 13 patients (36%) lasting up to a maximum of 31.3 months and ongoing at analysis. A partial remission (PR) was achieved in 14 patients (39%) lasting up to 10 months. The response rate for non-diffuse large B-cell lymphoma (DLBCL) sites was 86%,while it was 50% for sites with DLBCL histology. Median time to local progression for the entire group was 15 months. There was no statistical difference between the QOL before and after LD-IFRT. CONCLUSION: LD-IFRT is an effective and easy treatment for patients with advanced lymphoma that can be repeated at previously irradiated sites,a particularly useful attribute because of the relapsing nature,especially of advanced follicular subtypes.","Clin Lymphoma Myeloma 8(Number): 241-245","UK",2008,"DLBCL,NHL","Radiotherapy","EORTC QLQ-C30","Patient",null,"Clinical Trial","UK","Patient","DLBCL,NHL","Radiotherapy",null,"Clinical Trial","EORTC QLQ-C30","2005:2009","Advanced"]
[31,"Numbenjapon,T.,et al. (2002). \"Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.\" J Med Assoc Thai 85(11): 1156-1163.",null,"Numbenjapon,T.,et al.","Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma","Standard-dose (2 mg/day) oral granisetron seems to have more antiemetic efficacy than that of high-dose (0.5-1 mg/kg/dose) metoclopramide in moderately emetogenic chemotherapy. However,the cost of oral granisetron is much higher than that of metoclopramide so the authors tried to overcome this disadvantage by dose reduction and adding dexamethasone to enhance the antiemetic effect of oral granisetron. Twenty four young patients (aged < 50 years),with non-Hodgkin's lymphoma receiving CHOP-therapy were enrolled and evaluated in a randomized,double-blind,crossover study comparing the antiemetic efficacy,toxicity and patients' preference of a combination of low-dose oral granisetron plus intravenous dexamethasone (gran/dex) with a combination of high-dose metoclopramide plus intravenous dexamethasone (met/dex) on days 1-5 after chemotherapy. The acute,delayed (day 2-5) and 5-day total control of nausea and vomiting in the gran/dex group were significantly higher than those of the met/dex group (75.0% vs 25.0%; p-value = 0.004,79.2% vs 33.3%; p-value = 0.007 and 75.0% vs 25.0%; p-value = 0.004,respectively). Except for extrapyramidal reactions in the met/dex group,the side effects in both groups were comparable. The mean total score of antiemetic preference in the gran/dex group was also significantly higher than that of the met/dex group (9.0 vs 7.5; p-value = 0.004). In conclusion,low-dose oral granisetron combined with intravenous dexamethasone had significantly higher protective effects against both acute and delayed nausea and vomiting induced by CHOP-therapy. Thus,this regimen may be considered as an alternative outpatient antiemetic treatment for young patients with non-Hodgkin's lymphoma.","J Med Assoc Thai 85(Number): 1156-1163","Thailand",2002,"NHL","Chemotherapy,Granisetron","Unspecified","Patient",null,"RCT","Thailand","Patient","NHL","Chemotherapy,Granisetron",null,"RCT","Unspecified","2000:2004","Unspecified"]
[32,"Olivieri,A.,et al. (2001). \"Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience.\" Bone Marrow Transplant 27(11): 1189-1195.","10.1038/sj.bmt.1703034","Olivieri,A.,et al.","Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience","Between May 1994 and May 2000,we autotransplanted 48 consecutive patients,21 females and 27 males aged over 60 years (range: 60-78,median: 63). Sixteen patients had multiple myeloma (MM),14 high-grade non-Hodgkin's lymphoma (HGNHL),six low-grade non-Hodgkin's lymphoma (LGNHL),nine acute myeloid leukemia (AML),one chronic lymphocytic leukemia (CLL),one Hodgkin's disease (HD) and one breast cancer; the performance status (WHO) was 0-1. Seventeen patients were in 1st CR (35.4%) and one in 2nd CR (2.1%),25 in PR (52.1%),while five patients had been transplanted with progressive disease (10.4%); seven patients with MM received a double transplant. Patients received high-dose therapy including melphalan alone (13) or associated with other drugs (26),busulfan-cyclophosphamide (three),BEAM (11) and TBI (two). All patients took a median of 11 (range: 8-25) days to reach neutrophils >500/microl,13 (range: 9-83) days to reach platelets > 20,000/microl and 17 (range: 11-83) days to reach platelets > 50,000/microl. Hematological toxicity,hospital stay and supportive care did not differ from those of a cohort of younger patients. At present,31 patients are alive (14 in CR,five in PR,five in PD and seven in relapse) and 16 died from PD at a median follow-up of 37 months (1-67). Only one patient died from transplant-related toxicity. Quality of life,evaluated using a QLQ-C30 questionnaire in 25 patients at day +90,was good. In our experience PBPC mobilization and transplantation is feasible in patients aged > or = 60 years and the toxicity of this procedure is acceptable,with an early transplant-related mortality of 1.8%; therefore patients with hematological malignancies potentially curable with high-dose therapy (HDT) should also be candidates for HDT.","Bone Marrow Transplant 27(Number): 1189-1195","Italy",2001,"NHL,Hodgkins","SCT","EORTC QLQ-C30","Patient",null,"Cohort","Italy","Patient","NHL,Hodgkins","SCT",null,"Cohort","EORTC QLQ-C30","2000:2004","High grade,Low grade"]
[33,"Olney,H. J.,et al. (2014). \"Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated,rituximab-exposed,indolent non-Hodgkin lymphoma.\" Leuk Lymphoma 55(12): 2754-2760.","10.3109/10428194.2014.894190","Olney,H. J.,et al.","Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated,rituximab-exposed,indolent non-Hodgkin lymphoma","Radioimmunotherapy offers a unique treatment modality for indolent non-Hodgkin lymphoma (iNHL). We report 5-year outcomes and quality of life (QoL) in tositumomab and iodine(131)-tositumomab (TST/I(131)-TST) treated patients with iNHL previously treated with rituximab. Ninety-three patients with >/= 2 lines of therapy,responding to last treatment,were enrolled at 12 Canadian centers. Median age,disease duration and number of prior therapies (#PTx) were 59 years,4.9 years and 5,respectively. Outcomes were response rate (43.0%),median progression-free survival (mPFS) (12.0 months),5-year PFS (27%) and median overall survival (OS) (59.8 months). In responders,median response duration and mPFS were not reached. Improvements in QoL were seen by week 7. In univariate and multivariate analyses,hemoglobin,disease bulk and body surface area (BSA) predicted OS,whereas lactate dehydrogenase (LDH),bulk,BSA and #PTx predicted PFS. Most common adverse events (AEs) were fatigue and nausea. Two cases of myelodysplastic syndrome (MDS) were reported. TST/I(131)-TST was associated with durable responses,and prolonged OS and PFS in heavily pretreated iNHL.","Leuk Lymphoma 55(Number): 2754-2760","Canada",2014,"NHL","Tositumomab","Unspecified","Patient",null,"Clinical Trial","Canada","Patient","NHL","Tositumomab",null,"Clinical Trial","Unspecified","2010:2014","Unspecified"]
[34,"Park,Y. H.,et al. (2006). \"CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation.\" Leuk Lymphoma 47(7): 1253-1259.","10.1080/10428190600556239","Park,Y. H.,et al.","CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation","We aimed to define the role of cyclophosphamide,vincristine,doxorubicin,prednisone (CHOP) followed by involved field radiotherapy (IFRT) for treating localized primary gastric diffuse large B-cell lymphoma (DLBCL). Newly diagnosed patients with localized primary gastric DLBCL were to receive four cycles of CHOP followed by IFRT of 40.0 Gy. At 1 year after the completion of treatment,patients filled out the EORTC Quality of Life Questionnaire specified for stomach cancer (QLQ-C30-STO22). Fifty evaluable patients (25 men,25 women) were included. The median age was 54.5 years (range,21 - 73 years. The overall response rate to the CHOP was 94% (95% confidence interval [CI],87 - 100) in the intent-to-treat population. Forty-one of the 50 patients (82%; 95% CI,71 - 93) achieved complete remission (CR). After the completion of radiotherapy,five patients who were in PR following chemotherapy eventually attained CR. The overall complete response rate was thus 92% (95% confidence interval,84 - 99). With a median follow-up period of 30 months,the 2-year progression-free and overall survival rate was 92% and 92%,respectively. The gastric function was well preserved with negligible stomach-related symptoms at 1 year after the completion of treatment. This organ-preserving combined treatment is highly effective and well tolerated for the patients with localized gastric DLBCL.","Leuk Lymphoma 47(Number): 1253-1259","South Korea",2006,"DLBCL","Radiotherapy,Chemotherapy","EORTC QLQ-STO22","Patient",null,"Clinical Trial","South Korea","Patient","DLBCL","Radiotherapy,Chemotherapy",null,"Clinical Trial","EORTC QLQ-STO22","2005:2009","Unspecified"]
[35,"Razavi, D., et al. (1992). \"Screening for psychiatric disorders in a lymphoma out-patient population.\" Eur J Cancer 28a(11): 1869-1872.",null,"Razavi, D., et al.","Screening for psychiatric disorders in a lymphoma out-patient population","The Hospital Anxiety and Depression Scale (HADS), a four-point, 14-item self-assessment questionnaire, was tested as a screening method for psychiatric disorders in a sample of 117 Hodgkin's lymphoma and non-Hodgkin lymphoma consecutive out-patients. A receiver operating characteristic (ROC) analysis was performed, giving the relationship between the true positive rate (sensitivity) and the false positive rate (1--specificity). This makes it possible to choose an optimal cut-off score that takes into account the costs and benefits of treatment of psychiatric disorders (mainly adjustment, depressive and anxiety disorders) in a lymphoma out-patient population. A cut-off point of 10 gave 84% sensitivity and 66% specificity. HADS appears in this study to be a well accepted, simple, sensitive and specific tool.","Eur J Cancer 28a(Number): 1869-1872","Belgium",1992,"Hodgkins,NHL","None","HADS","Patient",null,"Validation","Belgium","Patient","Hodgkins,NHL","None",null,"Validation","HADS","1960:1999","Unspecified"]
[36,"Reeve, B. B., et al. (2009). \"Impact of cancer on health-related quality of life of older Americans.\" J Natl Cancer Inst 101(12): 860-868.","10.1093/jnci/djp123","Reeve, B. B., et al.","Impact of cancer on health-related quality of life of older Americans","BACKGROUND: The impact of cancer on health-related quality of life (HRQOL) is poorly understood because of the lack of baseline HRQOL status before cancer diagnosis. To our knowledge, this is the first population-based study to quantify the nature and extent of HRQOL changes from before to after cancer diagnosis for nine types of cancer patients and to compare their health with individuals without cancer. METHODS: The Surveillance, Epidemiology, and End Results cancer registry data were linked with the Medicare Health Outcomes Survey (MHOS) data; data were collected from Medicare beneficiaries who were aged 65 years and older from 1998 through 2003. Cancer patients (n = 1432; with prostate, breast, colorectal, lung, bladder, endometrial, or kidney cancers; melanoma; or non-Hodgkin lymphoma [NHL]) were selected whose first cancer diagnosis occurred between their baseline and follow-up MHOS assessments. Control subjects without cancer (n = 7160) were matched to cancer patients by use of propensity scores that were estimated from demographics and comorbid medical conditions. Analysis of covariance models were used to estimate changes in HRQOL as assessed with the Medical Outcomes Study Short Form-36 survey (mean score = 50, SD = 10). All statistical tests were two-sided. RESULTS: Patients with all cancer types (except melanoma and endometrial cancer) reported statistically significant declines in physical health (mean scores: prostate cancer = -3.4, 95% confidence interval [CI] = -2.5 to -4.2; breast cancer = -3.5, 95% CI = -2.5 to -4.5; bladder cancer = -4.3, 95% CI = -2.5 to -6.1; colorectal cancer = -4.4, 95% CI = -3.3 to -5.5; kidney cancer = -5.7, 95% CI = -3.2 to -8.2; NHL = -6.7, 95% CI = -4.4 to -9.1; and lung cancer = -7.5, 95% CI = -5.9 to -9.2) compared with the control subjects (mean score = -1.8, 95% CI = -1.6 to -2.0) (all P < .05). However, only lung (mean score = -5.4, 95% CI = -3.5 to -7.2), colorectal (mean score = -3.5, 95% CI = -2.2 to -4.7), and prostate (mean score = -2.8, 95% CI = -1.8 to -3.7) cancer patients showed statistically significant decreases in mental health relative to the mean change of the control subjects (mean score = -1.2, 95% CI = -0.9 to -1.4) (all P < .05). CONCLUSION: These findings provide validation of the specific deleterious effects of cancer on HRQOL and an evidence base for future research and clinical interventions aimed at understanding and remediating these effects.","J Natl Cancer Inst 101(Number): 860-868","USA",2009,"NHL","None","SF-36","Patient",null,"Cohort","USA","Patient","NHL","None",null,"Cohort","SF-36","2005:2009","Unspecified"]
[37,"Ribi, K., et al. (2017). \"Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.\" Support Care Cancer 25(9): 2833-2842.","10.1007/s00520-017-3698-4","Ribi, K., et al.","Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma","PURPOSE: To evaluate the efficacy and tolerability of chemotherapy, a geriatric assessment is recommended in elderly patients with cancer. We aimed to characterize and compare patients with aggressive lymphoma by objective response and survival status based on pre-treatment cancer-specific geriatric (C-SGA) and quality of life (QoL) assessments. METHODS: Patients not eligible for anthracycline-based first-line therapy or intensive salvage regimens completed C-SGA and QoL assessment before and after a rituximab-bendamustine-lenalidomide (R-BL) treatment in a phase II clinical trial. Clinical outcomes were compared based on pre-treatment individual and summary C-SGA measures, their cutoff-based subcategories and QoL indicators, using Wilcoxon rank sum or chi-square tests. RESULTS: A total of 57 patients (41 included in the clinical trial) completed a C-SGA. Participants with pre-treatment impaired functional status (Vulnerable Elders Survey-13 score >/=3) were more likely to experience worse outcomes: a higher proportion were non-responders, died before the median follow-up of 31.6 months (interquartile range (IQR) 27.9-37.9) or died during treatment. Non-responders were patients categorized as having possible depression (Geriatric Depression Scale-5 score >/=2) and with worse QoL scores for functional performance. Patients with worse C-SGA summary scores and with greater tiredness were more likely to die during treatment. CONCLUSION: A pre-treatment impaired functional status is an important factor with respect to clinical outcomes in patients receiving an R-BL regimen. Individual geriatric and related QoL domains showed similar associations with clinical outcomes. Whether interventions targeting specific geriatric dimensions also translate in better symptom- or domain-specific QoL warrants further research.","Support Care Cancer 25(Number): 2833-2842","USA,Switzerland,Italy",2017,"B-cell","Rituximab,Chemotherapy,Lenalidomide","C-SGA,VES-13,GDS-13","Patient",null,"Clinical Trial","USA,Switzerland,Italy","Patient","B-cell","Rituximab,Chemotherapy,Lenalidomide",null,"Clinical Trial","C-SGA,VES-13,GDS-13","2015:2018","Unspecified"]
[38,"Ruan, J., et al. (2015). \"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.\" N Engl J Med 373(19): 1835-1844.","10.1056/NEJMoa1505237","Ruan, J., et al.","Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","BACKGROUND: Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy. METHODS: We conducted a single-group, multicenter, phase 2 study with induction and maintenance phases. During the induction phase, lenalidomide was administered at a dose of 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles; the dose was escalated to 25 mg daily after the first cycle if no dose-limiting adverse events occurred during the first cycle and was reduced to 15 mg daily during the maintenance phase. Rituximab was administered once weekly for the first 4 weeks and then once every other cycle until disease progression. The primary end point was the overall response rate. Secondary end points included outcomes related to safety, survival, and quality of life. RESULTS: A total of 38 participants were enrolled at four centers from July 2011 through April 2014. The median age was 65 years. On the basis of the Mantle Cell Lymphoma International Prognostic Index scores, the proportions of participants with low-risk, intermediate-risk, and high-risk disease at baseline were similar (34%, 34%, and 32%, respectively). The most common grade 3 or 4 adverse events were neutropenia (in 50% of the patients), rash (in 29%), thrombocytopenia (in 13%), an inflammatory syndrome (\"tumor flare\") (in 11%), anemia (in 11%), serum sickness (in 8%), and fatigue (in 8%). At the median follow-up of 30 months (through February 2015), the overall response rate among the participants who could be evaluated was 92% (95% confidence interval [CI], 78 to 98), and the complete response rate was 64% (95% CI, 46 to 79); median progression-free survival had not been reached. The 2-year progression-free survival was estimated to be 85% (95% CI, 67 to 94), and the 2-year overall survival 97% (95% CI, 79 to 99). A response to treatment was associated with improvement in quality of life. CONCLUSIONS: Combination biologic therapy consisting of lenalidomide plus rituximab was active as initial therapy for mantle-cell lymphoma. (Funded by Celgene and Weill Cornell Medical College; ClinicalTrials.gov number, NCT01472562.).","N Engl J Med 373(Number): 1835-1844","USA",2015,"Mantle cell","Lenalidomide,Rituximab","Unspecified","Patient",null,"Clinical Trial","USA","Patient","Mantle cell","Lenalidomide,Rituximab",null,"Clinical Trial","Unspecified","2015:2018","Unspecified"]
[39,"Schimmer, A. D., et al. (2002). \"The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant.\" Support Care Cancer 10(3): 247-252.","10.1007/s00520-001-0316-1","Schimmer, A. D., et al.","The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant","The number of long-term survivors of autologous blood and marrow transplantation (ABMT) is increasing, but little is known about the models of care used to follow these patients. Such information would help in comparison of different methods of follow-up and allow other centers to create programs to follow their survivors. Here we describe a multidisciplinary long-term follow-up clinic for survivors of ABMT and report patient satisfaction with the clinic and economic analysis 1.5 years after its inception. In its first 1.5 years of operation, 83 new patients were seen in the clinic. Patients were evaluated a median of 4.0 years after ABMT (range 4.9 months to 12 years) and were a median of 48.5 years (range 22.5-69.0 years) old. Patients received their ABMT for non-Hodgkin's lymphoma ( n=26), Hodgkin's disease ( n=18), acute myeloid leukemia ( n=18), multiple myeloma ( n=15), breast cancer ( n=5), or desmoplastic round-cell tumor ( n=1). Patient satisfaction was assessed 1.5 years after the establishment of the long-term follow-up clinic by means of a self-report questionnaire. Seventy-five percent of patients returned the survey. Waiting times in the clinic were short, with 70% of patients seen within 30 minutes of arrival. Overall, patients were very satisfied with the new clinic model, with 85% patients reporting that the clinic met their expectations. An economic analysis indicated that the estimated annual cost of operating the clinic was approximately $53,000, which translates into $440 per patient visit, $962 per new patient or $172 per patient visit with the clinic operating at peak capacity. In conclusion, we present an inexpensive model of care for ABMT survivors that can be extended to adult survivors of malignancy not treated by ABMT.","Support Care Cancer 10(Number): 247-252","Canada",2002,"Hodgkins,NHL","SCT","Unspecified","Survivor",null,"Cross-sectional","Canada","Survivor","Hodgkins,NHL","SCT",null,"Cross-sectional","Unspecified","2000:2004","Any"]
[40,"Shin, D. Y., et al. (2016). \"Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.\" Cancer Chemother Pharmacol 77(4): 865-873.","10.1007/s00280-016-3005-y","Shin, D. Y., et al.","Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis","PURPOSE: Mantle cell lymphoma (MCL) is a disease that frequently relapses and primarily affects elderly people. We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL. METHODS: The treatment schedule was composed of four cycles of induction treatment with V-FND and subsequent consolidation therapy involving autologous hematopoietic stem cell transplantation or six cycles of vorinostat maintenance. QoL was assessed using EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) every 2 cycles. RESULTS: Data from a total of 20 patients were collected for an interim analysis. The median age was 67 years (range 49-75), and 14 or the patients (70 %) were male. The full course of V-FND induction treatment was completed in 11 patients, but only three completed all six cycles of maintenance therapy. Response to V-FND was not available in two patients. Among the other 18 patients, the objective response rate was 77.8 % (complete response in five patients + partial response in nine patients). Median progression-free survival was 9.3 months [95 % confidence interval (CI) 4.0-12.3]. Fifteen patients (75 %) experienced grade 3/4 toxicities. Analysis of QoL demonstrated significant deterioration of social functioning (p = 0.01), and significant aggravation of fatigue and nausea/vomiting (p = 0.04 and 0.01, respectively) after two cycles of V-FND induction. CONCLUSIONS: V-FND is effective in patients with relapsed or refractory MCL. However, significant toxicities were hurdles to sustained V-FND therapy.","Cancer Chemother Pharmacol 77(Number): 865-873","South Korea",2016,"Mantle cell","Vorinostat,Chemotherapy","EORTC QLQ-C30","Patient",null,"Clinical Trial","South Korea","Patient","Mantle cell","Vorinostat,Chemotherapy",null,"Clinical Trial","EORTC QLQ-C30","2015:2018","Refractory"]
[41,"Silverman, D. H., et al. (2004). \"Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues.\" Cancer Treat Rev 30(2): 165-172.","10.1016/j.ctrv.2003.07.006","Silverman, D. H., et al.","Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues","Anti-CD20 antibodies radiolabeled with I-131 tositumomab (Bexxar) or Y-90-Ibritumomab tiuxetan (Zevalin), are similarly efficacious in treating chemotherapy-refractory non-Hodgkin's lymphoma. The relative merits of both radioimmunoconjugates with respect to practical issues, including radiation exposure risk, the advantages and disadvantages of the respective isotopes and other parameters that could affect a patient's quality of life are also important. I-131-labeled antibody treatment often requires inpatient hospitalization due to the inherent risk of exposure from gamma emissions, and patients and families should follow detailed instructions to prevent undue exposure. Other issues relevant to patients and medical staff include: (1) the need for dosimetry to calculate effective therapeutic doses of I-131-labeled anti-B1 (Bexxar) compared with the lack of correlation of dosimetry with marrow toxicity for IDEC-Y2B8 (Zevalin), (2) determining the acute and long-term toxic effects of each agent, (3) time commitments for nuclear medicine staff and patients along with the relative ease of administration, and (4) cost considerations. A more challenging future issue will be to determine the optimal use of Bexxar and Zevalin alone and in combination in ways that will significantly affect patient outcome without compromising quality of life. The recent demonstration of significant response rates in patients having chemotherapy-refractory Non-Hodgkin's Lymphoma (NHL) using both on I-131- and Y-90-labeled anti-CD20 antibodies with minimal toxicity has stimulated comparison of I-131 tositumomab (Bexxar) and Ibritumomab tiuxetan (Zevalin) in terms of radiation safety requirements, the advantages and disadvantages of both radionuclides, and quality-of-life (QOL) issues. Therefore, in this review, we attempt to compare the relative merits of (Bexxar and Zevalin) and address important practical considerations that may influence patient and physician choices regarding treatment using these agents.","Cancer Treat Rev 30(Number): 165-172","USA",2004,"NHL","Tositumomab,Ibritumomab","Unspecified","Patient",null,"Review","USA","Patient","NHL","Tositumomab,Ibritumomab",null,"Review","Unspecified","2000:2004","Refractory"]
[42,"Smith, S. K., et al. (2008). \"Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors.\" J Clin Oncol 26(6): 934-941.","10.1200/jco.2007.12.3414","Smith, S. K., et al.","Post-traumatic stress outcomes in non-Hodgkin's lymphoma survivors","PURPOSE: A large body of evidence suggests that being diagnosed with and treated for cancer adversely affects functioning and quality of life, yet less is known about longer term outcomes. Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those that are amenable for screening and modifiable. PATIENTS AND METHODS: A total of 886 NHL survivors identified from the cancer registries of two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging from 2 to 44 years postdiagnosis. Survivors were mailed a survey that assessed PTSD symptoms and quality of life. RESULTS: Participants averaged 10.2 years postdiagnosis, and most (61%) reported no PTSD symptoms. The adjusted prevalence for full PTSD was 7.9%, with an additional 9.1% meeting criteria for partial PTSD. Modifiable risk factors that were independently associated with PTSD in multiple linear regression included less social support, negative appraisals of life threat and treatment intensity, and more employment and insurance issues. Additionally, several demographic characteristics (nonwhite race, less education, and younger age) and clinical or health-related factors (active disease, more recent diagnosis, and more comorbidity) were independently associated with PTSD. CONCLUSION: Although only 8% of survivors met PTSD diagnostic criteria, the impact of a cancer diagnosis and treatment persists for many survivors, as evidenced in 39% of this sample. Early identification of those at risk could enable treatment to minimize PTSD symptomatology.","J Clin Oncol 26(Number): 934-941","USA",2008,"NHL","None","Unspecified","Survivor",null,"Cross-sectional","USA","Survivor","NHL","None",null,"Cross-sectional","Unspecified","2005:2009","Any"]
[43,"Stalfelt, A. M. and B. Wadman (1993). \"Assessing quality of life in leukemia: presentation of an instrument for assessing quality of life in patients with blood malignancies.\" Qual Assur Health Care 5(3): 201-211.",null,"Stalfelt, A. M. and B. Wadman","Assessing quality of life in leukemia: presentation of an instrument for assessing quality of life in patients with blood malignancies","The Life Ingredient Profile (LIP)--a new instrument for iterated quality of life assessments in patients with haematological malignancies--is presented. It is intended to reflect the patient's estimation of the symptoms of disease as well as the side-effects of treatment and is designed for comparing different regimens of chemotherapy. In a pilot study of 35 patients with myeloma, lymphoma and acute leukaemia, the LIP showed good validity, reliability and sensitivity to change. It was easy to apply and the structured interviews took only 10-20 min. LIP appears to assess important dimensions of quality of life without being a burden to the patient or the nursing staff.","Qual Assur Health Care 5(Number): 201-211","Sweden",1993,"NHL","Chemotherapy","LIP","Patient",null,"Validation","Sweden","Patient","NHL","Chemotherapy",null,"Validation","LIP","1960:1999","Unspecified"]
[44,"Stienen, J. J., et al. (2013). \"Improvement of hospital care for patients with non-Hodgkin's lymphoma: protocol for a cluster randomized controlled trial (PEARL study).\" Implement Sci 8: 77.","10.1186/1748-5908-8-77","Stienen, J. J., et al.","Improvement of hospital care for patients with non-Hodgkin's lymphoma: protocol for a cluster randomized controlled trial (PEARL study)","BACKGROUND: Malignant lymphomas constitute a diverse group of cancers of lymphocytes. One well-known disease is Hodgkin's lymphoma; the others are classified as non-Hodgkin's lymphoma (NHL). NHLs are the most common hematologic neoplasms in adults worldwide, and in 2012 over 170,000 new cases were estimated in the United States and Europe.In previous studies, several practice gaps in hospital care for patients with NHL have been identified. To decrease this variation in care, the present study aims to perform a problem analysis in which barriers to and facilitators for optimal NHL care will be identified and, based on these findings, to develop (tailored) improvement strategies. Subsequently, we will assess the effectiveness, feasibility and costs of the improvement strategies. METHODS/DESIGN: Barriers and facilitators will be explored using the literature, using interviews and questionnaires among physicians involved in NHL care, and patients diagnosed with NHL. The results will be used to develop a tailored improvement strategy. A cluster randomized controlled trial involving 19 Dutch hospitals will be conducted. Hospitals will be randomized to receive either an improvement strategy tailored to the barriers and facilitators found or, a standard strategy of audit and feedback.The effects of both strategies will be evaluated using previously developed quality indicators. Adherence to the indicators will be measured before and after the intervention period based on medical records from newly diagnosed NHL patients. To study the feasibility of both strategies, a process evaluation will be additionally performed. Data about exposure to the different elements of the strategies will be collected using questionnaires. Economic evaluation from a healthcare perspective will compare the two implementation strategies, where the costs of the implementation strategy and changes in healthcare consumption will be assessed. DISCUSSION: The presence of variation in the use of diagnostic tests, treatment, and follow-up between different physicians in different hospitals in the Netherlands is important for patients. To reduce the existing variation in care, implementation of tailored interventions to improve NHL care is necessary. TRIAL REGISTRATION: This trial is registered at ClinicalTrial.gov as the PEARL study, registration number NCT01562509.","Implement Sci 8(Number): 77","Netherlands",2013,"NHL","None","Unspecified","Patient",null,"Protocol","Netherlands","Patient","NHL","None",null,"Protocol","Unspecified","2010:2014","Unspecified"]
[45,"Tchen, N., et al. (2002). \"Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients.\" Crit Rev Oncol Hematol 43(3): 219-226.",null,"Tchen, N., et al.","Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients","In the elderly population, cancer treatment aims to cure and/or maintain Quality of Life (QoL). However, there is little QoL data to provide evidence for QoL benefits for some of the cancer treatments. This pilot study developed valid QoL questionnaires in French, for patients over 65 years with a diagnosis of large cell lymphoma, part of the Lymage phase II study. They were asked to complete two questionnaires, the Medical Outcomes Study Short Form 20 (MOS SF20; generic) and the Rotterdam symptom checklist (RSCL; cancer-specific). Between June 1995 and April 1997, questionnaires were returned by 63 of 89 patients. This article reports the process undertaken to adapt the English version to a French setting, and provides the results of factor analysis, convergent and discriminant validity and reliability. Our data suggest that QoL questionnaires can be used in elderly patients. These two questionnaires are validated in French and would help us to analyse the QoL of elderly patients with the development of new treatments as done in the Lymage study.","Crit Rev Oncol Hematol 43(Number): 219-226","France",2002,"NHL","None","SF-20,RSCL","Patient",null,"Validation","France","Patient","NHL","None",null,"Validation","SF-20,RSCL","2000:2004","Unspecified"]
[46,"van Agthoven, M., et al. (2001). \"Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.\" Eur J Cancer 37(14): 1781-1789.",null,"van Agthoven, M., et al.","Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial","The cost-effectiveness of autologous peripheral blood stem cell transplantation (PBSCT) compared with autologous bone marrow transplantation (ABMT) for refractory or relapsed non-Hodgkin's lymphoma (NHL) or Morbus Hodgkin (MH) was assessed. Costs were determined from the induction chemotherapy regimen up to 3 months after discharge from hospital following the transplantation. Quality of life was measured by the EuroQol, the Rotterdam Symptom Checklist (RSCL) and the SF-36. Patients were randomised according to a 2:1 ratio to undergo either PBSCT or ABMT. 62 patients underwent PBSCT and 29 ABMT. Costs of the transplantation period were significantly lower in the PBSCT group (15008 Euros) than in the ABMT group (19000 Euros). Significant differences in quality of life were all in favour of PBSCT and emerged using the RSCL, both on 14 days after the transplantation and three months after discharge. We conclude that PBSCT is associated with lower costs and a better quality of life than ABMT for patients with refractory or relapsed NHL or MH.","Eur J Cancer 37(Number): 1781-1789","Netherlands",2001,"NHL","Chemotherapy,SCT","EQ-5D,RSCL,SF-36","Patient",null,"RCT","Netherlands","Patient","NHL","Chemotherapy,SCT",null,"RCT","EQ-5D,RSCL,SF-36","2000:2004","Refractory"]
[47,"Versteegh, M. M., et al. (2012). \"Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.\" Med Decis Making 32(4): 554-568.","10.1177/0272989x11427761","Versteegh, M. M., et al.","Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D","BACKGROUND: Responses on condition-specific instruments can be mapped on the EQ-5D to estimate utility values for economic evaluation. Mapping functions differ in predictive quality, and not all condition-specific measures are suitable for estimating EQ-5D utilities. We mapped QLQ-C30, HAQ, and MSIS-29 on the EQ-5D and compared the quality of the mapping functions with statistical and clinical indicators. METHODS: We used 4 data sets that included both the EQ-5D and a condition-specific measure to develop ordinary least squares regression equations. For the QLQ-C30, we used a multiple myeloma data set and a non-Hodgkin lymphoma one. An early arthritis cohort was used for the HAQ, and a cohort of patients with relapsing remitting or secondary progressive multiple sclerosis was used for the MSIS-29. We assessed the predictive quality of the mapping functions with the root mean square error (RMSE) and mean absolute error (MAE) and the ability to discriminate among relevant clinical subgroups. Pearson correlations between the condition-specific measures and items of the EQ-5D were used to determine if there is a relationship between the quality of the mapping functions and the amount of correlated content between the used measures. RESULTS: The QLQ-C30 had the highest correlation with EQ-5D items. Average %RMSE was best for the QLQ-C30 with 10.9%, 12.2% for the HAQ, and 13.6% for the MSIS-29. The mappings predicted mean EQ-5D utilities without significant differences with observed utilities and discriminated between relevant clinical groups, except for the HAQ model. CONCLUSIONS: The preferred mapping functions in this study seem suitable for estimating EQ-5D utilities for economic evaluation. However, this research shows that lower correlations between instruments lead to less predictive quality. Using additional validation tests besides reporting statistical measures of error improves the assessment of predictive quality.","Med Decis Making 32(Number): 554-568","Netherlands",2012,"NHL","None","EORTC QLQ-C30,EQ-5D","Patient",null,"Validation","Netherlands","Patient","NHL","None",null,"Validation","EORTC QLQ-C30,EQ-5D","2010:2014","Unspecified"]
[48,"Wettergren, L., et al. (2008). \"Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument.\" Psychooncology 17(4): 338-346.","10.1002/pon.1240","Wettergren, L., et al.","Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument","OBJECTIVE: The aim was to prospectively measure quality of life in patients with malignant blood disorders following stem cell transplantation (SCT) using an individualized and a standardized measure. METHODS: Twenty-two consecutive patients were assessed before and one year following SCT, using a generic and disease-related version of the Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW) and the EORTC QLQ-C30. Results of the QLQ-C30 were compared with Swedish norm values. RESULTS: A majority of the patients reported concerns related to health before as well as one year after SCT, recorded by both instruments. Mean scores produced by the SEIQoL-DW, and four scales of the EORTC QLQ-C30, showed a change over time, indicating improved quality of life one year after SCT. In comparison with Swedish norm values for the EORTC QLQ-C30, SCT recipients reported a worse functioning. CONCLUSIONS: In addition to well-known disease and treatment-related problems, areas not typically included in standardized instruments were nominated in the disease-related SEIQoL-DW. Such areas included positive aspects, e.g. a changed view of life and oneself. The results support the use of the generic and disease-related SEIQoL-DW to achieve a comprehensive picture of patient's clinical situation under treatment or when recovering from illness.","Psychooncology 17(Number): 338-346","Sweden",2008,"NHL","SCT","SEIQoL-DW,EORTC QLQ-C30","Patient",null,"Cohort","Sweden","Patient","NHL","SCT",null,"Cohort","SEIQoL-DW,EORTC QLQ-C30","2005:2009","Unspecified"]
[49,"Witzens-Harig, M., et al. (2009). \"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial.\" Ann Hematol 88(1): 51-57.","10.1007/s00277-008-0560-2","Witzens-Harig, M., et al.","Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial","The introduction of rituximab into the primary treatment of malignant lymphomas of the B cell lineage has had a major impact on the management of these diseases. In addition, prolonged exposure to rituximab as maintenance therapy has been beneficial in patients with follicular lymphoma and mantle cell lymphoma. For the individual patient, the effect of any prolonged antitumor therapy on the quality of life (QoL) is a very important question. However, so far, the question whether rituximab maintenance therapy may impair QoL in patients with non-Hodgkin's lymphoma remains unanswered. To investigate this subject, we have performed a prospective randomized trial of rituximab maintenance therapy (8 cycles rituximab 375 mg/m(2) every 3 months) versus observation in patients with CD20+B cell non-Hodgkin's lymphoma in our institution. Between July 2002 and December 2005, 122 patients were included into the trial. QoL was assessed with the standardized questionnaires EORTC-QLQ-C30, EuroQol-5D, and EuroQol-5D (VAS) in 91 patients. After statistical analysis with the exact Wilcoxon rank sum test, we found no significant differences of the QoL between the rituximab treatment group and the observation group. We conclude that rituximab maintenance therapy seems to be safe and does not impair quality of life in this patient population.","Ann Hematol 88(Number): 51-57","Germany",2009,"NHL","Rituximab","EORTC QLQ-C30,EQ-5D,EQ-VAS","Patient",null,"RCT","Germany","Patient","NHL","Rituximab",null,"RCT","EORTC QLQ-C30,EQ-5D,EQ-VAS","2005:2009","Any"]
[50,"Wortman, M. S., et al. (2016). \"Brief multimodal psychosomatic therapy in patients with medically unexplained symptoms: feasibility and treatment effects.\" Fam Pract 33(4): 346-353.","10.1093/fampra/cmw023","Wortman, M. S., et al.","Brief multimodal psychosomatic therapy in patients with medically unexplained symptoms: feasibility and treatment effects","BACKGROUND: Patients repeatedly presenting with medically unexplained symptoms (MUS) to their GPs, suffer from their symptoms. Experts in the field suggest a multicomponent approach for these patients. Brief multimodal psychosomatic therapy (BMPT) is such an intervention. OBJECTIVES: To test the systematic identification of eligible patients, acceptability of BMPT and potential treatment effects of BMPT. METHODS: The participants in this randomized pilot trial, patients consulting their GPs more than once with MUS, were randomized to intervention [usual care (UC) and additional BMPT] or control condition (UC alone).We monitored the number of patients identified and recruited, trial recruitment and retention. Potential treatment effects were measured with perceived symptom severity [Visual Analogue Scale (VAS)]; patients' self-rated symptoms of distress, depression, anxiety and somatization [(4DSQ)]; symptoms of hyperventilation [Nijmegen Hyperventilation List (NHL)]; physical and mental health status and quality of life [Short-Form Health Survey-36 items (SF-36)]; and level of functioning (measure of general functioning). Follow-up was 1 year. RESULTS: A total of 42 patients could be included in the trial. Four patients withdrew after randomization and two patients were lost to follow-up, resulting in 36 patients (86%). During the 12-month follow-up after BMPT, there was an improvement in perceived symptom severity [adjusted mean difference -2.0, 95% confidence interval (CI) -3.6 to -0.3], in somatization (adjusted mean difference -4.4, 95% CI -7.5 to -1.4) and in symptoms of hyperventilation (adjusted mean difference -5.7, 95% CI -10.5 to -0.8). CONCLUSIONS: This randomized pilot study shows that a larger trial studying the effectiveness of BMPT in patients with MUS in primary care is feasible and useful.","Fam Pract 33(Number): 346-353","Netherlands",2016,"Other","Psychosomatic therapy","4DSQ,VAS,NHL,SF-36","Patient",null,"Cohort study","Netherlands","Patient","Other","Psychosomatic therapy",null,"Cohort study","4DSQ,VAS,NHL,SF-36","2015:2018","Unspecified"]
[51,"Younossi, Z., et al. (2016). \"Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.\" Gastroenterology 150(7): 1599-1608.","10.1053/j.gastro.2016.02.039","Younossi, Z., et al.","Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden","BACKGROUND & AIMS: Hepatitis C virus (HCV) infection has hepatic and extrahepatic manifestations with various costs and impairments to health-related quality of life (HRQL). We performed a meta-analysis to determine the prevalence of extrahepatic manifestations in patients with HCV infection, how these impair HRQL, and their costs. METHODS: We performed systematic reviews of the literature using MEDLINE, CINAHL, and the Cochrane Systematic Review Database, from 1996 through December 2014, to identify studies of the following extrahepatic manifestations of HCV infection: mixed cryoglobulinemia, chronic kidney or end-stage renal disease, type 2 diabetes, B-cell lymphoma, lichen planus, Sjogren's syndrome, porphyria cutanea tarda, rheumatoid-like arthritis, or depression. We performed a separate meta-analysis for each condition to determine prevalence rates of extrahepatic manifestations of HCV infection and their effects on HRQL. We determined the annual costs (inpatient, outpatient, and pharmacy) associated with extrahepatic manifestations of HCV infection. RESULTS: In an analysis of data from 102 studies, we found the most common extrahepatic manifestations to be diabetes (in 15% of patients) and depression (in 25% of patients). HRQL data showed that HCV infection had negative effects on overall physical and mental health. Total direct medical costs of extrahepatic manifestations of HCV infection, in 2014 US dollars, were estimated to be $1506 million (range, $922 million-$2208 million in sensitivity analysis). CONCLUSIONS: In a systematic review and meta-analysis we determined the prevalence, risks, and costs associated with extrahepatic manifestations of HCV infection. These estimates should be added to the liver-related burden of disease to obtain a more accurate assessment of the total burden of chronic HCV infection. Prospective, real-world studies are needed to increase our understanding of the total clinical and economic effects of HCV infection and treatment on patients and society.","Gastroenterology 150(Number): 1599-1608","International",2016,"B-cell","None","Unspecified","Patient",null,"SLR","International","Patient","B-cell","None",null,"SLR","Unspecified","2015:2018","Unspecified"]
[52,"Zhou, X., et al. (2015). \"Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma.\" Hematology 20(3): 129-136.","10.1179/1607845414y.0000000179","Zhou, X., et al.","Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma","OBJECTIVES: The randomized phase 3 PRIMA trial established that 2 years of rituximab maintenance therapy after attaining disease response to immunochemotherapy as first-line treatment of follicular lymphoma, reduced the risk of disease progression, compared with observation, without adversely affecting patient-reported quality of life (QoL). We now report additional analyses of symptom burden and toxicity. METHODS: Symptom burden was measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items. The proportion of patients with worsening, no change, or improvement in symptoms from maintenance baseline was compared between rituximab maintenance and observation groups with Pearson chi(2) tests. Improvement in symptoms after 1 and 2 years of maintenance was further analyzed using generalized mixed models. The adverse event (AE) rate was calculated from the toxicity checklist at each visit to explore the frequency and timing of the toxicity AE in each treatment arm. The study protocol was approved by local ethics committees and is registered at ClinicalTrials.gov under NCT00140582. RESULTS: Being tired, needing to rest, feeling weak, and trouble sleeping were the most frequently reported symptoms at the end of immunochemotherapy. By the end of maintenance, notable improvement was seen for fatigue symptoms, trouble sleeping, shortness of breath, lack of appetite, and nausea, with no significant difference in QoL symptoms between the rituximab maintenance and observation groups. The rate of AEs was low, and hematologic toxicity induced during chemotherapy treatment improved in both rituximab maintenance and observation groups. DISCUSSION: These results indicated that rituximab maintenance did not negatively impact disease- or treatment-related symptoms.","Hematology 20(Number): 129-136","Unclear",2015,"Follicular","Rituximab","EORTC QLQ-C30","Patient",null,"RCT","Unclear","Patient","Follicular","Rituximab",null,"RCT","EORTC QLQ-C30","2015:2018","Unspecified"]

{"sheet":"Dashboard","index":6,"n_rows":36,"n_cols":51,"rows_kept":36,"cut":false,"hidden":true,"merged":[[26,11,26,12],[26,13,26,28],[26,5,26,8],[1,40,1,41],[1,44,1,46],[2,44,2,46],[5,40,5,46],[6,40,6,46],[7,40,7,46],[8,40,8,46],[9,40,9,46],[10,40,10,46],[37,5,37,7],[28,2,28,8],[29,2,29,8],[30,2,30,8],[31,2,31,8],[33,2,33,8],[34,2,34,8],[11,40,11,46],[12,40,12,46],[13,40,13,46],[14,40,14,46],[15,40,15,46],[21,40,21,46],[22,40,22,46],[23,40,23,46],[24,40,24,46],[28,9,28,28],[29,9,29,28],[30,9,30,28],[31,9,31,28],[32,9,32,28],[33,9,33,28],[34,9,34,28],[32,2,32,8],[1,1,1,4],[3,2,4,38],[16,40,16,46],[17,40,17,46],[18,40,18,46],[19,40,19,46],[20,40,20,46],[39,2,39,4],[39,5,39,7],[22,2,22,7],[24,2,24,4],[24,5,24,7],[25,2,25,4],[25,5,25,7],[26,2,26,4],[27,2,27,4],[27,5,27,7],[38,2,38,4],[38,5,38,7],[35,2,35,4],[35,5,35,7],[36,2,36,4],[36,5,36,7],[37,2,37,4],[40,2,40,4],[40,5,40,7],[41,2,41,4],[41,5,41,7],[42,2,42,4],[42,5,42,7],[43,2,43,4],[43,5,43,7],[44,2,44,4],[44,5,44,7],[45,2,45,4],[45,5,45,7],[46,2,46,4],[46,5,46,7],[47,2,47,4],[47,5,47,7],[48,2,48,4],[48,5,48,7],[49,2,49,4],[49,5,49,7],[50,2,50,4],[50,5,50,7],[51,2,51,4],[51,5,51,7],[52,2,52,4],[52,5,52,7],[53,2,53,4],[53,5,53,7],[54,2,54,4],[54,5,54,7],[55,2,55,4],[55,5,55,7],[56,2,56,4],[56,5,56,7],[57,2,57,4],[57,5,57,7],[58,2,58,4],[58,5,58,7],[59,2,59,4],[59,5,59,7],[65,2,65,4],[65,5,65,7],[60,2,60,4],[60,5,60,7],[61,2,61,4],[61,5,61,7],[62,2,62,4],[62,5,62,7],[63,2,63,4],[63,5,63,7],[64,2,64,4],[64,5,64,7]]}
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,4,null,null,null,"Year"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"SelectedYear","v":2016}]
[null,null,{"$f":"SelectedTitle","v":"Burke,J. M.,et al."}]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,6,0,null,null,null,null,null,null,1]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[null,null,"PMID",null,null,{"$f":"SelectedPMID","v":"NHL,Mantle cell"},null,null,null,null,null,"DOI",null,{"$f":"SelectedDOI","v":"Bendamustine-rituximab,Rituximab,Chemotherapy"}]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null," "]
[null,null,"Locations",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null," "]
[null,null,"Interventions",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null," "]
[null,null,"Diseases",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null," ",null," ",null,null," "]
[null,null,"PRO tools"]
[null,null,"Sub-populations"]
[null,null,"Study types",null,null,null,null,null,null,"Case control",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null," "]
[null,null,"Study methodologies"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null," "]

{"sheet":"custom","index":7,"n_rows":27,"n_cols":15,"rows_kept":27,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNTA(B1:AB1)","v":14},{"$f":"Setup!V4","v":"Stage"},{"$f":"Setup!V5","v":"C2"},{"$f":"Setup!V6","v":"C3"},{"$f":"Setup!V7","v":"C4"},{"$f":"Setup!V8","v":"C5"},{"$f":"Setup!V9","v":"C6"},{"$f":"Setup!V10","v":"C7"},{"$f":"Setup!V11","v":"C8"},{"$f":"Setup!V12","v":"C9"},{"$f":"Setup!V13","v":"C10"},"newCustom","newCustom","newCustom","newCustom"]
[{"$f":"IF(OFFSET($B$1,0,ROW()-2)=\"\",\"\",OFFSET($B$1,0,ROW()-2))","v":"Stage"},"Aggressive"]
[{"$f":"IF(OFFSET($B$1,0,ROW()-2)=\"\",\"\",OFFSET($B$1,0,ROW()-2))","v":"C2"},"Any"]
["C3","Early"]
["C4","High grade"]
["C5","Low grade"]
["C6","Refractory"]
["C7","Unspecified"]
["C8"]
["C9"]
["C10"]
[{"$f":"COUNTA(B:B)-1","v":7}]
[{"$f":"COUNTA(C:C)-1","v":0}]
[{"$f":"COUNTA(D:D)-1","v":0}]
[{"$f":"COUNTA(E:E)-1","v":0}]
[{"$f":"COUNTA(F:F)-1","v":0}]
[{"$f":"COUNTA(G:G)-1","v":0}]
[{"$f":"COUNTA(H:H)-1","v":0}]
[{"$f":"COUNTA(I:I)-1","v":0}]
[{"$f":"COUNTA(J:J)-1","v":0}]
[{"$f":"COUNTA(K:K)-1","v":0}]
[""]
[""]
[""]
[""]
[""]
[""]

{"sheet":"Setup","index":8,"n_rows":304,"n_cols":100,"rows_kept":304,"cut":false,"hidden":true,"merged":[[1,51,1,52],[42,1,42,3],[42,4,42,6],[43,1,43,3],[43,4,43,6],[33,1,33,3],[33,4,33,6],[34,1,34,3],[34,4,34,6],[35,1,35,3],[35,4,35,6],[30,1,30,3],[30,4,30,6],[31,1,31,3],[31,4,31,6],[32,1,32,3],[32,4,32,6],[27,1,27,3],[27,4,27,6],[28,1,28,3],[28,4,28,6],[29,1,29,3],[29,4,29,6],[44,1,44,3],[44,4,44,6],[39,1,39,3],[39,4,39,6],[40,1,40,3],[40,4,40,6],[41,1,41,3],[41,4,41,6],[36,1,36,3],[36,4,36,6],[37,1,37,3],[37,4,37,6],[38,1,38,3],[38,4,38,6],[24,1,24,3],[24,4,24,6],[25,1,25,3],[25,4,25,6],[26,1,26,3],[26,4,26,6],[21,1,21,3],[21,4,21,6],[22,1,22,3],[22,4,22,6],[23,1,23,3],[23,4,23,6],[18,1,18,3],[18,4,18,6],[19,1,19,3],[19,4,19,6],[20,1,20,3],[20,4,20,6],[15,1,15,3],[15,4,15,6],[16,1,16,3],[16,4,16,6],[17,1,17,3],[17,4,17,6],[12,1,12,3],[12,4,12,6],[13,1,13,3],[13,4,13,6],[14,1,14,3],[14,4,14,6],[10,1,10,3],[10,4,10,6],[11,1,11,3],[11,4,11,6],[9,1,9,3],[9,4,9,6],[6,1,6,3],[6,4,6,6],[7,1,7,3],[7,4,7,6],[8,1,8,3],[8,4,8,6],[5,1,5,3],[5,4,5,6],[1,1,1,6],[3,1,3,3],[3,4,3,6],[4,1,4,3],[4,4,4,6]]}
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"COUNTA(T4:T474)","v":7},null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"OFFSET($CI$1,0,domainChoice)","v":11},{"$f":"COUNTA(CJ3:CJ513)","v":27},{"$f":"COUNTA(CK3:CK513)","v":19},9,38,4,0,11,null,null,null,null,{"$f":"ADDRESS(2,1,1,1,domainSheet)","v":"studymethodCategories!$A$2"},{"$f":"INDIRECT(CU1)","v":"Unallocated"}]
[null,"Toggle age cut-offs",null,null,null,null,null,null,7,1,null,null,null,null,null,null,null,null,null,1,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"This year =",{"$f":"YEAR(NOW())","v":2018},null,"Years","Cut","Selected cut state","Start","End",{"$f":"COUNTA(CF3:CF58)","v":5},{"$f":"OFFSET($CI$2,0,domainChoice)","v":"Study methodologies"},"Locations","Interventions","Diseases","PRO tools","subPopulations","Study types","Study methodologies",null,null,null,null,"selected categories"]
[null,null,56,null,null,null,null,null,"Unallocated","Case-control",null,null,null,null,null,null,null,null,null,"Advanced",null,"New names","Existing names",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Low year =",{"$f":"MIN($CF$3:$CF$60)","v":1960},null,1960,false,true,1960,1999,{"$f":"IF(CF3<>\"\",_xlfn.CONCAT(CF3,\":\",CG3),\"\")","v":"1960:1999"},{"$f":"OFFSET($CJ$2,0,ROW()-3)","v":"Locations"},"Australia","Bendamustine","B-cell","4DSQ","Caregiver",null,"Case-control",null,null,null,null,{"$f":"OFFSET(INDIRECT($CU$1),ROW()-3,0)","v":"Unallocated"}]
[null,"From",null,null,"To",null,null,null,null,"Case-control",null,null,null,null,null,null,null,null,null,"Aggressive",null,"Stage","Stage","Locations",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"OFFSET($BY$5,domainChoice,0)","v":"studymethodCategories"},"High year =",{"$f":"MAX(CG3:$CG$60)","v":2018},null,1961,false,null,2000,2004,{"$f":"IF(CF4<>\"\",_xlfn.CONCAT(CF4,\":\",CG4),\"\")","v":"2000:2004"},{"$f":"OFFSET($CJ$2,0,ROW()-3)","v":"Interventions"},"Austria","Bendamustine-rituximab","Cutaneous T-cell","BFI","Children",null,"Clinical Trial",null,null,null,null,{"$f":"OFFSET(INDIRECT($CU$1),ROW()-3,0)","v":"Case-control"}]
[null,{"$f":"IF(CF3=\"\",\"\",CF3)","v":1960},null,null,{"$f":"IF(CG3=\"\",\"\",CG3)","v":1999},null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Any",null,"C2","C2","Interventions",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1962,false,"Segment count",2005,2009,"2005:2009","Diseases","Belarus","Chemotherapy","DLBCL","C-SGA","Patient",null,"Cohort",null,null,null,null,"Clinical Trial"]
[null,{"$f":"IF(CF4=\"\",\"\",CF4)","v":2000},null,null,{"$f":"IF(CG4=\"\",\"\",CG4)","v":2004},null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Early",null,"C3","C3","Diseases",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"locationCategories",null,null,null,1963,false,null,2010,2014,"2010:2014","PRO tools","Belgium","Denileukin diftitox","Follicular","EORTC QLQ-C30","Survivor",null,"Cohort study",null,null,null,null,"Cohort"]
[null,2005,null,null,2009,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"High grade",null,"C4","C4","Sub-populations",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"interventionCategories",null,null,null,1964,false,null,2015,2018,"2015:2018","subPopulations","Canada","Epoetin","Hodgkins","EORTC QLQ-STO22",null,null,"Cross-sectional",null,null,null,null,"Cohort study"]
[null,2010,null,null,2014,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Low grade",null,"C5","C5","PRO tools",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"diseaseCategories",null,null,null,1965,false,null,null,null,"","Study types","China","Filgrastim","Mantle cell","EQ-5D",null,null,"Economic evaluation",null,null,null,null,"Cross-sectional"]
[null,2015,null,null,2018,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Refractory",null,"C6","C6","Study types",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"protoolCategories",null,null,null,1966,false,null,null,null,"","Study methodologies","Czech Republic","Granisetron","NHL","EQ-VAS",null,null,"Protocol",null,null,null,null,"Economic evaluation"]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Unspecified",null,"C7","C7","Study methodologies",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"subpopulationCategories",null,null,null,1967,false,null,null,null,"",null,"France","Ibritumomab","Other","FACT-BR",null,null,"RCT",null,null,null,null,"Protocol"]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"C8","C8","Location categorised",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"studytypeCategories",null,null,null,1968,false,null,null,null,"",null,"Germany","Lenalidomide","PCNSL","FACT-G",null,null,"Review",null,null,null,null,"RCT"]
[null,{"$f":"IF(CF10=\"\",\"\",CF10)","v":""},null,null,{"$f":"IF(CG10=\"\",\"\",CG10)","v":""},null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"C9","C9","Intervention categorised",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"studymethodCategories",null,null,null,1969,false,null,null,null,"",null,"Hungary","None",null,"FACT-Lym",null,null,"SLR",null,null,null,null,"Review"]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"C10","C10","Disease categorised",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1970,false,null,null,null,"",null,"International","Obinutuzumab",null,"FAHI",null,null,"Validation",null,null,null,null,"SLR"]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Sub-populations categorised",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1971,false,null,null,null,"",null,"Israel","Psychosomatic therapy",null,"GDS-13",null,null,null,null,null,null,null,"Validation"]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PRO tool categorised",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1972,false,null,null,null,"",null,"Italy","Radiotherapy",null,"HADS",null,null,null,null,null,null,null,""]
[null,"",null,null,{"$f":"IF(CG14=\"\",\"\",CG14)","v":""},null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Study type categorised",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1973,false,null,null,null,"",null,"Japan","Rituximab",null,"IOC",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Study methodology categorised",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1974,false,null,null,null,"",{"$f":"COLUMN()","v":87},"Netherlands","SCT",null,"KS",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1975,false,null,null,null,"",null,"New Zealand","Targeted",null,"LIP",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1976,false,null,null,null,"",null,"Poland","Tositumomab",null,"MFI",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1977,false,null,null,null,"",null,"Portugal","Various",null,"MFI-20",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1978,false,null,null,null,"",null,"Serbia","Vorinostat",null,"MOS-SSS",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1979,false,null,null,null,"",null,"Slovenia",null,null,"NHL",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1980,false,null,null,null,"",null,"South Korea",null,null,"OMDQ",null,null,null,null,null,null,null,""]
[null,"",22,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1981,false,null,null,null,"",null,"Sweden",null,null,"PROMIS",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1982,false,null,null,null,"",null,"Switzerland",null,null,"PSI",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1983,false,null,null,null,"",null,"Thailand",null,null,"PTGI",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1984,false,null,null,null,"",null,"UK",null,null,"PTSDCC",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1985,false,null,null,null,"",null,"USA",null,null,"PTSDIS",null,null,null,null,null,null,null,""]
[null,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1986,false,null,null,null,"",null,"Unclear",null,null,"Q-TWiST",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1987,false,null,null,null,"",null,null,null,null,"RSCL",null,null,null,null,null,null,null,""]
[null,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1988,false,null,null,null,{"$f":"IF(CF31<>\"\",_xlfn.CONCAT(CF31,\":\",CG31),\"\")","v":""},null,null,null,null,"SAS",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1989,false,null,null,null,"",null,null,null,null,"SEIQoL-DW",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1990,false,null,null,null,"",null,null,null,null,"SF-20",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1991,false,null,null,null,"",null,null,null,null,"SF-36",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1992,false,null,null,null,"",null,null,null,null,"SymQ",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1993,false,null,null,null,"",null,null,null,null,"Unspecified",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1994,false,null,null,null,"",null,null,null,null,"VAS",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1995,false,null,null,null,"",null,null,null,null,"VES-13",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1996,false,null,null,null,"",null,null,null,null,"VSHSS",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1997,false,null,null,null,{"$f":"IF(CF40<>\"\",_xlfn.CONCAT(CF40,\":\",CG40),\"\")","v":""},null,null,null,null,"WHO-OTS",null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1998,false,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,1999,false,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2000,true,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2001,false,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,"",null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2002,false,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2003,false,null,null,null,{"$f":"IF(CF46<>\"\",_xlfn.CONCAT(CF46,\":\",CG46),\"\")","v":""},null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2004,false,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2005,true,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2006,false,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2007,false,null,null,null,"",null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2008,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2009,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2010,true,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2011,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2012,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2013,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2014,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2015,true,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2016,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2017,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2018,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2019,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2020,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2021,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2022,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2023,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2024,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2025,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"OFFSET(INDIRECT($CU$1),ROW()-3,0)","v":""}]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2026,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2027,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2028,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2029,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2030,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2031,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2032,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2033,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2034,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2035,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2036,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,2037,false,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"OFFSET(INDIRECT($CU$1),ROW()-3,0)","v":""}]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"OFFSET(INDIRECT($CU$1),ROW()-3,0)","v":""}]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"OFFSET(INDIRECT($CU$1),ROW()-3,0)","v":""}]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,""]

{"sheet":"studymethodCategories","index":9,"n_rows":503,"n_cols":13,"rows_kept":503,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNTA(B1:LT1)","v":12},"Unallocated","Case-control","Clinical Trial","Cohort","Cohort study","Cross-sectional","Economic evaluation","Protocol","RCT","Review","SLR","Validation"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Unallocated"},null,"Case-control","Clinical Trial","Cohort","Cohort study","Cross-sectional","Economic evaluation","Protocol","RCT","Review","SLR","Validation"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Case-control"}]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Clinical Trial"}]
["Cohort"]
["Cohort study"]
["Cross-sectional"]
["Economic evaluation"]
["Protocol"]
["RCT"]
["Review"]
["SLR"]
["Validation"]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]

{"sheet":"subpopulationCategories","index":10,"n_rows":503,"n_cols":6,"rows_kept":503,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNTA(B1:LT1)","v":5},"Unallocated","Caregiver","Children","Patient","Survivor"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Unallocated"},null,"Caregiver","Children","Patient","Survivor"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Caregiver"}]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Children"}]
["Patient"]
["Survivor"]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]

{"sheet":"studytypeCategories","index":11,"n_rows":503,"n_cols":2,"rows_kept":503,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNTA(B1:LT1)","v":1},"Unallocated"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Unallocated"}]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]

{"sheet":"diseaseCategories","index":12,"n_rows":503,"n_cols":11,"rows_kept":503,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNTA(B1:LT1)","v":10},"Unallocated","B-cell","Cutaneous T-cell","DLBCL","Follicular","Hodgkins","Mantle cell","NHL","Other","PCNSL"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Unallocated"},null,"B-cell","Cutaneous T-cell","DLBCL","Follicular","Hodgkins","Mantle cell","NHL","Other","PCNSL"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"B-cell"}]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Cutaneous T-cell"}]
["DLBCL"]
["Follicular"]
["Hodgkins"]
["Mantle cell"]
["NHL"]
["Other"]
["PCNSL"]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]

{"sheet":"protoolCategories","index":13,"n_rows":503,"n_cols":40,"rows_kept":503,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNTA(B1:LT1)","v":39},"Unallocated","4DSQ","BFI","C-SGA","EORTC QLQ-C30","EORTC QLQ-STO22","EQ-5D","EQ-VAS","FACT-BR","FACT-G","FACT-Lym","FAHI","GDS-13","HADS","IOC","KS","LIP","MFI","MFI-20","MOS-SSS","NHL","OMDQ","PROMIS","PSI","PTGI","PTSDCC","PTSDIS","Q-TWiST","RSCL","SAS","SEIQoL-DW","SF-20","SF-36","SymQ","Unspecified","VAS","VES-13","VSHSS","WHO-OTS"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Unallocated"},null,"4DSQ","BFI","C-SGA","EORTC QLQ-C30","EORTC QLQ-STO22","EQ-5D","EQ-VAS","FACT-BR","FACT-G","FACT-Lym","FAHI","GDS-13","HADS","IOC","KS","LIP","MFI","MFI-20","MOS-SSS","NHL","OMDQ","PROMIS","PSI","PTGI","PTSDCC","PTSDIS","Q-TWiST","RSCL","SAS","SEIQoL-DW","SF-20","SF-36","SymQ","Unspecified","VAS","VES-13","VSHSS","WHO-OTS"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"4DSQ"}]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"BFI"}]
["C-SGA"]
["EORTC QLQ-C30"]
["EORTC QLQ-STO22"]
["EQ-5D"]
["EQ-VAS"]
["FACT-BR"]
["FACT-G"]
["FACT-Lym"]
["FAHI"]
["GDS-13"]
["HADS"]
["IOC"]
["KS"]
["LIP"]
["MFI"]
["MFI-20"]
["MOS-SSS"]
["NHL"]
["OMDQ"]
["PROMIS"]
["PSI"]
["PTGI"]
["PTSDCC"]
["PTSDIS"]
["Q-TWiST"]
["RSCL"]
["SAS"]
["SEIQoL-DW"]
["SF-20"]
["SF-36"]
["SymQ"]
["Unspecified"]
["VAS"]
["VES-13"]
["VSHSS"]
["WHO-OTS"]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]

{"sheet":"locationCategories","index":14,"n_rows":503,"n_cols":29,"rows_kept":503,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNTA(B1:LT1)","v":28},"Unallocated","Australia","Austria","Belarus","Belgium","Canada","China","Czech Republic","France","Germany","Hungary","International","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Portugal","Serbia","Slovenia","South Korea","Sweden","Switzerland","Thailand","UK","USA","Unclear"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Unallocated"},null,"Australia","Austria","Belarus","Belgium","Canada","China","Czech Republic","France","Germany","Hungary","International","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Portugal","Serbia","Slovenia","South Korea","Sweden","Switzerland","Thailand","UK","USA","Unclear"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Australia"}]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Austria"}]
["Belarus"]
["Belgium"]
["Canada"]
["China"]
["Czech Republic"]
["France"]
["Germany"]
["Hungary"]
["International"]
["Israel"]
["Italy"]
["Japan"]
["Netherlands"]
["New Zealand"]
["Poland"]
["Portugal"]
["Serbia"]
["Slovenia"]
["South Korea"]
["Sweden"]
["Switzerland"]
["Thailand"]
["UK"]
["USA"]
["Unclear"]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]

{"sheet":"interventionCategories","index":15,"n_rows":503,"n_cols":21,"rows_kept":503,"cut":false,"hidden":true,"merged":[]}
[{"$f":"COUNTA(B1:LT1)","v":20},"Unallocated","Bendamustine","Bendamustine-rituximab","Chemotherapy","Denileukin diftitox","Epoetin","Filgrastim","Granisetron","Ibritumomab","Lenalidomide","None","Obinutuzumab","Psychosomatic therapy","Radiotherapy","Rituximab","SCT","Targeted","Tositumomab","Various","Vorinostat"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Unallocated"},null,"Bendamustine","Bendamustine-rituximab","Chemotherapy","Denileukin diftitox","Epoetin","Filgrastim","Granisetron","Ibritumomab","Lenalidomide","None","Obinutuzumab","Psychosomatic therapy","Radiotherapy","Rituximab","SCT","Targeted","Tositumomab","Various","Vorinostat"]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Bendamustine"}]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":"Bendamustine-rituximab"}]
["Chemotherapy"]
["Denileukin diftitox"]
["Epoetin"]
["Filgrastim"]
["Granisetron"]
["Ibritumomab"]
["Lenalidomide"]
["None"]
["Obinutuzumab"]
["Psychosomatic therapy"]
["Radiotherapy"]
["Rituximab"]
["SCT"]
["Targeted"]
["Tositumomab"]
["Various"]
["Vorinostat"]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[{"$f":"IF(OFFSET($A$1,0,ROW()-1)=\"\",\"\",OFFSET($A$1,0,ROW()-1))","v":""}]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]
[""]